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Carbapenem resistant Klebsiella pneumoniae is one of the most clinically relevant multidrug 
resistant pathogens, exacerbated by an ability to cause nosocomial infections. While 
treatment choices are limited, the introduction of two β-lactam/β-lactamase inhibitor 
combinations: meropenem/vaborbactam and ceftazidime/avibactam has revolutionised the 
management of cephalosporin and carbapenem resistant K. pneumoniae infections. With an 
increasing clinical dependence on these combination therapies, there is a need to study 
resistance mechanisms to allow prediction of what might be seen in the clinic and perhaps 
suggest ways to reverse resistance when it occurs. In particular, this project aims to better 
understand β-lactam/vaborbactam efficacy against laboratory grown bacteria and the 
mechanisms of resistance that emerge by generating mutants of K. pneumoniae clinical 
isolates with reduced susceptibility to β-lactams in combination with vaborbactam. We 
showed that vaborbactam is a potent inhibitor of class A and C β-lactamases in vivo but 
shows particular potency against bacteria carrying the class A, KPC carbapenemase, when 
used in combination with meropenem. Upon analysis of meropenem/vaborbactam resistant 
mutants, the outer membrane porin OmpK36 was frequently lost, as has been previously 
reported. We also identified a novel meropenem/vaborbactam resistance mechanism, which 
involves down-regulation of OmpK36 and the Maltoporin LamB2. An attempt was made to 
find a universal β-lactam/vaborbactam combination that would be clinically active against 
meropenem/vaborbactam resistant K. pneumoniae producing KPC, CTX-M or the OXA-48 
like carbapenemase OXA-232. While imipenem/vaborbactam and ceftazidime/vaborbactam 
were active against meropenem/vaborbactam mutants of CTX-M and OXA-232 producers, 
an alternative combination could not be found that was active against a 
meropenem/vaborbactam resistant mutant derived from a KPC producer. Furthermore, 
ceftazidime/vaborbactam resistance was identified in CTX-M producers as being caused by 
over-production of the CTX-M enzyme. Imipenem/vaborbactam resistance was not identified 
in this background. Finally, demonstrated for the first time that combining 
avibactam/ceftazidime with meropenem/vaborbactam overcomes meropenem/vaborbactam 
resistance in all mutants generated. Therefore, we conclude that combining these β-
lactam/β-lactamase inhibitor combinations in the same patient shows great potential in the 
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“Without urgent, coordinated action by many stakeholders, the world is headed for a post-
antibiotic era, in which common infections and minor injuries which have been treatable for 
decades can once again kill” 




























1.1. The History of Antibiotics 
 
Antibiotics, more specifically antibacterials, refer to substances capable of killing bacteria 
(bactericidal) or inhibiting their growth (bacteriostatic). The term is used generally to 
encompass both natural as well as synthetic products. The first antibiotic made available for 
clinical use was the anti-pseudomonal drug; pyocyaneoprotein, later referred to as 
pyocynase. It was successfully introduced by Ivan Honl (1866-1936) and Jaroslav Bukovský 
in 1911 to combat infections of the pharynx and larynx and was used continuously until the 
end of the first world war , where it was discontinued due to concerns over toxicity (1).  
Arguably, the most important antibiotic discovery was made in 1928 by Sir Alexander 
Fleming. Fleming noticed that Staphylococcus aureus contaminated with the mould 
Penicillium notatum showed an altered morphology which was due to bacterial cell lysis. He 
hypothesised that there must be some sort of lytic compound being produced by the 
Penicillium mould, which he subsequently named penicillin (2). However, Fleming was not 
responsible for the large-scale synthesis, purification and clinical testing of penicillin that 
confirmed its therapeutic potential as a bactericidal drug and made possible its use in the 
clinic (3, 4). The credit for this feat is often given to Howard Florey (1898-1968) and Ernst 
Chain (1906-1979), but, in reality, this would not have been possible if not for Norman 
Heatley (1911-2004), who perfected the purification of penicillin, allowing sufficient quantities 
to be made and further tested (5). Penicillin was introduced in the clinic in 1941, where it was 
used to treat Albert Alexander for a scratch on the inside of his mouth (6). This heralded 
the first use of possibly the most successful class of antibiotics to date; the β-lactams. 
Perhaps more importantly, Fleming shone the light onto the phenomenon of antibiosis. 
This term describes the ability of microorganisms to kill other microorganisms by the 
production and subsequent secretion of chemicals. The discovery of penicillin was the 
first observation of this famous phenomenon, that later lead to the discovery of several 
other antibiotics during the 19th century (7).  
The first use of the term ‘antibiotic’ was by Selman Waksman (1888-1973), who was later 
credited as being the ‘Father of Antibiotics’. The first antibiotic he discovered was 
Actinomycin which was isolated from Actinomyces antibioticus (8, 9). Waksman later worked 
on the discovery and isolation of the first member of the aminoglycoside antibiotics: 
streptomycin produced by the common environmental bacteria Streptomyces griseus. In 
total, Waksman identified over 20 new natural antibacterial substances using a screening 
technique of looking for inhibitory zones of growth around colonies of soil dwelling bacteria 





1.2. Current Bacterial cell targets  
 
Importantly, antibiotics must exert their effect with minimum cross reactivity on human cells. 
This makes it more difficult to find antibiotics that act on bacterial specific pathways. 
Currently, all antibiotics exploit one of five bacterial targets (11). What is common for all 
targets is their vital function for bacterial cell growth as interference with the function of any 
of these targets either results in cell lysis or a negative impact on cellular growth. These are:  
1.  Bacterial cell wall biosynthesis. Antibiotics that inhibit the bacterial this pathway include 
the β-lactams (e.g. penicillin see section 1.3.) and glycopeptides (e.g. vancomycin) which 
inhibit penicillin binding proteins (PBPs) and peptidoglycan monomers respectively (12, 13). 
Both result in loss of cell shape an osmotic instability leading to bacterial cell lysis.  
2. Protein synthesis. Bacterial protein synthesis is sufficiently different to human protein 
synthesis to allow it to be an effective antibiotic target. Specifically, it is the interaction with 
the ribosomal subunits that leads to inhibition of protein synthesis. Macrolides (e.g. 
azithromycin), linezolid and chloramphenicol inhibit the larger 50s subunit. Whereas the 
smaller 30S ribosomal subunit is the target of aminoglycosides (e.g. streptomycin) and 
tetracyclines (e.g. minocycline) (11, 14).   
3. Nucleic acid synthesis. DNA synthesis is an essential bacterial pathway that can be 
inhibited by the synthetic quinolones (e.g. ciprofloxacin) which act on DNA topoisomerase II 
(DNA gyrase) in Gram negative bacteria and a gyrase homologue; DNA topoisomerase IV in 
Gram positive bacteria. These enzymes are responsible for regulating the torsional stress 
associated with DNA supercoiling (11, 15). Inhibition of these enzymes results in the 
sheering of DNA leading to cell death. Contrastingly, rifampicin prevents DNA dependant 
RNA synthesis by inhibiting DNA dependant RNA polymerase. This stops bacterial 
transcription from being able to take place (16).  
4. Folate synthesis. The folate synthesis pathway is required for nucleotide synthesis and 
can be inhibited by antibiotics such as trimethoprim and sulphonamides. Trimethoprim 
inhibits dihydrofolate reductase, preventing the conversion of dihydrofolate to 
tetrahydrofolate (17). Whereas sulphonamides prevent the conversion of para-aminobenzoic 








5. Cell membrane structure. Finally, polymyxins (e.g. colistin) and daptomycin target the 
bacterial cell membrane. Polymyxins bind to LPS with a higher affinity than Mg2+ and Ca2+ 
ions, which are required for LPS stability. This results in an altered cell membrane 
permeability leading to cell death (19). Whereas daptomycin binds to LPS, inserting its 
lipophilic tail which causes membrane depolarisation and a rapid efflux of potassium ions 
resulting in cell death (20) (21).  
 
1.3. Antibiotic Resistance  
 
Antibiotic or antibacterial resistance (ABR) is a term that describes a phenotype whereby 
bacteria show a lack of sensitivity to an antibiotic of which they previously were sensitive. 
Antibiotics are invaluable as a means to cure patients suffering from bacterial infections. 
Therefore, in the clinic ABR refers to whether or not a specific antibiotic treatment will be 
able to succeed or indeed fail. ABR can occur due to the acquisition of resistance 
mechanisms or the presence of existing intrinsic mechanisms that are able to promote 
survival in the presence of the antibiotic. Resistance mechanisms fall into four main 
categories: Target site modification (including enzymatic modifications), acquisition of a non-
susceptible target, altering outer membrane permeability and enzymatic degradation of the 
antibiotic (see section 1.4.) (22). It is important to understand that antimicrobials, more 
specifically antibacterial, are by and large semi-synthetic and show similarity to natural 
products. Therefore, the evolution of ABR is understood to have occurred naturally over 
millions of years and is not by any means a new phenomenon. It is thought that ABR 
mechanisms could have originated in antibiotic producing organisms (such as Streptomyces 
griseus) as a means of protecting themselves against the antibiotics they produce. However, 
it is clear that the increased utilisation of antibiotics worldwide is accelerating this process 
and providing a significant selection pressure, leading to the selection of ABR in many 
bacterial species (23). This is no more important than in the case of hospital acquired 
infections (infections that are not present at the time of admission and not occurring 48 hours 
after admittance (24)). Due to the fact that antibiotics select for resistant bacteria, it therefore 
follows that environments with higher antibiotic levels would have more resistant bacteria 
(25). Consequently, hospitals tend to have a high incidence of antibiotic resistant bacterial 
isolates. This is highlighted by the number of infections caused by bacteria resistant to one 






ABR has been described as one of the direst threats currently facing the public health sector 
(27, 28). ABR frequently causes treatment failure, which is often fatal, especially in 
immunocompromised individuals (29). Indeed, it is estimated that ABR contributes to the 
deaths of roughly 50,000 people across Europe and the United States and 700,000 people 
globally (28). However, the full extent of the threat that ABR poses globally is surely an 
underestimation due to the lack of information and surveillance regarding this current issue. 
The threat that ABR has on public health is by no means the only issue, the financial burden 
surrounding increased ABR is estimated to cost the NHS £1.5 billion and $41 billion in the 
US annually (30).   
We have seen the problems of increased mortality, morbidity as well as the increased 
financial issues surrounding ABR. However, worryingly, this is exacerbated by the lack of 
discovery of new antimicrobial classes. Figure 1 shows that the last antimicrobial class 
discovered, which has been used in clinical practice, was the Lipopeptides in 1987, almost 
30 years ago, highlighting the need, not only to discover new antibiotics but to also protect 
our current antibiotics (31, 32). The reason for the reduced number of antibiotics reaching 
clinical trial is largely due to pharmaceutical companies having little economic incentive to 
develop drugs that combat infectious disease. Not only are antibiotics prescribed for short 
treatments, but they also end up being used less and less over time due to the inevitable 
intervention of antibiotic resistance. Therefore, there is little incentive for pharmaceutical 












Figure 1. A timeline presenting the ‘Golden era’ of antibiotic discovery. The first 
antibiotic discovered was penicillin in 1928, isolated from the mould Penicillium spp. Many 
other naturally derived antibiotics soon followed including: aminoglycosides, glycopeptides, 
pleuromutilin’s etc. Around 20 classes of antibiotics where discovered between 1928 and 
1987 leading to this period being referred to as the apt ‘Golden era’ of antibiotic detection 
and synthesis. From 1987 onwards, no new antibiotics reached the clinic meaning we are 
currently in a discovery void and have been for over 30 years. Figure taken from (34). 
 
Additionally, the situation surrounding ABR is not helped by the important roles that 
antibiotics provide in the marine and agricultural industries. Antibiotics are frequently added 
to animal feed or water to act as a growth promoter but also to provide a mass prophylaxis 
treatment to prevent the outbreak of disease (35, 36). It is known that this is having a 
significant impact on the prevalence of ABR. A great example of this is the case of 
vancomycin resistance. Vancomycin is a glycopeptide antibiotic produced by the 
environmental soil bacterium; Streptomyces oreintalis. Therefore, vancomycin resistance is 
common in environmental bacterial species, the most clinically significant of which is 
Enterococcus faecium. The prevalence of vancomycin resistant enterococci (VRE), specially 
E. faecium, in farm animals was found to increase significantly due to the use of  a 
glycopeptide analogue avoparcin as a prophylaxis treatment and growth promoter. 
Therefore, using avoparcin provided a strong selection pressure for glycopeptide resistant 
bacteria. Consequently, the use of avoparcin ceased and the prevalence of VRE in farm 






In conclusion, the threat of ABR is not one that has a simple solution. It is a multifaceted 
problem consisting of an increase in occurrence of antibiotic resistant bacterial pathogens, 
exacerbated by the lack of discovery of new antibiotics combined with the increase in 
utilisation of antibiotics in the public health and agricultural sectors. If ABR is not combatted 
urgently and universally it is estimated that deaths could rise to as high as 10 million per 
year by 2050, exceeding the deaths attributed to cancer, costing the healthcare system an 
additional $100 trillion (28). What is more, since the discovery of penicillin, we have been 
unable to pinpoint a single antibiotic class which can bypass the development of resistance 
(25, 38).  
 




The antibiotic class of β-lactams includes the ‘original’ antibiotic penicillin discovered by Sir 
Alexander Fleming as well as penicillin derivatives and cephalosporins, carbapenems and 
monobactams. Collectively they make up the most commonly prescribed group of antibiotics 
and have been estimated to account for up to 53% of total antibiotic sales and consumption 
globally (figure 2). The reason for their popularity is largely down to their specificity combined 
with impressive potency as a bactericidal antibiotic. It is for this reason that β-lactams have 
become vital for the treatment of infections caused by the Gram-negative human pathogens 
Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. It was the 
elucidation of the structure of penicillin in 1945 by Dorothy Hodgkin that allowed the 
mechanism of action to be defined. The structure of β-lactams can differ to varying degrees, 
however all of contain a nitrogen based β-lactam ring. It is their varying ring structures and 
side chains that lead to the increased activity/potency seen with the newer members of the 







Figure 2. Global antibiotic consumption between 2000 and 2010. Both broad-spectrum 
penicillins, narrow-spectrum penicillins, cephalosporins, carbapenems and monobactams 
belong to the β-lactam class of antibiotic. This graph shows the how important β-lactams are 
and how frequently they are prescribed. The X axis shows consumption as the log of daily 












1.4.2. β-lactam subgroups  
 
  
Figure 3. The chemical structure of the four main sub-groups belonging to the 
antibiotic class of β-lactams. The main ring structures are shown on the right of each 
antibiotic, with the sidechains denoted by the letter ‘R’. We can see that each group within 
the β-lactam class contain a 4 membered, nitrogen containing β-Lactam ring, highlighted in 
red. Penicillin contains a thiazolidine ring, cephalosporins contain a dihydrothiazinic ring. We 
see that carbapenems contain a very similar overall structure to penicillin’s, however the 
Sulphur group in the thiazolidine ring is replaced with a Carbon atom. Monobactams do not 





Penicillin G otherwise called benzylpenicillin (1st generation penicillin) was the original, 
natural β-lactam initially isolated from the mould Penicillium notatum (2). It was the first β-
lactam clinically used. It showed a range of activity that only included Gram-positive bacteria, 
specifically, infections caused by Streptococcus, Staphylococcus and Enterococcus species 
(41). However, penicillin G showed limited activity against β-lactamase producing Gram-
positive cocci, such as blaZ (penicillinase) producing S. aureus (42). This is because 
penicillin G showed vulnerability to acid hydrolysis. To combat the action of these enzymes, 
larger, semi-synthetic penicillins such as methicillin (2nd generation penicillin) were 
synthesised. Methicillin was able to evade binding of these enzymes, whilst still retaining 
bactericidal activity (43). However, methicillin still only showed a narrowed spectrum, specific 
to Gram-positive bacteria. The addition of a hydrophilic group to the α-carbon produced the 





first penicillin that showed an extended activity and could target both Gram-positive and 
Gram-negative bacteria (44, 45).  
Once the structure of penicillin was solved by Dorothy Hodgkin, it was found that there were 
several constituents that were central to penicillin’s function as a bactericidal antibiotic. 
These include: the β-lactam ring which is vital as it shows steric similarity to D-Ala-D-Ala 
(see section 1.4.3.) allowing the acylation of PBPs (46). The carboxyl group at the C3 carbon 
which facilitates irreversible binding to the PBP active site. The carbonyl group is highly 
susceptible to nucleophiles as it is prone to losing its’ hydrogen and subsequently becoming 
negatively charged, allowing it to interact with the NH3+ on the lysine residue present in the 
PBP active site. The sulphur group is thought to promote the electrophilic potential of the 
carbonyl group, further facilitating binding to the PBP active site (39, 47, 48). Modifications of 
the R group present at the C6 carbon give rise to penicillin’s with different potency’s but also 
different acid-hydrolysis sensitivity (47, 49).  
 
 
Figure 4. Chemical structures of first, second and third generation penicillins. Figure 
was made using ChemDraw professional 16.0. All penicillins contain the invariable β-lactam 








Even with the synthesis of the aminopenicillins, the activity on Gram-negative pathogens 
remained limited, largely due to the existence of intrinsic resistance mechanisms (see 
section 1.5.) and the presence of β-lactamases. This combined with the mobilisation and 
subsequent dissemination of the TEM-1 and SHV-1 β-lactamases (see section 1.5.) 
provided a significant blow in the antibiotic ‘arms race’. The first cephalosporin, 
cephalosporin C, was discovered in 1948 from the common saprophytic mold; 
Cephalosporium acremonium (50, 51). Cephalosporins tend to have a much greater 
spectrum of activity with regards to Gram-negative pathogens. However, this comes at a 
price, as the Gram-negative activity increases with the later generations of cephalosporins, 
the Gram-positive activity becomes compromised. While penicillins contain a 5-membered 
thiazolidine ring, cephalosporins differ in their structure as they contain a 6-membered 
dihydrothiazinic ring instead (52). Several generations of cephalosporins have been made 
and grouped based on their in vitro activity and chemical structure. Newer generations of 
cephalosporins show greater activity against Gram-negative bacteria. Cephalosporins 
remain, to this day, some of the most frequently prescribed antibiotics in the U.S. (53, 54). 
Historically, cephalosporins have not been prescribed to target infections caused by Gram-
positive bacteria (55). An overview of the different generations cephalosporins and their 
activity is provided below.  
1st Generation Cephalosporins. First-generation cephalosporins, such as cephalothin, tend 
to have a reduced or comparable potency to that of penicillins. However, advantages of 
cephalosporins include the insensitivity to penicillinases, acid-hydrolysis stability as well as 
the ability to target Gram-negative bacteria. The first generation cephalosporins show the 
greatest activity towards Gram-positive bacteria of all the cephalosporins (53).  
2nd Generation Cephalosporins: Second-generation drugs show an increased activity against 
Gram-negative bacteria; however this is at the cost of a reduced activity against Gram-
positive bacteria. Second generation cephalosporins include the cephamycins (e.g. cefoxitin) 
and oxyimino cephalosporins (e.g. cefuroxime). Cephamycins were initially isolated from 
several members of the Streptomyces spp. including Streptomyces lactamdurans. 
Cephamycins differ in their structure from first-generation cephalosporins, these are: a 
methoxyl group as well as a D-α-aminoadipic acid added to the C7 carbon position. 
Additionally, cephamycins also show a variety of side chains present at the C3 carbon 
position. It is thought that these modifications extend the activity against β-lactamase 
producing Gram-negative bacteria. Activity against members of the Proteus genus is 





carbon position of the acylamino chain. They are approved for use against many Gram-
positive bacteria such as: S. aureus and Streptococcus pneumoniae. They are also 
approved for use against Gram-negative bacteria such as Escherichia coli and specifically, 
Haemophilus influenzae (53). Usefully, cefuroxime can be used to treat certain types of 
meningitis (e.g. caused by Neisseria sp.), as it is the only second-generation drug capable of 
passing the normally restrictive blood-brain barrier (59). 
3rd and 4th Generation Cephalosporins: Third (e.g. ceftazidime) and fourth (e.g. cefepime) -
generation cephalosporins are generally grouped together as they are both described as 
showing an extended-spectrum of activity with the only significant difference being their 
respective Gram-positive activity. Certain members of the third and fourth-generation 
cephalosporins have impaired Gram-positive activity compared to first and second-
generation cephalosporins but even greater Gram-negative activity (53). Similarly to 
cefuroxime, third-generation cephalosporins can cross the blood-brain barrier meaning they 
can be used to treat meningitis, caused by a wide variety of organisms (60). Third-
generation cephalosporins are usually reserved in the clinic as the first-choice antibiotic for 
the treatment of gonorrhoea infections (61). Cefepime shows an improved activity against 
Gram-negative bacterial infections, including those caused by: Serratia marcescens, 
Citrobacter freundii and Enterobacter cloacae (62). Importantly, fourth-generations are 
capable of being used in combination with other antibiotic classes, mainly aminoglycosides 
and fluoroquinolones for the treatment of persistent P. aeruginosa  in cystic fibrosis patients 
(63-65).  
5th Generation Cephalosporins: More recently, two fifth-generation cephalosporins have 
been made: ceftobiprole in 2002 and ceftaroline in 2005. However, their labelling as fifth-
generation cephalosporins remains a disputed term. Ceftobiprole was initially developed as 

















































































































































































































1.4.2.3. Carbapenems  
 
Carbapenems show the most potent activity of all the sub groups within the β-lactam 
antibiotic class (67). Because of this, carbapenems are often labelled as ‘last-resort’ 
antibiotics for use when patients are not responding to alternative antibiotic treatments (68). 
Carbapenems have, not only the most potent activity, but also the broadest spectrum of 
activity being able to target Gram-positive, Gram-negative, including aerobic and anaerobic 
bacteria. It is for this reason that carbapenems remain the favoured therapy for serious multi 
drug-resistant infections, especially those caused by the Gram-negative bacterial species: E. 
coli, K. pneumoniae and P. aeruginosa (69). The first carbapenem to be discovered was 
thienamycin, produced by the Gram positive heterotrophic soil bacterium; Streptomyces 
cattleya (70). This bacterium is of great interest in the synthesis of new β-lactams as it is 
also known to produce the second-generation cephalosporin; cephamycin C as well as the 
first-generation penicillin; penicillin N (71). The sulphur atom in the five-membered 
thiazolidine ring of penicillins is replaced by a carbon atom in carbapenems. A double bond 
is introduced between the carbon atoms C2 and C3 and the C6/C7 acylamino group present 
in penicillins and cephalosporins is replaced by a hydroxyethyl group. Unfortunately, while 
thienamycin showed great potential in vitro, it could not be successfully introduced for clinical 
used due to its poor in vivo stability. This lead to a derivative of thienamycin being 
synthesised by the addition of a formamidine group at the C3 carbon position. Imipenem 
(thienamycin-formamidine) subsequently became the first clinically available carbapenem 
(71). However, it was quickly realised that imipenem was sensitive to hydrolysis by the 
human renal dehydropeptidase: DHP-1, which meant that it had to be co administered with a 
DHP-1 inhibitor such as betamipron or more commonly cilastatin (72, 73). To negate the 
need to co-administer imipenem with a dehydropeptidase inhibitor, a methyl group was 
introduced at the C1 position. This new carbapenem was named meropenem and was non-
susceptible to hydrolysis by renal dehydropeptidase. Meropenem also contains a unique ‘R’ 
group side chain at the C2 position that greater enhances its Gram-negative bactericidal 
activity (figure 6) (67, 74). Carbapenems are stable against a large selection of β-
lactamases, including the Ambler class A enzymes: TEM-1, SHV-1, CTX-M and the class C 
enzyme CMY. It is thought that this important property shown by carbapenems is due to the 







Figure 6. Chemical structure of Carbapenems. Figure was made using ChemDraw 
professional 16.0.  
1.4.2.4. Monobactams 
 
Like carbapenems, monobactams were originally discovered from producer bacteria, 
whereas penicillins and cephalosporins (with the exception of cephamycins) are produced by 
fungi. However, that is where the similarities to carbapenems end. The only chemical 
similarity monobactams have to the other members of the β-lactam class of antibiotics, is 
that they contain the invariable 4-membered nitrogen-containing β-lactam-ring. Unlike 
penicillins, cephalosporins and carbapenems, monobactams do not contain a fused ring 
system. Instead, monobactam derivatives contain a methoxyl group present at the C3 
carbon position which improves its stability against β-lactamases. Monobactams initially 
showed limited Gram-negative activity and no Gram-positive activity. To try and improve this, 
alterations of the C3 carbon acylamido chain were introduced. Unusually, monobactams also 
contain the ‘N-SO3H’ group, which is an incredibly rare occurrence for a natural product 
(figure 7) (75). The most important, and first clinically available member of the monobactam 
family was aztreonam. Aztreonam was discovered as a new β-lactam class in 1981 originally 
identified as a metabolic product of the Gram-negative soil bacterium; Chromobacterium 





aerobic bacteria (including P. aeruginosa) and again has poor Gram-positive activity. 
However, the Gram-negative activity is comparable in its bactericidal potency to that of third 













Figure 7. Chemical structure of the monobactam Aztreonam. Figure was made using 
ChemDraw professional 16.  
1.4.3. Mechanism of action  
 
In a bacterium, the cell wall is vital for maintaining cell shape, rigidity and osmotic stability 
(77). It is made of a polymer compromising of alternating N-acetylglucosamine (GlcNAc) and 
N-acetylmuramic acid (MurNAc) monomers joined by β,1-4 glycosidic bonds. However, 
these bonds are not enough to provide the strength required to maintain cell shape or 
rigidity, instead this is achieved via the trans-peptidase activity of PBPs (77, 78). It is these 
PBPs that are essential for bacterial cell viability. Each MurNAc monomer contains a 
pentapeptide: L-Ala-γ-D-Glu-L-Lys (or -meso-diaminopimelic acid in Gram-negative 
bacteria)-D-alanyl-D-alanine sub-unit, which serves as a cross link between the glycan 
polymers through PBP activity (79). It is the high molecular mass (HMM) PBPs that contain 
this essential trans-peptidase activity but can also have glycosyltransferase activity such is 
the case with class B PBPs (78, 80). The transpeptidase activity of HMM PBPs cleaves the 
terminal D-Ala sub-unit of the pentapeptide chain present on the MurNAc monomers. This is 
achieved by the formation of a Ser-D-Ala ester bond. This bond is highly reactive and can 
interact with the diaminopimelic acid residue of another pentapeptide chain. This results in 





low molecular mass (LMM) PBPs which serve to provide D, D-carboxypeptidase activity. 
They cleave the terminal D-alanine from the pentapeptide of MurNAc, preventing the ability 
of MurNAc to act as a donor for further cross linking. This D, D-carboxypeptidase activity 
serves as an additional layer of control in peptidoglycan synthesis. An overview of 
peptidoglycan synthesis is provided in figure 8 (82-84). It is the essential trans-peptidase 
activity of PBPs, that β-lactams can successfully inhibit. They do this by covalently binding to 
the active site of PBPs and subsequently inactivating the trans-peptidase activity. 
Specifically, it is the electrophilicity of the carbonyl group in the β-lactam that enables 
covalent binding and modification of the active serine residue of the PBP (85). It was first 
proposed by Tipper and Strominger in 1965 that β-lactams show extensive structural and 
steric similarity to D-Ala-D-Ala (figure 9) which is present in the MurNAc pentapeptide 
subunit (46). This explains the ability of β-lactams to bind to the active site of PBPs. The loss 
of the cross-linking activity combined with the cell-wall recycling action of peptidoglycan lytic-
trans-glycosylases (see figure 10) leads to the degradation of the cell wall. This results in a 



























Figure 8. An overview of peptidoglycan bio-synthesis and PBP action. A) 
Peptidoglycan synthesis begins in the bacterial cytoplasm with the synthesis of MurNAc and 
GlcNAc monomers. B) These are then transported to the periplasm where they are 
polymerised through the action of glycosyltransferase activity of class A HMM PBPs. This 
results in the formation of ‘immature’ peptidoglycan. The pentapeptide chain present in 
MurNAc is then crosslinked to other MurNAc/GlcNAc polymers through the transpeptidase 
activity of class B PBPs resulting in the formation of ‘mature’ peptidoglycan. Figure taken 







Figure 9. The steric and structural resemblance of the β-Lactam Penicillin compared 
to D-Ala-D-Ala, present in the pentapeptide of the peptidoglycan monomer MurNAc. 
Elements of the chemical highlighted in red are present in both penicillin and D-Ala-D-Ala. 
Figure was made using ChemDraw professional 16. Figure based on (89).  
 
 
1.4.4. Cell wall recycling 
 
The bacterial cell wall is by no means a static structure. It undergoes a continuous cycle of 
breakdown, followed by recycling and finally re-synthesis. It is estimated that 50% of the 
bacterial cell wall is turned over in one generation. During the cell wall recycling process, the 
majority of the peptidoglycan constituents are released back into the cytoplasm via active 
transport and then used to rebuild the cell wall. Alternatively, the cell wall constituents can be 
used as an effective energy source (90). It is this process of cell wall recycling that β-lactams 
interfere with. We have seen previously that β-lactams inhibit the crosslinking ability of 
certain PBPs. Therefore, no new peptidoglycan can be made. However, whilst β-lactams are 
inhibiting the synthesis of new peptidoglycan, cell wall recycling and more importantly, cell 
wall degradation continues to take place. Eventually it is the action of peptidoglycan-lytic-
transglycosylases that lead to the complete breakdown of the cell wall and consequently the 
death of the bacterial cell. A summary of the bacterial cell wall recycling process is provided 
in figure 10. While bacterial cell wall recycling is important for recovering resources, it can 
also serve as a mechanism for the recognition of cell wall acting antibiotics such as β-
lactams. This recognition allows the bacterium to use the cell wall recycling process as a 
switch to turn on intrinsic resistance mechanisms, such as the production of the AmpC β-




























Figure 10. An overview of cell-wall recycling and its link with β-lactamase production. 
Bacterial cell wall recycling is initiated in the periplasm by the hydrolysis of MurNAc/ GlcNAc 
polymers through the action of peptidoglycan lytic transglycosylases (e.g. Slt70). This results 
in the formation of MurNAc/GlcNAc peptides which are actively pumped in to the cytoplasm 
for recycling by the action of the AmpG permease (92, 93). NagZ, a glucosaminidase, 
removes the GlcNAc sugar residue to produce 1,6 anhydro-MurNac peptides (serve as 
AmpR activators) (94, 95). The amidase AmpD can then cleave these molecules to form 1,6 
anhydro-MurNac, which can re-enter the peptidoglycan biosynthesis pathway through an 
Mpl dependant-catalysed reaction to form UDP- MurNAc pentapeptides (AmpR repressors) 





the balance between AmpR activator and repressor ligand concentration, and so the activity 
of AmpR and transcription levels of the ampC β-lactamase gene. Figure taken from (96). 
 
1.5. Antibiotic resistance against β-lactams 
 
Resistance to β-lactams can occur through four main mechanisms. The first, and by far the 
most clinically significant, is the hydrolysis of β-lactams through the action of β-lactamase 
enzymes (an in-depth overview of β-lactamases is provided in section 1.6.) (89). It is 
approximated that the global financial impact of β-lactamase producing bacteria is in excess 
of $30 billion per year (97). The second resistance mechanism is due to the presence of 
target site modifications. This is where the target of the antibiotic is altered, through 
mutation, so that the antibiotic is no longer, or is less able to bind. Importantly, these 
mutations must be sufficient to avoid the action of the drug but also maintain their function. 
This particular mechanism is rare in Gram-negative bacteria but is important in Gram-
positive bacteria such as S. pneumoniae and also in Mycobacterium tuberculosis (98). The 
third is the acquisition of a non-susceptible target such is the case with Methicillin-resistant 
S. aureus (MRSA). The final mechanism of β-lactam resistance is achieved by altering the 
bacterial cell permeability, either by blocking entry through porins and/or through active 
removal using efflux pumps. Frequently, more than one mechanism is present at the same 
time in the same bacterium. 
 
1.5.1. Acquisition of a non-susceptible target 
 
We have already seen the essential role that high-molecular mass PBPs play with regards to 
cellular rigidity and osmotic stability of the bacterial cell. Therefore, organisms cannot evade 
β-lactam action by simply discarding PBPs. However, mutation of PBPs to reduce binding 
and or acylation by β-lactams is possible. Perhaps the most famous example of the 
acquisition of a non-susceptible target is the acquisition of the mecA gene in S. aureus (99). 
The mecA gene was first identified in 1985 and was found to be the resistant determinant for 
MRSA (100). The mecA gene expresses a novel PBP that became commonly referred to as 
PBP2a or PBP2’. It is hypothesised that the mecA gene originated in the animal pathogen 
Staphylococcus sciuri and mobilised onto the staphylococcal cassette chromosome mec 
(SCCmec) allowing horizontal transfer between different Staphylococcus spp. (101, 102). β-
lactams interact with PBPs by forming a stable covalent complex which subsequently allows 





that the reduced sensitivity of PBP2a to β-lactams is due to a reduced acylation rate 
constant, resulting in a failure to form the initial non-covalent complex (103). The impact of 
Staphylococcus spp. carrying the mecA gene, is that they become resistant to Methicillin and 
many other β-lactams. However, several β-lactams have been identified that retain activity 
against the novel PBP2a. These are synthetic cephalosporins and carbapenems that are 
currently in different stages of development and display a specifically high affinity for PBP2a 
(104) (99). 
 
1.5.2. Target-site modification 
 
Organisms such as the Gram-positive S. pneumoniae achieve β-lactam resistance through 
alteration of their PBPs. Pneumococci such as S. pneumoniae possess five HMM PBPs 
which are thought to be of significant importance with regards to β-lactam resistance: 
PBP1A, PBP1B, PBP2A, PBP2B and PBP2X. They also contain a LMM PBP, PBP3 which is 
not thought to have an implication in β-lactam resistance (105).  
The alterations to these PBPs results in a greatly decreased affinity for many β-lactams, 
including third generation cephalosporins (106). These PBPs that have a low affinity for β-
lactams are encoded by mosaic genes. Mosaic PBPs are achieved by which part of the 
original PBP sequence is replaced by allelic variants in patches along the gene. These 
mosaic PBPs can differ in their sequence by up to 25% (107, 108). The origin of these 
patches of variation is thought to have occurred through horizontal gene transfer from non-
pathogenic commensal species (109). Mosaic PBPs are also an important β-lactam resistant 
determinant in other naturally transformable bacteria such as H. influenzae (110).  
 
1.5.3. Outer Membrane Permeability  
 
The outer membrane of Gram-negative bacteria provides an additional layer of defence 
against antibiotics. The membrane acts as a discriminatory barrier, restricting the entry of 
toxic substances and antibiotics. However, while the gram-negative outer membrane is 
notably impermeable, nutrients must still be allowed to enter the cell. They enter through 
outer membrane proteins called porins. Porins are substrate-selective channels that facilitate 
the entry of hydrophilic molecules less than 600 Da into the cell (111). Some hydrophilic 
antibiotics, such as β-lactams can also pass through these porins into the periplasmic space, 
while hydrophobic antibiotics (e.g. aminoglycosides and macrolides) use a lipid mediated 





has been well documented. The production of porins is often downregulated or modified to 
limit the entry of the antibiotic and therefore protect the antibiotic target. The downregulation 
of porins has been described in a wide selection of organisms including, but not limited to: E. 
coli, P. aeruginosa, K. pneumoniae and Enterobacter aerogenes (113). Many studies on 
porins are focused on OmpF and OmpC of E. coli because of the presence of almost 
identical proteins in many Gram-negative enteric species, for example K. pneumoniae 
contains OmpK35 (an OmpF homolog) and OmpK36 (an OmpC homolog) (114, 115).  A 
good example of the role or porin downregulation in antibiotic resistance is provided by 
resistance to the carbapenem ertapenem in K. pneumoniae. A CTX-M expressing clinical 
isolate was found to be ertapenem resistant, even though CTX-M is not considered to be a 
carbapenemase. It was found that the isolate was down-regulating the OmpK36 porin and 
that ertapenem sensitivity could be restored, via the introduction of an OmpK36 expressing 
plasmid (116). In another analysis, surveying of antibiotic resistant E aerogenes in a hospital 
found that 44% of 45 β-lactam resistant isolates, had reduced production of porins (117). For 
a more detailed overview of outer membrane permeability in K. pneumoniae, see section 
1.7.3.  
 
1.5.4. Efflux pumps 
 
Efflux pumps are present in both Gram-positive and Gram-negative bacteria and are located 
on the cytoplasmic membrane. Their genes are commonly found on the bacterial 
chromosome, though they have been found on mobile genetic elements. Efflux pumps are 
transport systems involved in the active expulsion of toxic substances (including antibiotics) 
(118). Efflux pumps can be divided in to five major families, these are: Major facilitator 
superfamily (MFS), multidrug and toxic efflux (MATE), resistance-nodulation-division (RND), 
small multidrug resistance (SMR) and ATP binding cassette (ABC). ABC efflux pumps use 
ATP-hydrolysis to provide the energy needed to extrude toxic substrates, whereas all 
remaining efflux families exploit proton motive force as an their energy source (119). Efflux 
pumps can either be substrate specific or are able to expel multiple substrates. Many 
antibiotic classes, including β-lactams are pumps (efflux pumps that are capable of 
conferring resistance to three or more classes of antibacterials are described as displaying a 
multi-drug resistance phenotype (MDR)). Therefore, it should be of no surprise that over-
production of efflux-pumps is seen as a resistance mechanism in both Gram-positive and 
negative bacteria. Over-production of efflux pumps has been described in several clinically 
important bacterial species including: AcrAB-TolC of E. coli and K. pneumoniae, MexAB-





of the RND family tripartite efflux pumps whose substrates include β-lactams. Although 
overproduction of these efflux pumps is thought to provide a role in acquired β-lactam 
resistance, resistance is usually a result of effluent pumps alone (120, 121). More 
commonly, over-production of efflux pumps is combined with the production of a β-
lactamases or down-regulation of porins or both.  
 




The most common mechanism of β-lactam resistance in Gram-negative bacteria is the 
hydrolysis of the antibiotic by β-lactamases (122) (123). Although the production of β-
lactamases is not the prominent resistant mechanism in Gram positive bacteria, it still poses 
a large threat in bacteria such as S. aureus (124). β-lactamases are responsible for 
hydrolysis of the β-lactam ring, subsequently inactivating the β-lactams’ bactericidal activity. 
The resulting product from β-lactam hydrolysis is inactive β-amino acids (35). Without the 
action of the β-lactam, the bacterium retains its transpeptidase cross-linking activity, allowing 
the cell wall to maintain its rigidity and prevent lysis. So far, in excess of 200 types of β-
lactamases have been discovered(89). β-lactamases carry out their function in the bacterial 
periplasm, which is also the location of β-lactam action and can either be carried on 
plasmids, transposons or intrinsically encoded on the bacterial chromosome (125). They are 
classified either according to the Ambler classification system based on their amino acid 
sequence and hydrolysis mechanism (123) or according to the Bush-Jacoby-Medeiros group 
system according to their functionality and substrate specificity (table 1) (126). Concerningly, 
all classes of β-lactamases can be found in the large Gram-negative family of 
Enterobacteriaceae which include the clinically relevant pathogens E. coli and K. 
pneumoniae (127). The increased prevalence of β-lactamases has followed the 
development  and increased consumption of new β-lactams. There are four distinct 
examples of this. The first was the dissemination of penicillinases in response to the use of 
aminopenicillins for treating Gram-negative infections. Penicillinases included the Ambler 
class A TEM-1 and SHV-1 enzymes, which show high potency against penicillins but a 
narrow spectrum of activity against cephalosporins (128). The second example was the 
mutation of TEM-1 and SHV-1 selected for by the increased usage of cephalosporins. These 
mutations enabled them to extend their β-lactam hydrolytic profile to include cephalosporins. 
This increase in activity to allow hydrolysis of larger substrates lend to these enzymes being 





the unexpected dissemination of the class A ESBL CTX-M, which became mobilised from 
the chromosome of the environmental bacterial species Kluyvera spp. (see section 1.9.2.1.) 
(131). The last and most recent example was the dissemination of enzymes capable of 
hydrolysing carbapenems. These carbapenem hydrolysing enzymes (carbapenemases) 
include the Ambler class A K. pneumoniae carbapenemase (KPC) (132), the Ambler class B 
metallo- β-lactamases: IMP, VIM, NDM. And finally, a variety of Ambler class D oxacillinases 

















Table 1.  β-Lactamase class and a 
description of enzyme type, host and 
substrate specificity. The Ambler class 
system divides β-lactamases into four 
distinct families: A, B, C and D. Ambler 
class A β-Lactamases contain 
penicillinases: TEM and SHV, ESBLS 
such as CTX-M and finally, 
carbapenemases such as KPC and 
SME. Ambler class C β-lactamases 
include the chromosomally encoded, 
cephalosporinase AmpC.  Ambler class 
D β-lactamases contain the oxacillinases 
OXA of which some are 
carbapenemases. Ambler class A, C and 
D are all serine β-lactamases (SBLs), so 
named due to the serine catalytic active 
site. The serine residue of SBLs works 
by becoming self-acylated following the 
hydrolysis of the β-lactam ring. SBLs 
show structural and steric similarity to 
PBPs, which explains their ability to bind 
β-lactams. However, Ambler class B  β-
lactamases show little structural 
similarity to SBLs and instead work 
though a zinc-dependant active site that 
requires water molecules to carry out β-
Lactam hydrolysis. Ambler class B β-
lactamases are referred to as metallo- β-
lactamases or MBLs due to their zinc-
dependency in their active site (123). 
MBLs can be divided in to three sub-
classes; B1, B2 and B3, depending on 
the amino acid sequence, number of 
zinc ions and coordinate water 
molecules present in the active site (135, 







Figure 11. Structural representation of β-lactam hydrolysis by β-lactamases. Figure 
was made using ChemDraw professional 16. 1. Overall hydrolysis mechanism common to all 
β-lactamases. 2. Mechanism of β-lactam hydrolysis by Serine- β-lactamases. SBLs utilise a 
serine residue to hydrolyse the β-lactam ring. They subsequently utilise a water molecule to 
de-acylate the acyl-enzyme intermediate allowing recycling of the enzyme 3. Mechanism of 
β-lactam hydrolysis by MBLs. MBLs utilise a metal ion, in this case zinc, to co-ordinate a 
hydroxide to attack the β-lactam ring.  
 
1.6.2. Serine -β-lactamase mechanism of hydrolysis 
 
As mentioned previously, SBLs are thought to be evolved from PBPs. Similarly, to PBPs, 
SBLs utilise a serine residue to hydrolyse β-lactams. However, they differ to PBPs in that 
they possess the ability to exploit a water molecule to subsequently de-acylate the acyl-
enzyme intermediate (figure 11). This allows the enzyme to be recycled and therefore able 
to be present for subsequent hydrolysis reactions. All SBLs contain an SXXK motif whereby 
the serine is the active residue, used as a nucleophile. Deprotonation of this serine residue 
using a general base creates a potent nucleophile which can subsequently carry out a 
nucleophilic attack on the β-lactam ring, resulting in the formation of an acyl-enzyme 
intermediate (figure 11). The acyl-enzyme intermediate is then resolved by the use of a 
water molecule previously activated by the general base. The three different ambler classes 
of SBLs (A, C and D) differ in the exact detail of their hydrolysis mechanism as they utilise 





1.6.2.1. Class A 
 
It is widely accepted the class A SBLs utilise the Glu166 residue as the general base, which 
carries out the deprotonation of the water molecule allowing de-acylation of the acyl-enzyme 
intermediate. However, the exact identity of the general base responsible for deprotonation 
of catalytic serine residue remains a more contentious topic. One hypothesis states that 
Glu166 is also involved in the acylation reaction, whereby it deprotonates a water molecule 
which can subsequently deprotonate the catalytic Ser70. Alternative theories state the 
involvement of the Lys73 residue and a combinative mechanism using both Glu166 and 
Lys73 (137). However, an NMR analysis of the TEM-1 enzyme showed that the Lys73 
residue had a pKA of >10 meaning that it is unlikely that this could act as a proton acceptor 
to allow the deprotonation of the Ser70 (138). Class A SBLs contain an Arg244 residue that 
is responsible for the sensitivity to classical β-lactamase inhibitors such as clavulanic acid 
(see section 1.6.1.) (139).  
 
1.6.2.2. Class C 
 
Similarly, to class A SBLs, the mechanism of hydrolysis by class C SBLs remains poorly 
understood. There is a clear lack of an equivalent Glu166 in class C SBLs to facilitate the 
de-acylation process. It is theorised that the Tyr150 residue could potentially act as the 
general base for this reaction. The protonation of Tyr150 has been observed in an analysis 
of the structure of AmpC, thus supporting the theory that Tyr150 could act as a proton 
acceptor (140, 141). Recently, the amino acid residue responsible for the acylation reaction 
has been elucidated. This is the Lys67 residue. It is also thought that Ser64, Asn152, and 
Ala220 play a role in the protonation of Tyr150 and Lys 67 (142). Class C SBLs lack the 
Arg244 residue that is present in class A SBLs. This means that class A SBLs are 
insusceptible to β-lactamase inhibitors such as clavulanic acid (139).  
 
1.6.2.3. Class D 
 
The mechanism of hydrolysis by class D SBLs is far better understood. The presence of 
carbamylated Lys70 residue is thought to provide the deprotonation potential for both the 
activation of the catalytic Ser67 for the acylation of the β-lactam, but also the water molecule 
allowing de-acylation of the enzyme (143, 144). Again, class D SBLs do not contain an 





clavulanic acid. However, they are sensitive to reversible non-β-lactam β-lactamase 
inhibitors such as avibactam (see section 1.5.3.2.) (145).  
 
1.6.3. Metallo- β-lactamases mechanism of hydrolysis 
 
The first identified MBL was the chromosomally encoded enzyme BcII in 1967, produced by 
the Gram-positive bacterium Bacillus cereus (146). They differ to SBLs not only due to their 
metal ion dependency but also their hydrolytic mechanism. Their substrate profile includes 
penicillins, cephalosporins and carbapenems (147). MBLs can be found as chromosomally 
encoded enzymes such as L1 of Stenotrophomonas maltophilia or mobilised on plasmids 
such as the IMP, VIM and NDM enzymes and can therefore be found in many bacterial 
species. MBLs are  of clinical importance, as they are able to confer carbapenem resistance 
(148).   
All MBLs contain an αββα motif which contains a metal ion binding site in the β sandwich 
(149). There are three distinct sub classes of MBLs, that differ by the number of metal ions in 
their catalytic site, but also their hydrolytic mechanisms. Class B1 MBLs usually contain two 
zinc ions locate in the Zn1 and Zn2 sites. The coordination of these metal ions is completed 
by two water molecules, one of which bridges the two metal ions whereas the other is bound 
to the Zn2 zinc ion. It is thought that the Zn1 zinc ion is responsible for the catalytic activity, 
however this is heavily debated (150). The substrate profile of class B1 MBLs includes 
penicillins, cephalosporins and carbapenems. Class B2 MBLs utilise a single zinc ion bound 
in the Zn2 site to activate the nucleophilic water molecule (151, 152). The catalytic domain is 
comparatively narrower than that of class B1 MBLs. This is theorised to be the reason why 
class B2 MBLs have a limited substrate specificity directed mainly at carbapenems (153). 
The hydrolytic mechanisms of class 3 MBLs remains relatively poorly understood compared 
to the other classes. It is thought that class 3 MBLs utilise two zinc ions located at the Zn1 
and Zn2 sites, however the zinc ion coordination differs to that of class 1 MBLs (136). Class 
3 MBLs are able to hydrolyse penicillins, cephalosporins and carbapenems, with reduced 
efficiency against carbapenems compared to class 1 and 2 MBLs (153). All classes of MBLs 









1.7. β-lactamase Inhibitors  
 
As a result of the continual consumption and prescription of β-lactams, the selection 
pressure on β-lactamase carrying bacteria will only continue to increase. This is of greatest 
concern in Gram-negative Enterobacteriaceae family, whereby E. coli and K. pneumoniae 
are the most important members. It is also of concern in bacteria belonging to the non-
fermenting Gram-negative bacilli: S. maltophilia, A. baumannii and P. aeruginosa (155). We 
are currently reaching a dire situation in which these Gram-negative pathogens are 
becoming resistant to last resort antibiotics such as carbapenems. Promisingly, β-lactamase 
inhibitors have been discovered and as the name suggests, inhibit the β-lactamase 
hydrolytic activity, restoring the sensitivity and bactericidal activity to β-lactams used in 
combination with them. So far, several class A β-lactamase inhibitors are available for 
clinical use including clavulanic acid, tazobactam and sulbactam. More recently avibactam 
and vaborbactam have been licensed for clinical use and have activity against class A, C, 
and D and class A and C β-lactamases, respectively (156, 157).  
 
1.7.1. Classical β-lactamase inhibitors 
 
Since the discovery of β-lactamases in the 1940s efforts soon became focused on finding 
compounds capable of inhibiting these enzymes (158). However, it was not until the early 
1970s that this yielded any success. The discovery of the olivanic acids, which included 
carbapenems and clavulanic acid, in 1976 heralded the first example of a compound 
capable of inhibiting β-lactamases (159). These compounds where isolated from 
Streptomyces spp. Carbapenems where shown to have potent antibacterial activity, but 
clavulanic acid, conversely had a very poor antibacterial activity. Interestingly though, 
clavulanic acid was shown to have impressive inhibitory activity as it was able to reduce 
ampicillin minimal inhibitory concentrations (MICs) against a diverse range of β-Lactamase 
producing E. coli and S. aureus. Since then several β-lactam related inhibitors have been 
discovered including the penicillin sulfones: sulbactam and tazobactam (158, 160, 161).  
Clavulanic acid, tazobactam and sulbactam are all ‘classical’ β-lactamase inhibitors so 
named due to their structural similarity to the β-lactam penicillin. They function by forming a 
stable, irreversible covalent attachment to the serine active site present in class A β-
lactamases. Consequently, the total hydrolytic activity in the cell is reduced to near zero. The 
activity of classical β-lactamase inhibitors against class A ESBLs is well documented, 





carbapenemase KPC and even induce the production of the chromosomally encoded class 
C β-Lactamase AmpC, which they cannot inhibit (162, 163). To thwart β-lactam resistance 
caused by AmpC induction, and to improve activity against the KPC β-Lactamase, two non-
classical class A/C β-lactamase inhibitors have been developed and licensed for clinical use: 




Avibactam was the first ‘non-classical’ or ‘non-β-lactam β-lactamase inhibitor’ used clinically. 
Synthesised in 2012, it was designed to contain a diazabicyclo-octane cyclic core (164). It 
was made clinically available in 2014 in combination with the third-generation cephalosporin 
ceftazidime, trading under the name ‘AvyCaz’. In vitro, avibactam shows good activity 
against many class A (TEM-1, SHV-1, CTX-M-15), C (AmpC) and even some class D (OXA-
24 and OXA-48) β-lactamases. Impressively, it also shows inhibitory activity against the 
class A carbapenemase KPC (166, 167).  
Avibactam has a novel inhibitory mechanism by having structural similarity to the 
electrophilic carbonyl group present in the serine active site of β-lactamases. Therefore, it 
functions by forming a reversible interaction with the serine active site, subsequently 
inhibiting the β-lactamase’s hydrolytic activity (164). Interestingly, although it has been 
shown to have activity in vitro against the class A carbapenemase KPC, when used in vivo, 
resistance to ceftazidime/avibactam developed quickly. This was reported as being caused 
by a series of point mutations in the blaKPC gene resulting in a change in amino acid 
sequence: a D179Y/T243M double substitution, or single substitutions in D179Y or V240G. 
These changes each resulted in a 4-fold increase in MIC against ceftazidime when put in 
combination with the standard concentration of avibactam (168). This rapid emergence of 
ceftazidime/avibactam resistance in KPC producing bacteria, highlighted the need for an 
alternative class KPC inhibitor. A similar mechanism of ceftazidime/avibactam resistance 
was seen with the class A cephalosporinase CTX-M. Two single nucleotide polymorphisms 
were identified in the blaCTX-M gene leading to a double amino acid substitution, P170S 
and T264I. These two amino acid changes collectively gave rise to a novel derivative of 
CTX-M-14 that had increased ceftazidime hydrolytic activity and so increased ceftazidime 








Figure 12. β-lactamase inhibitor structures. Figure was made using ChemDraw 
professional 16.0. Clavulanic acid and Tazobactam are examples of so called classical β-
lactamase inhibitors, as they have significant resemblance to the structure of penicillins. 
Both clavulanic acid and tazobactam contain the 4-membered nitrogen based β-lactam ring. 
Avibactam and vaborbactam are non-β-lactam β-lactamase inhibitors, which contain a 
diazabicyclo-octane cyclic core and a cyclic boronic acid core respectively.  
 
1.8.  Vaborbactam  
 
1.8.1. Overview  
 
Vaborbactam is another non-β-lactam β-lactamase inhibitor, first synthesised in 2015. It was 
licensed for clinical use in 2017, in combination with the carbapenem meropenem and has 
since been trading under the name ‘Vabomere’. It was discovered during a screen 
specifically looking for inhibitors capable of inhibiting KPC carbapenemases (165). 
Therefore, it is of no surprise that it has potent activity against many class A 
carbapenemases including KPC variants as well as NMC-A and SME. It has also been 
shown to have inhibitory activity against other class A enzymes (TEM, SHV and CTX-M) and 
class C β-lactamases (AmpC), although to a lesser extent when compared to its activity 
against KPC (170). Unfortunately, vaborbactam is unable to inhibit class B and D β-
lactamases. Vaborbactam has been shown to restore meropenem sensitivity in KPC-
producing K. pneumoniae and E. coli, but does not restore meropenem sensitivity in non-





(figure 12). It has been known for nearly 50 years that boronic acids are capable of inhibiting 
serine proteases. It is the strong electrophilic potential of the boron atom that means it has a 
high tendency to form covalent bonds with enzymes that contain serine catalytic active sites 
(172). vaborbactam is therefore able to form reversible covalent bonds with β-lactamases. 
Because this reaction is reversible, vaborbactam is not hydrolysed and rendered inactive 
during the reaction. This allows vaborbactam to be continuously recycled to inhibit other β-
lactamase enzymes (165). Avibactam also works by forming reversible covalent bonds. The 
exception of this is with KPC, which can slowly convert avibactam in to inactive fragments 
(145). It is for this reason combined with point mutations in the blaKPC gene seen in 
avibactam-ceftazidime resistant mutants, that makes vaborbactam the β-lactamase inhibitor 
of choice with regards to KPC carrying strains (173). Vaborbactam and meropenem are both 
known to enter K. pneumoniae through the OmpK35 (OmpF) and OmpK36 (OmpC) porins. 
Therefore, resistance to meropenem/vaborbactam has been observed due to loss of function 
mutations in ompC and ompF, inhibiting the entry of the both vaborbactam and meropenem 
(170, 174). Increased efflux and increased KPC production have also been described as a 
determinant for vaborbactam resistance. More specifically, increased KPC production has 
been linked to the transfer of the Tn4401 transposon (carrying blaKPC) from the pKpQIL 
plasmid, which has a low-copy number, to the comparatively higher-copy number plasmid 
ColEST258 as well as to blaKPC duplication events (174). As of yet, mutations in the 
blaKPC and blaCTX-M genes have not been observed that confer reduced vaborbactam 
inhibition. It is unclear if combinations of these resistance mechanisms are possible and 
whether increased vaborbactam use will lead to the development of alternative resistance 
mechanisms (173).   
  




K. pneumoniae is the most important member of the Klebsiella genus and belongs to the 
large Gram-negative family Enterobacteriaceae second only to E. coli in its ability to cause 
nosocomial infections (175) (176, 177). Such is the nosocomial ability of K. pneumoniae, that 
it is estimated that up to 8% of all nosocomial infections in the US and Europe annually, are 
caused by K. pneumoniae (175). Increasingly, it is an MDR human pathogen that can be 
found as a normal member of the mouth, skin, lung and intestinal flora, but commonly 
causes infections in patients that are already immunocompromised. The most common 





of bronchitis closely followed by bacteraemia. In addition to pneumonia, it can cause a 
notably broad range of infections, including: wound infections, urinary tract infections (UTIs), 
diarrhoea, osteomyelitis and even meningitis (175). More recently other members of the 
Klebsiella genus including Klebsiella oxytoca and Klebsiella rhinoscleromatis are becoming 
increasingly prevalent as causes of nosocomial infections (178). But it is K. pneumoniae that 
is responsible for the most cases as it is estimated that in the UK alone, K. pneumoniae is 
responsible for 9617 (as of March 2018) cases of bacteraemia’s annually, with 2853 of these 
being hospital acquired and over 2000 isolates showing MDR (179, 180). Since 2017, it has 
become mandatory to report bacteraemia caused by K. pneumoniae, such is the threat that 
it poses. K. pneumoniae has very quickly become a major threat due to its ability to gain 
resistance to multiple classes of antibiotics. However, it is K. pneumoniae strains resistant to 
carbapenems, which is of greatest concern. These strains that show carbapenem resistance 
are referred to as carbapenem resistant Enterobacteriaceae (CRE) (181). 
 
1.9.2. Antibiotic resistance in K. pneumoniae  
 
K. pneumoniae that are cephalosporin and/or carbapenem resistant are top on the World 
Health Organisations (WHO) list of critically resistant pathogens (182). Critically resistant 
pathogens are often referred to as ESKAPE pathogens: Enterococcus faecium, S. aureus, 
K. pneumoniae , Acinetobacter baumannii, P. aeruginosa and Enterobacter spp. Together 
these pathogens contribute to the majority of nosocomial infections as they are able to 
escape the action of multiple antibiotic classes due to their frequently having an MDR 
phenotype (183).  K. pneumoniae can become resistant due to its ability to increase the 
production of two MDR, RND efflux pumps (figure 13) as well as being able to reduce porin 
production. Loss of the porin OmpK36 has been well documented in reduce carbapenem 
susceptibility (184). But it is the loss of OmpK35 and OmpK36 porins and the presence of a 
β-lactamase such as CTX-M that is usually required to give carbapenem resistance (185). 
Undoubtedly, the biggest problem is the ability of K. pneumoniae to carry a wide range of 
plasmid acquired β-lactamases (186). The most clinically significant of which are the SBLs 
CTX-M (cephalosporinase), KPC (carbapenemase and cephalosporinase) and the OXA-48 
like (carbapenemase). These three enzymes are the focus for this project, therefore a more 
detailed overview of these three enzymes is provided in sections 1.9.2.1, 1.9.2.2. and 1.9.2.3 
(187-189). It has been known for some time that K. pneumoniae can have a MDR 
phenotype, with aminoglycoside and fluoroquinolone resistance being reported as early as 
the 1990s (177) and the first carbapenem resistance outbreak being described in 2001 





54% in some studies (132).This means even last resort antibiotics are not providing a 
sufficient treatment for patients, leading to less effective and sometimes even sub-optimal 




Figure 13. Diagrammatic representation of permeability and efflux components 
present in the Gram-negative cell wall. Tripartite or multi-component efflux pumps are 
shown on the which can include the families: RND, MFS and ABC. Single component efflux 
pumps are shown on the bottom left and may include the families: MFS, RND, ABC, MATE 
and SMR. In K. pneumoniae , the tripartite RND efflux pumps AcrAB-TolC and OqxAB-TolC 
are the most important indicators of ABR (192). Substrates of the RND efflux pumps present 
in K. pneumoniae include: tetracyclines, β-lactams and fluoroquinolones (193, 194). acrAB 
transcription is regulated by the production of the activator RamA, which is in turn controlled 
though the action of the complementary repressor RamR (belonging to the TetR family of 
repressors). oqxAB transcription is regulated by the RarA protein which is also under the 
control of a TetR family repressor, in this case OqxR. Over-expression of ramA or rarA, due 





oqxAB leading to increased efflux activity and therefore an MDR phenotype (192, 195, 196). 
Porins indicated on the top left and facilitate the entry of a large range of antibiotic classes 
and other substrates. There are four key porins present in K. pneumoniae : OmpK35 
(homologous to OmpF in E. coli), OmpK36 (homologous to OmpF in E. coli), OmpA and the 
inducible OmpK37 (197). However, only the porins OmpK35 (OmpF) and OmpK36 (OmpC), 
play an important role in ABR, as they are known to be substrates of β-lactams (198, 199). 
Arrows show direction of antibiotic transport in to the bacterial cell. As indicated, the 
antibiotic enters through porins, but then can be pumped out of the cell either by tripartite 





CTX-M is a plasmid encoded class A serine β-Lactamase (126) capable of hydrolysing a 
broad range of β-Lactam substrates which includes, notably, third generation cephalosporins 
such as cefotaxime and ceftazidime (202). The CTX-M enzyme was first discovered in 1989 
(131), but did not become particularly prominent until the early 2000s, whereby an extensive 
dissemination of the enzyme took place, often referred to as the ‘CTX-M pandemic’ (203).  
CTX-M enzymes can be classified into five major groups based on their amino acid 
sequence: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25. The origin of CTX-M is 
thought to have come from the chromosome of Kluyvera spp. , but it was subsequently 
mobilised by the ISECp1 element on to various plasmids and it is the mobilisation of different 
blaCTX-M genes from different Kluyvera spp. that lead to the difference between CTX-M 
enzymes and ultimately the classification into five groups (204). Currently, CTX-M is 
incredibly common within the Enterobacteriaceae family, with a large number of bacterial 
species including E. coli and K. pneumoniae carrying the enzyme. In fact, it is so common 
that is has displaced TEM and SHV variants as the most prevalent ESBL (187).  
Of all the CTX-M enzymes it is CTX-M-15 that is by far the most important. First described in 
1999 in India, it has quickly spread and nowadays is found all over the world in both human, 
animal and environmental bacteria (202, 205). A survey carried out in Asia highlighted the 









K. pneumoniae carbapenemase (KPC), is another class A serine β-lactamase (126) that has 
potent hydrolysing activity against penicillins, cephalosporins and most notably, 
carbapenems. KPC was first discovered in 2001 during a large outbreak in New York 
hospitals (190). The incidence of KPC carrying strains of K. pneumoniae was initially 
estimated at 9% in 2002 in the US. However, this soon rose to 33% (of carbapenem 
resistant infections) by 2008 (132). The first report of a KPC carrying strain of K. 
pneumoniae outside of the US was in Israel in 2004 (207). The spread of the KPC enzyme 
has been so successful that is now endemic in countries such as Israel and Greece and has 
been frequently identified in countries such as Brazil, Colombia, The United Kingdom, China 
and India (208).  
Upon examination of the molecular epidemiology of the blaKPC gene it was found that the 
majority of isolates of carbapenem resistant K. pneumoniae belonged to a single sequence 
type; ST258 and the most common KPC variants found with in ST258 were KPC-3 and 
KPC-2 (208). This makes KPC-3 and -2 by far the most clinically important KPC enzymes. 
The reason for successful spread of KPC is largely down to its location within the transposon 
Tn4401 allowing it to easily transfer between a vast number of plasmids. Because of this 
KPC has been found not only in K. pneumoniae but also several other Gram-negative 
bacteria including E. coli, Proteus mirabilis, S. marcescens and E. aerogenes (132). 
KPC carrying isolates of K. pneumoniae is of great concern as there are not only financial 
implications associated with increased length of hospital stay. But also, treatment failure is 
very common and consequentially the mortality rates associated with infection of KPC 
expressing K. pneumoniae tends to be very high. Mortality rates have been reported as 
between 47-66% in the US and as high as 70% outside of the US (209, 210). This is further 
exacerbated as KPC is also often accompanied by other resistance genes, meaning isolates 
that carry KPC often show an MDR phenotype.  
 
1.9.2.3. OXA-48 like carbapenemases 
 
Unlike CTX-M and KPC, OXA enzymes are class D serine-β-lactamases. Some OXA 
enzymes are carbapenemases, and where first discovered in 1993 as conferring resistance 
to imipenem in A. baumannii (211). However, whereas KPC enzymes have strong 
carbapenemase activity, OXA enzymes have a relatively poor carbapenemase activity. Also, 





cephalosporinase activity (212). Historically, class D serine-β-lactamases where referred to 
as oxacillinases due to their ability to hydrolyse oxacillin, which TEM and SHV could not. It is 
for this reason that the term OXA was coined for class D serine-β-lactamases (126). OXA 
enzymes are varied but can be divided into many distinct groups based on amino acid 
sequence (134). Table 2 shows example enzymes belonging to each of the 8 clusters of 
OXA carbapenemase enzymes. 
 
 
Table 2. Example enzymes for each OXA carbapenemase cluster and the most 
common host these enzymes are found in (213).  
 
The majority of OXA carbapenemases are found in the non-enterobacterial A. baumannii 
encoded on the chromosome (212). However, the plasmid borne OXA-48 like enzymes can 
be found In K. pneumoniae and are therefore of clinical significance (214). As of yet, six 
OXA-48 variants have been described: OXA-48, OXA-163, OXA-181, OXA-204 and OXA-
232 all of which differ by up to five amino acid substitutions (213). Like all OXA 
carbapenemases, OXA-48 like enzymes show strong hydrolysing activity against penicillins, 
a moderate hydrolysis of carbapenems and a very poor activity against cephalosporins. 
However high carbapenem MICs have been described in K. pneumoniae strains that 
produce OXA-48 like carbapenemases and also down regulate outer membrane porins 
(214). OXA-48 like enzymes have been found in many species including, but not limited to: 
Cluster  Enzyme  Natural host 
1 OXA-23, OXA-27, OXA-49 A. baumannii 
2 OXA-24,25,26 and 72 A. baumannii 
3 OXA-51 A. baumannii 
4 OXA-58 A. baumannii, Acinetobacter junii 
5 OXA-55, OXA-SHE Shewanella algae 
6 OXA-48, OXA 54 K. pneumoniae, Shewanella oneidensis 
7 OXA-50 P. aeruginosa 





K. pneumoniae, E. coli, C. freundii and E. cloacae. Originally, most reports of OXA-48 
carriage were limited to North African countries and Turkey (215). However, more recently 
OXA 48-carriage has been found across North Africa, South Asia, the Middle-East and have 
even spread to several European countries, notably France, Germany, Spain and the UK 
(216).  
The main concern associated with OXA-48 producing K. pneumoniae is the difficulty in 
detecting it. Many OXA-48 producers are thought to ‘slip through the net’ due to the absence 
of a sufficient phenotypic test for recognising OXA-48 production (213). This is because 
OXA-48 doesn’t necessarily give carbapenem resistance, rather it gives decreased 
carbapenem susceptibility. (217). Therefore, the impact that this has with regards to clinical 
outcome is very hard to decipher. Studies into the prevalence of OXA-48 like enzymes in 
carbapenem resistant K. pneumoniae suggest that it could be as high as 60% (218). It is 
clear that OXA-48 enzymes are of great importance with regards to a MDR phenotype in K. 
pneumoniae. 
 
1.10. Aims of project 
 
K. pneumoniae is undoubtedly a very important pathogen not only in its nosocomial ability 
but also in its ability to cause a wide variety of infections. This is exacerbated by K. 
pneumoniae strains producing β-lactamases of which KPC, CTX-M and OXA-48 like 
enzymes are the most clinically important. Infection with strains producing these β-
lactamases will often result in β-lactam treatment failure and limit the number of viable 
therapeutic options to combat the infection. Promisingly, inhibitors of some or all of these 
enzymes have been identified, the most recent of which is the cyclic boronic acid 
vaborbactam licensed in combination with meropenem. MBLs, are also undoubtedly of 
concern in K. pneumoniae, but the fact that meropenem/vaborbactam is not capable of 
inhibiting MBLs means that this project focused on SBLs only.  
It is important to characterise meropenem/vaborbactam resistance mechanisms in K. 
pneumoniae producing SBLs in an effort to aid clinical prediction of resistance and potential 
ways of overcoming it. Meropenem/vaborbactam resistance is known to occur but the 
mechanisms remain poorly understood. As mentioned previously, one study reported loss of 
the OmpC (OmpK36) porin as causing an increase in meropenem MICs seen in the 
presence of vaborbactam. However, it was also reported that several KPC strains had 
increased meropenem MICs without loss or reduced production of OmpC (170). It is possible 





a result of changes to the blaKPC and blaCTX-M genes, as seen to cause ceftazidime 
resistance in the presence of avibactam (167, 169). Alternatively, it could be a result of 
changes in permeability and efflux, not previously implemented in meropenem/vaborbactam 
resistance.  
Therefore, the first aim of this project was to better understand if and how permeability 
and efflux are involved in meropenem/vaborbactam resistance. To achieve this aimed 
to test meropenem in combination with vaborbactam against a range of clinical isolates 
containing well defined permeability, permeability regulator, porin and efflux mutations, in the 
following genes: ramR, oqxR, ompC, ompF and also those over-expressing micF. More 
specifically, loss of function mutations in ramR and oqxR were of interest as they result in 
increased efflux (figure 13) (192). micF encodes a 93-base antisense RNA that binds and 
inhibits translation of ompF mRNA therefore reducing OmpF(OmpK35) porin production 
(219). Our aim was to test these mutations in an otherwise isogenic background in 
combination with the production of either the class A carbapenemase KPC, the class A 
ESBL CTX-M or the class D OXA-48 like carbapenemase OXA-232.  
Secondly to confirm the previously reported importance of OmpC loss in meropenem 
vaborbactam we aimed to produce in vitro meropenem/vaborbactam resistant mutants 
of clinical isolates, again either producing CTX-M, KPC or OXA-232.  
Although meropenem/vaborbactam is not a potent inhibitor of class D β-lactamases, 
vaborbactam activity against the class D β-lactamase OXA-2 has been reported in 
combination ceftazidime. Although ceftazidime/vaborbactam did not restore sensitivity it did 
result in decreased ceftazidime MICs in a number of different OXA producers (170). 
Vaborbactam has also been shown to potentiate the activity of biapenem against OXA-2,-1 
and -30 in vitro (220). Therefore, because of this and the potential for 
meropenem/vaborbactam resistance, we were interested in whether alternative partners for 
vaborbactam could be used to target not only OXA-232 producing K. pneumoniae, but also 
KPC and CTX-M. Therefore, the third aim of this project was to investigate potential 
alternative partners of vaborbactam that extend the spectrum to include OXA-232. The 
alternative partners for vaborbactam tested were  a selection of carbapenems (ertapenem, 
meropenem, imipenem and doripenem) as well as the second-generation cephalosporin 
cefuroxime, the third-generation cephalosporins ceftazidime, cefotaxime, ceftriaxone and the 
fourth-generation cephalosporin cefepime. If efficacious alternative partners of vaborbactam 
were to be identified, our final aim was to identify and characterise mutants resistant to 






In summary, our aims are as follows:  
1. To test a range of permeability, permeability regulator, porin and efflux mutations in an 
isogenic background in combination with the production of either KPC, CTX-M or OXA-232 
against meropenem/vaborbactam. Our hypothesis is that loss of OmpC will cause the 
greatest decrease in meropenem/vaborbactam susceptibility. 
2. To select for in vitro meropenem/vaborbactam resistant mutants of clinical isolates, again 
either producing CTX-M, KPC or OXA-232 and to characterise the resistant mechanism. 
Again, we hypothesise that loss of OmpC could be the causative mechanism as we believe 
that meropenem/vaborbactam resistance is actually just meropenem resistance.  
3. To test a range of alternative vaborbactam partners that could extend activity to also 
include OXA-232. Class D β-lactamases, although capable of hydrolysing carbapenems, are 
relatively weak cephalosporinases. Therefore, we hypothesise that the cephalosporins 
tested in combination with vaborbactam could show potential.  






















































2.1. Media  
 
Media used throughout this project were Luria Bertani (LB) broth and agar, Mueller Hinton 
agar and cation adjusted Mueller Hinton broth: all purchased from Oxoid. All media was 
sterilised by autoclaving at 121oC for 20min. 
 
2.2. Antibiotics/ Inhibitors 
 
Vaborbactam was purchased from MedChemExpress MCE and was solubilised in dimethyl-
sulfoxide (DMSO).  Avibactam was kindly supplied by Professor Schofield, Department of 
Chemistry, University of Oxford and was solubilised in DMSO. Both vaborbactam and 
avibactam were stored at -20ᴼC in powder form and -80ᴼC dissolved in DMSO. Tazobactam 
was obtained from Sigma-Aldrich and was solubilised in water. Tazobactam was stored at 
4ᴼC in powder form and -80ᴼC dissolved in water. Antibiotic discs and bacterial growth 
media were supplied by Oxoid.  
 
Antibiotic Manufacturer Solvent Class 
Kanamycin Bio Basic Canada Inc. Water Aminoglycoside 
Meropenem Department of Chemistry, University 
of Oxford 
DMSO Carbapenem 
Chloramphenicol Sigma-Aldrich 70% Ethanol Phenicol 
Cefotaxime Sigma-Aldrich Water Cephalosporin 
Ampicillin Sigma-Aldrich Water Penicillin 
Gentamicin  Sigma-Aldrich Water Aminoglycoside 
Doripenem Insight Bio-Tech DMSO Carbapenem 
Ceftazidime Sigma Aldrich DMSO Cephalosporin 
Piperacillin  Sigma Aldrich Water Ureidopenicillin 
Imipenem  Insight Bio-Tech DMSO Carbapenem 
 
Table 3: Companies supplying antibiotics. Stored in powder form at 4ᴼC or -20ᴼC, stored 









Equipment Manufacturer  
Centrifuge ALC Multispeed Refrigerated Centrifuge PK 121R 
Ultracentrifuge Sorvall® RC 5B Plus  
Plate reader POLARstar Omega 
Sonicator Sonics Vibra cell VCX750 
PCR thermal cycler  Bio Rad Peltier Thermal Cycler PTC-100 
Heat Block Eppendorf Thermomixer 5436 
Vortex Whirlmixer Fisons Scientific Equipment 
Biofuge pico Heraeus 
Gene sys gel reader  Bio Rad Gel Doc 1000 system 
Nanodrop Lite Spectrophotometer Nanodrop Thermo Scientific 
Gene Pulser Bio Rad 
Ultraspec 2100pro Amersham Bioscience 
G:BOX Syngene 
 
Table 4. Equipment used, and Company purchased from.  
 
 
2.4. Storage and growth conditions of Bacterial strains 
 
All strains used throughout this project, were stored at -80ᴼC contained in glycerol bead 
stocks (Protect Bacterial Preservers). All bacterial strains were cultured by growing overnight 
with 180 rpm shaking in LB broth or Mueller Hinton broth at 37ᴼC. An estimate of bacterial 












2.5. Lab Bacterial Strains 
 
Strain/Isolate (reference) Species 
DH5α (221) E. coli 
Ecl8 (222) K. pneumoniae  
Ecl8 44 K. pneumoniae  
Ecl8 16-1 K. pneumoniae  
Ecl8 0.125 K. pneumoniae  
Ecl8 0.03-2 (223) K. pneumoniae  
Ecl8 0.03-1 (223) K. pneumoniae  
Ecl8 35 (ΔompF) K. pneumoniae  
Ecl8 36 (ΔompC) K. pneumoniae  
Ecl8 Delta (ΔramR) (196) K. pneumoniae  
Ecl8 Delta 35 (ΔramR ΔompF) K. pneumoniae  
Ecl8 Delta 36 (ΔramR ΔompC) K. pneumoniae  
Ecl8 Delta 36 micF (ΔramR ΔompC pK18: 
micF) (192) 
K. pneumoniae  
S17 (224) E. coli 
 
Table 5. Bacterial strains/Isolates used and their reciprocate species.  KPC-3, CTX-M-
15 and OXA-232 transformants of DH5α were used for plasmid purification. Strains 44, 16-1, 
0.125, 0.03-2, 0.03-1, Ecl8 ΔompF, Ecl8 ΔompC, Ecl8 ΔramR ΔompF, Ecl8 ΔramR ΔompC, 
Ecl8 ΔramR ΔompC pK18: micF were all derived from the wild type Ecl8 strain (222). For 
genotypic information on these strains see table 9. S17 was used as a donor for conjugation 
(see section 2.12.). Knockouts were constructed by visiting PhD student Punyawee 
Dulyayangkul. Genotypes of these strains are provided in table 9.  
 
2.6. Clinical isolates 
 
Throughout this project, a library of 30 clinical isolates of K. pneumoniae was used, obtained 







Isolate Location of infection Date Isolated 
R1 Blood culture 12/04/2016 
R2 Blood culture 08/03/2016 
R3 Tissue 10/01/2016 
R4 Tissue 07/12/2015 
R5 Blood culture 05/10/2015 
R6 Blood culture 25/09/2015 
R7 Blood culture 01/09/2015 
R8 Ascitic Fluid 23/02/2015 
R9 Tissue/Kidney Stone 05/12/2014 
R10 Blood culture 27/10/2014 
R11 Screening Swab 10/10/2014 
R12 Blood culture 01/10/2014 
R13 Groin Swab 02/07/2014 
R14 Wound Swab 11/06/2014 
R15 Blood culture 20/05/2014 
R16 Blood culture 20/04/2014 
R17 Sputum 19/03/2014 
R18 Catheter Urine 18/02/2014 
R19 Catheter Urine 17/10/2013 
R20 Sputum 01/08/2013 
R21 Sputum 30/07/2013 
R22 Blood culture 27/07/2013 
R23 Wound Swab 23/07/2013 
R24 Mid-Stream Urine 23/07/2013 
R25 Blood culture 22/07/2013 
R26 Mid-Stream Urine 03/07/2013 
R27 Central Line Tip 17/04/2013 
R28 Bronchio-alveolar Lavage 11/03/2013 
R29 Blood culture 09/03/2013 
R30 Blood culture 07/08/2012 
 









Figure 14. pUBYT vector map. pUBYT vector was designed and made by Dr Yuiko 
Takebayashi derived from the pYMAb2 plasmid (225). Genes encoding CTX-M-15, KPC-3 
and CMY-2 were cloned by Dr Juan-Carlos Jimenez-Castellanos and subsequently sub-
cloned into the pUBYT vector by Dr Yuiko Takebayashi (226). KanR is a kanamycin 
resistance gene and was used to select for successful transformants using 50 mg/L of 



























Figure 15. pKNOCK suicide vector map. The pKNOCK vector was kindly gifted by the 
Chulabhorn Research Institute, Thailand. Knockout primers were used to amplify fragment of 
desired gene. The gene fragment was then cloned into the pKNOCK vector by visiting PhD 
student Punyawee Dulyayangkul. The Polylinker in which a gene fragment was inserted, 
consists of: EcoRI-SacII-BstXI-NotI-EagI-XbaI-SpeI-BamHI-SmaI-PstI-EcoRI-EcoRV-HindIII-
ClaI-SalI-HincII-AccI-XhoI-ApaI-DraII-KpnI. In this case the pKNOCK vector contained the 
chloramphenicol resistance gene (Cm) or the gentamicin resistance gene resulting in a total 












Figure 16. pK18 vector map (228). micF was cloned into the pK18 vector by Dr Juan-
Carlos Jimenéz-Castellanos (192). NeoR/KanR is a neomycin/ kanamycin resistance gene. 
In this case 30 mg/L of kanamycin was used to select for successful transformants followed 










2.8.1. Crude DNA extraction 
 
DNA was extracted from bacterial cells via boiling on a heating block. One colony was 
resuspended in 90 μl of sterile Elgastat water. Cells were then boiled at 95ᴼC for 10 min. 
Cells were subsequently centrifuged at 13,000 rpm for 1 min, whereby 1 μl of the resulting 




Primers Sequence Annealing 
temperature 
CTX-M 15 F 5’- ACACACGTGGAATTTAGGGA-3’ 55.3 
CTX-M 15 R 5’- TTTTGCCGTCTAAGGCGATA-3’ 55.3 
OmpK36 sequencing F 5’- GAGGCATCCGGTTGAAATAG-3’ 57.3 
OmpK36 sequencing R 5’- ATTAATCGAGGCTCCTCTTAC-3’ 55.9 
pYT insert check F 5’- GCAAGAAGGTGATGAATCTAC-3’ 56.6 
pYT insert check R 5’- GTGGCAGCAGCCAACTCA-3’  58.2 
OmpK35 F amplification 5’- CACTTCGATGTATTTAACCAG-3’ 52.4 
OmpK35 R amplification 5’- ATGATGAAGCGCAATATTCTG-3’ 54.8 
OmpK35 F knockout 5’- TCCCAGACCACAAAAACCCG-3’ 59.4 
OmpK35 R knockout 5’- CCAGACCGAAGAAGTCGGAG-3’  61.4 
OXA 232 check F 5’- GAATGCCAGCGGTAGCAAAG-3’ 59.9 
OXA 232 check R 5’- CGATATCACGCGTCTGTCCA-3’ 59.9 
M13 (pK18, pSU18 check) F 5’- GTAAAACGACGGCCAG-3’ 52.8 
M13 (pK18, pSU18 check) R 5’- CAGGAAACAGCTATGAC-3’ 46.6 
OmpK36 promoter F 5’- CCAAAGATCAGGGCTTCGGT-3’ 59.4 
OmpK36 promoter R 5’- ACGACCGTAGTCGAAAGAGC-3’ 59.4 
NlpD sequencing F 5’-GTCGGCGAAGAGCATCAGT-3’ 58.8 
NlpD sequencing R 5’-CACCTTCCACGGCACATCA-3’ 58.8 
 
Table 7. Primers used, showing oligonucleotide sequence 5’-3’ and annealing 





Ismah Kamil. OmpK35 knockout primers were designed by visiting PhD student Punyawee 
Dulyayangkul. CTX-M 15, OXA 232 and OmpK36 promoter primers were designed 
personally. All primers were purchased and synthesised by Eurofins Genomics.  
 
2.8.3. PCR amplification 
 
PCR reactions contained 1 μl (10-50 ng) of DNA template, 1 μl (10 ρmol) of forward and 
reverse primer, 12.5 μl of RedTaq or MyTaq (Sigma-Aldrich) made up to 25 μl by adding 
10.5 μl of sterile Elgastat water. PCR reactions were performed in a Bio Rad Peltier Thermal 
cycler in 0.2 ml thick PCR tubes. The program remained the same in all PCR reactions used, 
however the annealing temperature differed depending on the primers used (see Table 7). 
DNA template was denatured at 95ᴼC for 10 min followed by a further 35-37 cycles of 
denaturing at 95 ᴼC for 1 min, primer annealing at 50-65ᴼC for 1 min, fragment extension at 
72ᴼC for 1 min ending with a final 10 min extension at 72ᴼC before being stored at 4ᴼC. 
PCR reactions were then analysed by agarose gel electrophoresis 
 
2.8.4. Colony PCR 
 
To confirm successful transformation via electroporation (see section 2.8.), colony PCR was 
performed. Ten colonies of each transformant were picked and resuspended in PCR master 
mix (12.5 μl of RedTaq or MyTaq, 1 μl (10 ρmol) of forward and reverse primer (e.g. pYT 
insert check primer), 10.5 μl of sterile Elgastat water). Colony PCR reactions were then 
analysed by agarose gel electrophoresis.  
 
2.8.5. Agarose gel electrophoresis  
 
DNA products were run on 1% w/v agarose gels, prepared as follows: 1 g of agarose was 
dissolved in 100 ml of 1X TAE buffer (0.09 M Tris base, 2 mM Ethylenediaminetetra-acetic 
acid (EDTA), 0.09 M Boric acid, adjusted to pH 8) followed by addition of Ethidium Bromide 
to give a final concentration of 0.1 mg/L. Samples were loaded (8 μl) alongside 5 μl of 
Hyperladder (Bioline, UK) 100 bp/1 kbp depending on product size. Gels were run at 100 V 
for 30-45 min depending on product size. The resulting gel was then visualised using 






2.8.6. PCR purification 
 
When sending PCR products for sequencing, PCR reactions where first confirmed to contain 
correct product size via agarose gel electrophoresis. Remaining PCR reaction was purified 
using the QIAquick® PCR purification kit (Qiagen Ltd, UK), where instructions where 
followed in accordance with the accompanying manufacturers protocol. Purified DNA 
product was eluted using 30-50 μl of Elution buffer or sterile molecular grade water 
depending on concentration required. The concentration of the purified DNA product was 
quantified using a Nanodrop, where sterile molecular grade water was used as a blank for 
calibration purposes.  
 
2.8.7. DNA sequencing and analysis  
 
Purified DNA (PCR product or Plasmid) was sent to Eurofins genomics for Sanger 
sequencing. Samples were standardized to a final concentration of 10-50 ng/μl depending 
on product size, plus 1 μl (10 ρmol) of the relevant forward and reverse primer. Results were 
analysed using sequence alignment software such as Multialin and Benchling (229, 230).  
 
2.9. Competent cell generation 
 
Electro-competent cells for use in transformation, were generated as follows: 1 colony was 
inoculated in 10 ml of LB broth (containing antibiotic for selection when needed) and grown 
overnight in a shaking incubator 180 rpm, 37ᴼC for 20-24 h. 1 ml of overnight culture was sub-
cultured in 50 ml of fresh LB broth and grown to OD600 0.4-0.6, in a 250 ml conical flask, 180 
rpm, 37ᴼC. Cells were then centrifuged at 4000 rpm, 10 min at 4ᴼC, followed by two washes 
with ice chilled sterile elgastat water with subsequent centrifugation (4000 rpm, 10 min at 4ᴼC), 
discarding the supernatant each time.  Cells were then resuspended and washed twice with 










2.10. Plasmid purification  
 
Each bacterium containing a relevant plasmid (pUBYT, CTX-M, KPC, CMY, OXA 232, micF, 
pK18) was grown overnight (180 rpm, 37ᴼC) in LB broth containing 50 mg/L kanamycin (for 
pUBYT plasmids: CTX-M, KPC, CMY), 30 mg/L kanamycin (for pK18 plasmids: micF), 30 
mg/L chloramphenicol (for pSU18 plasmids: KPC, CTX-M, CMY) or 8 mg/L piperacillin and 4 
mg/L tazobactam for selection of the natural pOXA232 (JX423831) plasmid. Plasmid was 
then purified using the QIAprep Spin Miniprep Kit (Qiagen Ltd, UK) where instructions where 
followed in accordance with the accompanying manufacturers protocol. Plasmid was eluted 
using 30 μl sterile molecular grade water or Elution buffer. Purified plasmid concentration 
was quantified using a Nanodrop where sterile molecular grade water was used as a blank 
for calibration purposes. Purified plasmid was stored at -20ᴼC for later use in electroporation 
 
2.11. Electroporation  
 
Electro-competent cells and desired plasmid were thawed on ice. 100 μl of competent cells 
were mixed with 5 μl plasmid containing desired gene product (pUBYT, CTX-M, KPC or 
OXA-232). Samples were transferred to an ice chilled 2 mm electroporation cuvette and 
pulsed using a Bio Rad Gene Pulser at 2.5 kV, 25 μF and 200 Ω. One millilitre of 37ᴼC 
warmed Super Optimal Broth with Catabolite repression (SOC) was added and immediately 
transferred to the shaking incubator (180 rpm, 37ᴼC) for 1 h. Cells were then centrifuged at 
8000 rpm for 5 min and resuspended in 100 μl of SOC broth. Cells where then spread on 
selective 1.6% LB agar containing relevant selection. Colony PCR was then performed on 
resulting transformants to confirm insertion of plasmid.  
 
2.12. Antimicrobial susceptibility testing  
 
2.12.1. Disc susceptibility testing 
 
Antimicrobial disc susceptibility testing was performed to Clinical Laboratory Standards 
Institute (CLSI) guidelines using Mueller Hinton agar (Sigma-Aldrich) on 15 cm agar plates 
(231). Bacterial suspensions of OD600 0.1 were made by resuspending bacterial colonies in 
Phosphate Buffer Saline (PBS) followed by spreading on to the plate. Antibiotic selection 
and 8 mg/L vaborbactam were added to agar if required. Agar volume was standardised at 





performed in triplicate on all accounts and results reported as the average change in 
inhibitory zone diameter. Changes of inhibitory zone diameter of ≥2 mm was considered 
significant based on the previously observed reproducibility of the CLSI disc susceptibility 
method. Breakpoints of non-susceptibility and susceptibility were determined by the CLSI 
performance standards (231).  
 
2.12.2. Minimal inhibitory concentration (MIC) assays 
 
MICs were determined according to CLSI microtitre MIC methodology (232). 1:2 dilutions 
were carried out in a Costar 96-well plate using a starting concentration of 256 mg/L of 
desired antibiotic. MICs were tested with and without vaborbactam at a final concentration of 
8mg/L, which was fixed in each well. Each well contained 180 μl of Cation Adjusted Mueller 
Hinton broth containing antibiotic and 20 μl of bacterial suspension. Bacterial suspensions of 
OD600 0.01 were made by resuspending bacterial colonies in Phosphate Buffer Saline 
(PBS). 20 μl of bacterial suspension was then added to each well giving a final bacterial 
OD600 of 0.001. Plates were then incubated for 18-20 h at 37ᴼC. Bacterial growth in plates 
were measured using a POLARstar Omega plate reader at OD600. The MIC was defined as 
the minimal concentration of antibiotic required to completely prevent bacteria growth 
determined using the susceptibility/non-susceptibility CLSI performance standards (231). 
200 μl of PBS was used as a negative control to indicate zero growth, conversely 180 μl of 
PBS (without antibiotic) and 20 μl of bacterial suspension to indicate maximum overnight 
growth.  
 
2.12.3. Chequerboard MIC 
 
Chequerboard MICs (i.e. were two antibiotics were combined) were performed according to 
CLSI guidelines. 1:2 dilutions of antibiotic ‘A’ (e.g. meropenem) were carried out on the y-
axis and 1:2 dilutions of antibiotic ‘B’ (e.g. ceftazidime) were carried out on the x-axis of a 
Costar 96-well plate. MICs were tested with and without vaborbactam and avibactam at final 
concentrations of 8mg/L and 10mg/L respectively in each well. Each well contained 180 μl of 
Cation Adjusted Mueller Hinton broth containing antibiotic ‘A’, antibiotic ‘B’ and 20 μl of 
bacterial suspension. Bacterial suspensions of OD600 0.01 were made and used as above. 








2.13.1 Whole cell protein extraction through Mechanical lysis (Sonication)  
 
Ten millilitres of bacterial overnight culture were inoculated up as previously described in 
triplicate. The cells were subsequently sub-cultured by adding 1 ml of overnight culture to 50 
ml of fresh Cation Adjusted Mueller Hinton broth and grown to mid logarithmic phase 
(OD600 0.4-0.6) in a 250 ml conical flask. Bacterial cells were then pelleted by centrifugation 
at 4000 rpm, 15 min, 4ᴼC in a ALC Multispeed Refrigerated Centrifuge. The supernatant 
was then discarded, and the pellet was resuspended in 30 ml of Tris-hydrochloride buffer (30 
mM adjusted to pH 8 with NaOH). Cells were then lysed via sonication, by 1 cm insertion of 
a 13 mm probe and subjected to 1 s on/ 1 s off pulses for 3 min at 63% amplitude. Cell 
debris and un-lysed cells where separated from whole cell protein by centrifugation at 8000 
rpm for 20 min at 4ᴼC. Whole cell protein samples where then stored at -80ᴼC for later 
analysis by SDS-PAGE. 
 
2.13.2. Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Whole cell protein samples obtained from sonication were thawed on ice. Protein 
concentration was measured using Bio-Rad Protein Assay Dye Reagent: 10 μl of protein 
sample was mixed with 100 μl Bio-Rad Protein Assay Dye Reagent, 890 μl sterile elgastat 
water and OD595 was subsequently recorded and protein concentration calculated.15 μl of 
protein sample was added to 15 μl of loading buffer (100 mM Tris adjusted to pH6.8, 4% 
(w/v) SDS, 0.2% (w/v) bromophenol blue with 20% (v/v) glycerol). The mixture was then 
heated at 95ᴼC for 5 min. One microgram of protein sample was then loaded onto a 12.5 % 
SDS-PAGE gel which was made as set out in table 8. The gel was run at 170 V, 300 mA for 
10-15 min to give a 1 cm run. The gel was then removed from its mould and stained with 
InstantBlue (Expedeon ISBIL) for around 10 min until protein bands show up blue. 
InstantBlue stain was removed and destained using sterile elgastat water. The protein bands 









Reagents Separating Gel (ml) Stacking Gel (ml) 
37:1 30% Bis-acrylamide 
(161-0158 Bio Rad) 
5 2 
Separating buffer (1.5 M 
Tris, 0.4% SDS pH 8.8) 
2.5 - 
Stacking buffer (0.5 M Tris, 





TEMED 0.01 0.01 
Elgastat water  2.75 4.5 
 
Table 8. Composition of Separating and Stacking gels used for SDS-PAGE. SDS-PAGE 
was used to test protein presence and abundance. Reagents were mixed, with Ammonium 
persulphate and TEMED being added just before casting the gel.  
 
 
2.13.3. Proteomic analysis  
 
Whole cell proteomics was analysed by Dr Kate Heesom in the Proteomics Facility at the 
University of Bristol. In brief, the 1 cm gel run containing the whole cell protein content was 
cut out of the gel and digested with trypsin using a ProGest automated digestion unit 
(Digilab, UK). This resulted in the formation of tryptic peptides which were subsequently 
fractioned into fragments using a Dionex Ultimate 3000 nanoHPLC system, combined with 
an LTQ-Orbitrap Velos mass spectrometer (Thermo-Scientic). The resulting proteomics data 
was analysed using the Proteome Discover software v1.2 (Thermo-Scientic) and compared 
against the K. pneumoniae strain ATCC 700721 on the UniProt MGH 78578 database. Data 
analysis was carried out using Microsoft excel, whereby a paired t-test was used to test for 
any significant difference in protein abundance. In this case a p-value of ≤0.05 was 
considered to be a significant result. The fold change of protein abundance was calculated 
by averaging the absolute abundances for each of the biological triplicates of the ‘parental’ 
strain compared to the ‘mutant’ strain. Protein abundances were normalised based on 50S 
and 30S ribosomal content. This involved averaging the abundances of ribosomal content 






2.14. Gene Knockout using Bacterial conjugation  
 
Gene knockouts were achieved via the pKNOCK suicide vector method (figure 9). 
Overnights of a gene knockout donor (e.g. E. coli S17 carrying pKNOCK plasmid) and a 
recipient were set up as previously described in 10 ml of LB broth at 180 rpm, 37ᴼC. The 
cells were subsequently sub-cultured by adding 1 ml overnight to fresh 20 ml of LB broth. 
Sub cultures were incubated at 180 rpm, 37ᴼC to mid logarithmic phase OD600 of 0.5 which 
took roughly 1 h. Bacterial cells were collected by centrifugation at room temperature (RT), 
4000 rpm for 10 min using the ALC Multispeed Refrigerated Centrifuge PK 121R. 
Supernatant was discarded, and bacterial pellet resuspended in 1 ml of fresh LB broth. 
Mixtures of 1:1, 1:2 and 2:1 (donor (S17): recipient (K. pneumoniae Ecl8) ratios were made 
in 1 ml Eppendorf tubes. 10 μl of bacterial mixtures were added to individual strips of 
nitrocellulose membrane on 1.6% LB agar. Nitrocellulose membrane strips were left to dry at 
room temperature followed by overnight incubation at 37ᴼC. Nitrocellulose strips were then 
placed in 1.5 ml Eppendorf tubes containing 1 ml of LB broth and subjected to vortexing to 
resuspend bacterial cells. This was followed by spreading on selective media containing 
pKNOCK selection and 100 mg/L ampicillin plus chloramphenicol or gentamicin used to 
select for pKNOCK vector. Ampicillin used to kill S17 to ensure any bacteria grown was the 
recipient K. pneumoniae Ecl8 (AmpR) containing the pKNOCK vector. Colony PCR was then 
performed as described previously, for example using ompK35 amplification primers against 
a strain with intact ompK35. If colonies of recipient produced a larger PCR product, then the 
pKNOCK vector had successfully inserted into the chromosome by homologous 

















Figure 17. Overview of theory for insertional mutagenesis by pKNOCK suicide 
vectors. A gene fragment of gene X was cloned into the Polylinker section of the pKNOCK 
vector. The resulting pKNOCK geneX is mobilised and transported to the recipient by 
conjugation as described previously. As a result of homologous recombination, the geneX 
pKNOCK is inserted into geneX on the bacterial chromosome resulting in insertional 














2.15. Selection of β-lactam/β-lactamase inhibitor resistant mutants 
 
Selection of mutants that were resistant to combinations of meropenem/vaborbactam, 
ceftazidime/vaborbactam and imipenem/vaborbactam was attempted. A range of increasing 
concentrations of meropenem/ceftazidime/imipenem (0.125 mg/L- 64 mg/L) were tested in 
the presence of a fixed concentration of vaborbactam (8 mg/L) on Mueller Hinton agar. 
Overnight bacterial cultures were set up as described previously. 50 μl of overnight culture 
(grown in Cation Adjusted Mueller Hinton broth) was spread on plates and incubated at 
37ᴼC for 24 h. Colonies growing at the highest concentration of 
meropenem/ceftazidime/Imipenem were selected for further analysis (233). 
 
2.16. Whole genome sequencing 
 
Bacterial strains chosen for whole genome sequencing were grown on Mueller Hinton agar. 
Glycerol bead stocks were made and sent to MicrobesNG (Birmingham, UK) for genome 
sequencing on a HiSeq 2500 instrument (Illumina). The reads were subsequently trimmed 
using Trimmomatic (234) and assembled into contigs by using the SPAdes 3.10.1 software. 
The resulting data files sent back were: fasta, gbk and trimmed.fastq. These data files were 
retained for further analysis.  
 
2.17. Whole genome sequence analysis 
 
Three programmes were used for whole genome sequence analysis. These were: Mauve - 
Multiple Genome Alignment (Mauve 2015-02-26), Galaxy (Galaxy version 18.05) and 
Intergrative Genomics Viewer-IGV 2.4 (235-237). The assembled contigs for each bacterial 























Chapter 3. Factors 
affecting the ability of 


















To test the effect of increased efflux and also porin mutations on the ability of vaborbactam 
to restore meropenem susceptibility in K. pneumoniae, a panel of isogenic strains were 
created based on the domestic lab strain Ecl8. Plasmids encoding the class A β-lactamase 
CTX-M or the class D β-lactamase OXA-232 were then used to transform these strains 
using electroporation as outlined in section 2.8. CTX-M was encoded on the pUBYT vector 
(see figure 7), whereas OXA-232 was carried on the natural plasmid pOXA232 (JX423831). 
The efflux and porin mutations present in each Ecl8 derivative is highlighted in table 9. Some 
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Table 9. Panel of isogenic strains containing efflux and porin modifications. a Deletion 
of ramR. b in vitro ramR point mutant, Thr124Pro. c in vitro oqxR point mutant Tyr109STOP. d 
ompK35 knockout, constructed by visiting PhD student Punyawee Dulyayangkul. e ompK36 
knockout, constructed by visiting PhD student Punyawee Dulyayangkul. f in vitro mutant, 
deletion of ramR, oqxR Arg93Cys. g in vitro mutant, deletion of ramR, oqxR Arg93Cys, nlpD 
Asn277FS, dhaR Asp395FS (nlpD and dhaR mutations currently uncharacterised but 
thought to be linked to porin expression (Kamil et al unpublished)). h in vitro mutant, deletion 
of ramR, oqxR Arg93Cys, nlpD Asn277FS, dhaR Asp395FS, ompK36 Gln170STOP. Arrows 
indicate the level of down or up-regulation. Ecl8 44, 16.1 and 0.125 mutants selected by Dr 
Wan Nur Ismah Kamil. Numbers in brackets represent number of mutations present in each 
strain.  
 
The K. pneumoniae lab strain Ecl8 is more permeable than K. pneumoniae clinical isolates 
(238). Accordingly, we found that it was difficult to show increases in β-lactam MIC against 
these Ecl8 derivatives (in the presence of vaborbactam) as Ecl8 is already highly 
susceptible, and the MIC assay uses a doubling series scale. The benefit of using 
antimicrobial disc susceptibility tests is that it provides a continuous scale, and so more 
clearly showed the different effects that the efflux and porin mutations have on β-
lactam/vaborbactam activity. Also, because of this elevated basal permeability for Ecl8, we 
were less concerned here with whether the efflux or porin mutations gave resistance 
according to the clinical breakpoints, but more so which mutation or combination of 
mutations resulted in the largest decrease in inhibition zone diameter when compared to the 
Ecl8 wild-type strain. Antimicrobial susceptibility testing was carried out in the presence and 
absence of vaborbactam against a range of β-lactam antibiotics (meropenem MEM, 
ertapenem ERT, imipenem IPM, doripenem DOR, cefotaxime CTX, cefuroxime CXM, 
ceftazidime CAZ, ceftriaxone CRO and cefepime FEP). Tables 10-12 show these results, 
which are summarised below. 
 
Ecl8 0.03-1 
This oqxR point mutant overproduces the OqxAB efflux pump. Figure 18 indicates, if 
producing KPC, CTX-M or OXA-232, in both the presence and absence of 
vaborbactam there is only a limited effect on carbapenem susceptibility when 
compared to the wild type strain. There was only case of which 0.03-1 produced a 
significant decrease in zone diameter when compared to Ecl8 WT. Ecl8 WT KPC 





0.03-1 KPC has a doripenem zone diameter of 25 mm in the presence of 
vaborbactam. This is a significant decrease p=0.0009. Overall, this fits with the 
recent observation that OqxAB overproduction has little effect on carbapenem 
susceptibility even in the presence of a β-lactamase (223).  
 
 
Figure 18. Graphical representation of carbapenem antimicrobial disc susceptibility 
tests carried out against Ecl8 and Ecl8 0.03-1. The panel of efflux and porin mutants were 
transformed with plasmids encoding either KPC-3, CTX-M-15 or OXA-232 and tested in the 
presence and absence of vaborbactam. Disc susceptibility tests were performed on Mueller 
Hinton agar. Assays were performed according to CLSI guidelines in triplicate. Data 
presented is the average of triplicate values. Error bars indicate the variation according to 
the standard deviation. The black lines indicate significance between Ecl8 0.03-1 and Ecl8 
Delta, in this instance ‘NS’ stands for ‘Not Significant, *** = p ≤ 0.001. The red line is the 
susceptibility cut off for meropenem ( i.e. zone diameters above this breakpoint are 







Ecl8 0.03-2 and Delta 
Both are ramR mutants, that result in up regulation of the AcrAB and OqxAB efflux pumps, 
though OqxAB up-regulation is to a lesser extent when compared to oqxR mutants (223). 
Overall RamR loss combined with KPC, CTX-M or OXA-232 production seemed to have a 
greater effect than OqxR loss on cephalosporin susceptibility. This is probably because 
AcrAB can efflux cephalosporins more than OqxAB (217) However, like OqxR loss, figure 19 




Figure 19. Comparison of meropenem/vaborbactam antimicrobial susceptibility 
testing between Ecl8 0.03-1 and Ecl8 Delta. The panel of efflux and porin mutants were 
transformed with plasmids encoding either KPC-3, CTX-M-15 or OXA-232 and tested in the 
presence and absence of vaborbactam. Disc susceptibility tests were performed on Mueller 
Hinton agar. Assays were performed according to CLSI guidelines in triplicate. Data 
presented is the average of triplicate values. Error bars indicate the variation according to 
the standard deviation. The black lines indicate significance between Ecl8 0.03-1 and Ecl8 
Delta, in this instance ‘NS’ stands for ‘Not Significant. The red line is the susceptibility cut off 







Ecl8 35 and 36 
Ecl8 35 and 36 are porin knockout strains of ompK35 and ompK36 respectively. The role of 
porin loss in carbapenem resistance has been well documented, and even implicated in 
meropenem/vaborbactam non-susceptibility (170, 174, 239). Here we show that loss of 
OmpK35 results in a decrease in meropenem zone diameter of 4 mm, 0 mm and 1 mm 
against CTX-M, KPC and OXA-232 respectively, in the presence of vaborbactam, compared 
to Ecl8 WT (tables 10,11,12). OmpK36 loss had a larger impact with a decrease in 
meropenem zone diameter, in the presence of vaborbactam, of 6 mm, 2 mm and 2 mm in 
strains producing CTX-M, KPC and OXA-232 (tables 10,11,12). In fact, figure 20 indicates 
that the decrease in zone diameter caused by OmpK35 loss in Ecl8 35 KPC and OXA, is not 
significant. Whereas OmpK36 loss was significant in each transformant. Vaborbactam and 
meropenem have been reported of having preferential OmpK36 mediated entry (165), so 











Figure 20. Comparison of meropenem/vaborbactam antimicrobial susceptibility 
testing between Ecl8 WT, Ecl8 35 and Ecl8 36. The panel of efflux and porin mutants were 
transformed with plasmids encoding either KPC-3, CTX-M-15 or OXA-232 and tested in the 
presence and absence of vaborbactam. Disc susceptibility tests were performed on Mueller 
Hinton agar. Assays were performed according to CLSI guidelines in triplicate. Data 
presented is the average of triplicate values. Error bars indicate the variation according to 
the standard deviation. The black lines indicate significance between Ecl8 0.03-1 and Ecl8 
Delta, in this instance ‘NS’ stands for ‘Not Significant, * = 0.01 ≤ p ≤ 0.05, *** = p ≤ 0.001. 
The red line is the susceptibility cut off for meropenem ( i.e. zone diameters above this 
breakpoint are considered susceptible meropenem) 
 
Ecl8 Delta 35 and Ecl8 Delta 36 
Ecl8 Delta 35 and 36 are double mutants that contain a loss of RamR combined with either 
ompK35 or ompK36 knockout. Loss of RamR, which up-regulates AcrAB, on its own was not 
shown to be a major indicator of meropenem/vaborbactam. However, when combining 
RamR loss with porin loss, much more significant changes were seen. Figure 21 shows that 
combining porin loss with efflux over expression resulted in significant decreases in zone 
diameters for CTX-M, KPC but not for OXA-232. In fact, Ecl8 Delta 36 KPC was 
meropenem/vaborbactam non-susceptible with a meropenem zone diameter of 21 mm. 
Therefore, over expression of AcrAB does have an effect on meropenem/vaborbactam 
susceptibility, even when producing a vaborbactam susceptible carbapenemase, but only 













Figure 21 . Comparison of meropenem/vaborbactam antimicrobial susceptibility 
testing between Ecl8 35, Ecl8 36 and Ecl8 Delta 35 and Ecl8 Delta 36. The panel of 
efflux and porin mutants were transformed with plasmids encoding either KPC-3, CTX-M-15 
or OXA-232 and tested in the presence and absence of vaborbactam. Disc susceptibility 
tests were performed on Mueller Hinton agar. Assays were performed according to CLSI 
guidelines in triplicate. Data presented is the average of triplicate values. Error bars indicate 
the variation according to the standard deviation. The black lines indicate significance 
between Ecl8 0.03-1 and Ecl8 Delta, in this instance ‘NS’ stands for ‘Not Significant, * = 0.01 
≤ p ≤ 0.05, ** = 0.001 ≤ p ≤ 0.01, *** = p ≤ 0.001. The red line is the susceptibility cut off for 




Ecl8 44 is also a double mutant that combines loss of RamR and OqxR. Figure 23 shows 
that RamR combined with OqxR loss does not lead to a decrease in meropenem zone 
diameters, in the presence of vaborbactam, against bacteria producing any of the test β-
lactamases, compared to Ecl8 0.03-1, 0.03-2 and Delta. This reiterates that efflux, on its own 








Ecl8 Delta 36 micF 
This triple mutant combines RamR loss with ompK36 knockout and OmpK35 loss, achieved 
through transformation of the inhibitory antisense RNA micF on the pK18 plasmid. The loss 
of OmpK35 further decreases meropenem zone diameters by 3 mm, 1 mm and 2 mm (KPC, 
CTX-M and OXA-232) in the presence of vaborbactam. However these decreases are only 
of significance in Ecl8 Delta 36 micF KPC and Ecl8 Delta 36 micF OXA-232 (figure 22). Ecl8 
Delta 36 KPC is meropenem/vaborbactam non-susceptible and the over-expression of micF 
further reduced the zone diameter to 18 mm. Additionally, table 11 indicates that Ecl8 Delta 
36 mic F KPC was ertapenem, imipenem and doripenem non-susceptible in the presence of 
vaborbactam.  
 
Figure 22. Comparison of meropenem/vaborbactam antimicrobial susceptibility 
testing between Ecl8 Delta 36 and Ecl8 Delta 36 micF. The panel of efflux and porin 
mutants were transformed with plasmids encoding either KPC-3, CTX-M-15 or OXA-232 and 
tested in the presence and absence of vaborbactam. Disc susceptibility tests were 
performed on Mueller Hinton agar. Assays were performed according to CLSI guidelines in 
triplicate. Data presented is the average of triplicate values. Error bars indicate the variation 
according to the standard deviation. The black lines indicate significance between Ecl8 0.03-
1 and Ecl8 Delta, in this instance ‘NS’ stands for ‘Not Significant, * = 0.01 ≤ p ≤ 0.05, ** = 
0.001 ≤ p ≤ 0.01, *** = p ≤ 0.001. The red line is the susceptibility cut off for meropenem ( i.e. 







Ecl8 16-1 is an in vitro mutant derived from Ecl8 44. This mutant has the loss of RamR and 
OqxR that is present in Ecl8 44, as well as mutations in nlpD, dhaR and down-regulation of 
OmpK36 (shown by proteomics by Dr Wan Nur Ismah Kamil). However, no mutation was 
shown to be present in the open reading frame or promoter region of ompK36. Neither NlpD 
or DhaR have previously been implicated in β-lactam resistance. Therefore, one would 
assume Ecl8 16-1 to have a similar antimicrobial disc susceptibility profile to Ecl8 44. This is 
clearly not the case as Ecl8 16-1 KPC, CTX-M and OXA-232 has a distinct decreased 
carbapenem and more so cephalosporin susceptibility both in the presence and absence of 
vaborbactam. This is highlighted that Ecl8 16-1 and 0.125 OXA are both resistant to 
cefotaxime (figure 23), even though OXA-232 is not considered a cephalosporinase, 
Therefore, either NlpD, DhaR or indeed both seem to be a novel cephalosporin resistance 
mechanism that could potentially be working via reduced porin production.  
 
Ecl8 0.125 
Finally, Ecl8 is a mutant which has RamR loss, OqxR loss, nlpD and dhaR mutations an 
OmpK36 loss. This OmpK36 loss (combined with all β-lactamases tested) causes a 
significant decrease in meropenem zone diameter compared to Ecl8 16-1 (figure 23), again 
highlighting the importance of OmpK36 in meropenem/vaborbactam susceptibility. This 
mutant has a comparable level of cephalosporin resistance of that shown by Ecl8 Delta 36 
micF but shows more susceptibility to carbapenems. Ecl8 0.125 KPC gave meropenem and 
ertapenem non-susceptibility in the presence of vaborbactam but remained susceptible to 
doripenem and imipenem. Ecl8 0.125 CTX-M gave ertapenem non-susceptibility in the 
presence of vaborbactam but remained susceptible to the remaining carbapenems tested. 
Ecl8 0.125 OXA gave meropenem, ertapenem, imipenem and doripenem non-susceptibility 







Figure 23 . Comparison of meropenem/vaborbactam antimicrobial susceptibility 
testing between Ecl8 Delta 36 and Ecl8 Delta 36 micF. The panel of efflux and porin 
mutants were transformed with plasmids encoding either KPC-3, CTX-M-15 or OXA-232 and 
tested in the presence and absence of vaborbactam. Disc susceptibility tests were 
performed on Mueller Hinton agar. Assays were performed according to CLSI guidelines in 
triplicate. Data presented is the average of triplicate values. Error bars indicate the variation 
according to the standard deviation. The black lines indicate significance between Ecl8 0.03-
1 and Ecl8 Delta, in this instance ‘NS’ stands for ‘Not Significant’ all other decreases in zone 
diameter compared to Ecl8 WT are in this case of significance (p ≤ 0.05). The red line is the 
susceptibility cut off for meropenem and cefotaxime ( i.e. zone diameters above this 










We have found that of single mutants tested, OmpK36 loss had the greatest impact on 
meropenem/vaborbactam susceptibility. Although on their own, RamR and OqxR loss did 
not alter meropenem/vaborbactam activity, when combined with OmpK36 loss resulted in 
further decrease in meropenem zone diameter in the presence of vaborbactam. Finally, 
further decrease in meropenem/vaborbactam non-susceptibility can be achieved through 
mutants that display significant porin and efflux mutations. The most resistant mutants tested 
contained RamR, OqxR, OmpK36 loss and nlpD and dhaR mutations (Ecl8 0.125) or RamR, 
OmpK36 and OmpK35 loss. This is important as it shows a combination of porin loss and 
increased efflux is required to give high-levels of meropenem/vaborbactam resistance and 
that many clinical isolates, as shown in chapter 4 already show a significant decrease in 
permeability.  
Additionally, table 11 indicates that vaborbactam is preferentially a KPC inhibitor. Although, 
still showing a spectrum of activity that includes CTX-M, it is to a lesser extent when 
compared to vaborbactam inhibition of KPC. When combined with meropenem, this is not so 
much of a problem, as CTX-M is not a carbapenemase. However, this is highlighted when 
looking at the antimicrobial disc susceptibility tested of Ecl8 CTX-M against cephalosporins 
in the presence and absence of CTX-M. Cefotaxime zone diameters of Ecl8 36 CTX-M in the 
absence of vaborbactam was 6mm, whereas in the presence of vaborbactam, was 23mm, 
which is non-susceptible according to the CLSI breakpoints. Therefore, when combined with 
meropenem, the poor carbapenemase capability of CTX-M, rather than vaborbactam 
inhibitory activity, determines the meropenem/vaborbactam activity. Whereas, when 
combined with cephalosporins, vaborbactam struggles to restore susceptibility, highlighting 
the weaker inhibitory capability of vaborbactam against CTX-M. The permeability and efflux 
modifications also seem to show a larger effect on cephalosporin/vaborbactam susceptibility 
rather than carbapenem/vaborbactam susceptibility in the presence of CTX-M.  
Table 12 shows that vaborbactam is a relatively poor inhibitor of OXA-232. For example, 
meropenem zone diameter of Ecl8 WT OXA-232 is 26mm, whereas meropenem zone 
diameter in the presence of vaborbactam is 24mm, showing that vaborbactam is unable to 
inhibit the carbapenemase potential of OXA-232. Vaborbactam did increase the zone 
diameters for ertapenem against the OXA-232 mutants, however it was unable to restore 
susceptibility. The only case of vaborbactam restoring susceptibility was found with Ecl8 44 
OXA-232 against cefuroxime (zone diameters of 8 mm and 20 mm respectively). In 
conclusion, we have found that vaborbactam is a class A β-lactamase inhibitor but shows 
potency against the KPC carbapenemase. Contrastingly, vaborbactam is a poor inhibitor of 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 10. Antimicrobial disc 
susceptibility testing of Ecl8 
CTX-M and derived mutants 
with and without vaborbactam. 
Green, susceptible; Red, non-
susceptible. Disc susceptibility 
assays were performed on Cation 
adjusted Ca2+ Mueller Hinton. 
Assays were performed in 
triplicate according to CLSI 
guidelines. Numbers in brackets 
represent the difference in zone 
diameter with and without 
vaborbactam. Changes in zone 
diameter ≥2 mm is considered a 
significant change. Data 
presented as the average zone 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 11. Antimicrobial disc 
susceptibility testing of Ecl8 
KPC and derived mutants with 
and without vaborbactam. 
Green, susceptible; Red, non-
susceptible. Disc susceptibility 
assays were performed on Cation 
adjusted Ca2+ Mueller Hinton. 
Assays were performed in 
triplicate according to CLSI 
guidelines. Numbers in brackets 
represent the difference in zone 
diameter with and without 
vaborbactam. Changes in zone 
diameter ≥2 mm is considered a 
significant change.  Data 
presented as the average zone 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 12. Antimicrobial disc 
susceptibility testing of Ecl8 
OXA and derived mutants with 
and without vaborbactam. 
Green, susceptible; Red, non-
susceptible. Disc susceptibility 
assays were performed on Cation 
adjusted Ca2+ Mueller Hinton. 
Assays were performed in 
triplicate according to CLSI 
guidelines. Numbers in brackets 
represent the difference in zone 
diameter with and without 
vaborbactam. Changes in zone 
diameter ≥2 mm is considered a 
significant change. Data 
presented as the average zone 

















Chapter 4. Alternative β-
lactam/vaborbactam 

















4.1. Vaborbactam is an efficacious inhibitor of class A and C β-lactamases 
 
The spectrum of β-lactamase inhibition provided by vaborbactam was examined using a 
clinical isolate library, generously gifted by Southmead Hospital, Bristol.  The clinical isolate 
library, outlined in table 13, contained a panel of K. pneumoniae strains carrying a diverse 
range of β-lactamases. These included: the class A β-lactamases KPC-3 (carried on the 
natural pKpQIL plasmid), CTX-M-15 and various chromosomal TEM and SHV variants, the 
class D β-lactamases OXA-1, OXA-9 and the OXA-48 like carbapenemase OXA-232, and 
finally the class B β-lactamases NDM-1 and VIM-1. Additionally, variations of the R21 strain 
were made by transforming with plasmids encoding CTX-M-15, KPC-3, OXA-232 and the 
class C enzyme CMY-2.  
 
 



























Truncated  No change 
R4 NDM-1, OXA-
232, OXA-1, 


















































R9 TEM-1, SHV-28, 
CTX-M-15   
Deleted 
 




























Truncated  No change 
 







R13 TEM-1, SHV-11, 
CTX-M-15, OXA-
1 










































































No change No change 








R21 CTX-M TEM-1, SHV-11, 
CTX-M-15 
 








R21 KPC TEM-1, SHV-11, 
KPC-3 
 








R21 OXA TEM-1, SHV-11, 
OXA-232 
 












R21 CMY TEM-1, SHV-11, 
CMY-2 
 



































































Truncated  No change 
R28 SHV-11 *T141I 
 



























Table 13. K. pneumoniae clinical isolate library, expressing a diverse range of β-
lactamases. Details of the β-lactamases of each strain are provided, as well as any efflux or 
porin mutations present (226). *T141I and 194K are changes in amino acid sequence but 
are not associated with a change in protein function. It is likely that these are due to genetic 








The results of antimicrobial disc susceptibility testing carried out against each of the clinical 
isolates is shown in table 14. Each isolate was tested against meropenem (disc contained 10 
μg) alone and then meropenem in combination with vaborbactam (present in the agar) at a 
final concentration of 8 mg/L. As expected, strains containing the β-lactamases TEM, SHV 
and CTX-M were already susceptible to meropenem in the absence of vaborbactam 
(breakpoint cut of >23mm) 
Isolate Without vaborbactam With vaborbactam 
R1  (SHV-11) 26.0 28.0 (+2.0) 
R2  (TEM-1, SHV-11, CTX-M-15, 
OXA-1) 
27.0 29.0 (+2.0) 
R3  (TEM-1, SHV-28, CTX-M-15, 
OXA-1) 
28.0 30.0 (+2.0) 
R4  (NDM-1, OXA-232, OXA-1, OXA-
9*(2 - stop codon), TEM-1, SHV-28, 
CTX-M-15) 
6.0 6.0 (NC) 
R5  (SHV-11) 27.0 30.0 (+3.0) 
R6  (TEM-1, SHV-83, CTX-M-15, 
OXA-1) 
29.0 31.0 (+2.0) 
R7  (TEM-1, SHV-83, CTX-M-15, 
OXA-1) 
28.0 31.0 (+3.0) 
R8  (TEM-1, SHV-33, CTX-M-15, 
OXA-1) 
31.0 32.0 (+1.0) 
R9  (TEM-1, SHV-28, CTX-M-15) 29.0 29.0 (NC.0) 
R10  (TEM-1, SHV-28, CTX-M-15, 
OXA-1) 
26.0 33.0 (+7.0) 
R11  (OXA-232, TEM-1, SHV-1, CTX-
M-15) 
11.0 15.3 (+4.3) 
R12  (VIM-1, SHV-11) 8.0 11.0 (+3.0) 
R13  (TEM-1, SHV-11, CTX-M-15, 
OXA-1) 
22.0 27.0 (+5.0) 
R14  (TEM-1, SHV-11, CTX-M-15, 
OXA-1) 
29.0 31.0 (+2.0) 
R15  (TEM-1, SHV-108, CTX-M-15, 
OXA-1) 
29.0 30.0 (+1.0) 
R16  (TEM-1, SHV-11) 30.0 32.0 (+2.0) 
R17  (TEM-1*(del18), SHV-28, CTX-
M-15) 
31.0 33.0 (+2.0) 
R18  (TEM-1, SHV-28, CTX-M-15, 
OXA-1) 







Table 14. Antimicrobial disc susceptibility testing results of clinical isolates tested 
against meropenem and meropenem in combination with vaborbactam. Isolates non-
susceptible to meropenem are highlighted in red. Isolates susceptible to meropenem are un-
highlighted. Numbers in brackets show the increase in zone diameters. ‘NC’ denotes an 
unchanged meropenem zone diameter when combined with vaborbactam (8 mg/L) (present 




R19  (TEM-1, SHV-1, CTX-M-15, 
OXA-1) 
28.0 31.0 (+3.0) 
R20  (CTX-M-15, SHV-11) 25.0 31.0 (+6.0) 
R21  (TEM-1, SHV-11) 31.0 31.0 (NC) 
R21 CTX-M  (TEM-1, SHV-11, 
CTX-M-15) 
31.0 31.0 (NC) 
R21 KPC  (TEM-1, SHV-11, KPC-3) 6.0 26.0 (+20.0) 
R21 OXA  (TEM-1, SHV-11, OXA-
232) 
21.0 21.0 (NC) 
R21 CMY  (TEM-1, SHV-11, CMY-
2) 
21.0 27.0 (+6.0) 
R22  (TEM-1, SHV-1, CTX-M-15, 
OXA-1) 
30.0 30.0 (NC) 
R23  (TEM-1, SHV-1, CTX-M-15, 
OXA-1) 
30.0 30.0 (NC) 
R24  (TEM-1, SHV-11, CTX-M-15, 
OXA-1) 
30.0 30.0 (NC) 
R25  (TEM-1, SHV-76, CTX-M-15, 
OXA-1) 
30.0 31.0 (+1.0) 
R26  (TEM-1, SHV-11, CTX-M-15, 
OXA-1) 
25.0 29.0 (+4.0) 
R27  (TEM-1, SHV-119, CTX-M-15, 
OXA-1) 
26.0 28.0 (+2.0) 
R28  (SHV-11) 30.0 30.0 (NC) 
R29  (SHV-11, OXA-1) 30.0 32.0 (+2.0) 
R30  (TEM-1, SHV-11, OXA-9, KPC-
3) 





Of the 34 clinical isolates tested against meropenem, 26 were susceptible (76.5%). The 8 
non-susceptible isolates contained either KPC-3, OXA-232, NDM-1, VIM-1 or CMY-2. It has 
previously been reported that CMY-2 in combination with a ramR mutation gives meropenem 
non-susceptibility, (192) and isolate R21, which here is producing CMY-2 is a ramR mutant. 
The isolate R13 also showed non-susceptibility to meropenem. We believe this to be due to 
the presence of a ramR mutation as well as a truncated ompF and carriage of CTX-M, as all 
other isolates containing CTX-M-15 (a total of 23) which did not have these permeability 
defects were susceptible to meropenem (192). We have also already shown that RamR, and 
OmpK35 loss combined with the expression of CTX-M contributes to 
meropenem/vaborbactam non-susceptibility in K. pneumoniae Ecl8 (figure 18).  Indeed, the 
clinical isolate R14 contains the same panel of β-lactamases as R13 and is a ramR mutant, 
but has an intact ompK35, and is susceptible to meropenem.  
When combined with vaborbactam, the number of clinical isolates susceptible to meropenem 
increased to 30 (88.2%). Vaborbactam was able to restore meropenem susceptibility against 
R13 (CTX-M-15), R21 (KPC-3), R21 (CMY-2) and R30 (KPC-3). Meropenem susceptibility 
was recovered, therefore, due to the inhibition of the class A or C enzymes carried in these 
strains. The greatest increase in zone diameter, when meropenem was combined with 
vaborbactam, was shown by the two isolates expressing KPC-3. These isolates, R21 KPC 
and R30, had an increase in zone diameter of 20mm and 19mm respectively. This shows 
that, in vivo, as well as in vitro, vaborbactam is a class A and C β-lactamase inhibitor but 
shows a particular and potent inhibitory activity against KPC. A total of 4 strains remained 
non-susceptible to meropenem even in the presence of vaborbactam. These were R4 (NDM-
1, OXA-232, CTX-M-15), R11 (OXA-232, CTX-M-15), R12 (VIM-1) and R21 (OXA-232). It is 
known that vaborbactam is a poor inhibitor of metallo-β-lactamases and class D OXA-48 like 
β-lactamases at least in combination with meropenem, so this observation is not a surprise. 
This agrees with observations found in chapter 3, that vaborbactam is able to efficiently 
inhibit class A and C enzymes but cannot inhibit class B and D enzymes.  
 
 4.2. Meropenem/vaborbactam resistance is associated with a decreased production 
of the outer membrane porin OmpK36 
 
As vaborbactam is only clinically available with meropenem, mutants of K. pneumoniae 
clinical isolates were selected against meropenem in combination with vaborbactam (see 
section 2.13.). Ultimately, we wanted to characterise meropenem/vaborbactam resistance. 





CTX-M-15 producer R13, the KPC-3 producer R30, the OXA-232, CTX-M-15 producer R11 
and the OXA-232 transformant R21 OXA. Although R11 and R21 were already resistant to 
meropenem/vaborbactam, because OXA-232 is not significantly inhibited by vaborbactam, 
these strains were later used to test alternative partners for use in combination with 
vaborbactam, therefore mutants exhibiting higher meropenem/vaborbactam MICs derived 
from R11 (OXA-232, CTX-M-15) and R21 (OXA-232) were also generated. 
 






R13-1M 20.0 (-2.0) 22.0 (-5.0) 






R11-64M 6.7 (-3.3) 6.3 (-9.0) 





R21-16M  6.0 (-8.0) 6.0 (-11.0) 





R30-2M 6.0 (NC) 14.0 (-11.0) 
 
Table 15. Antimicrobial disc susceptibility testing of clinical isolates and derived 
mutants against meropenem and meropenem/vaborbactam. White, susceptible; Red, 
non-susceptible. Disc susceptibility assays were performed on Mueller Hinton agar. Assays 
were performed according to CLSI guidelines in triplicate. Values in table represent the 
mean of the three repetitions adjusted to the nearest one decimal point. Numbers in brackets 
represent the difference in zone diameter compared to the parental strain. ‘NC’ denotes No 
Change in zone diameter compared to the parent. Breakpoints are based on a dosage 





Table 15 shows the antimicrobial disc susceptibility results of R13 and its 
meropenem/vaborbactam resistant mutant 1M (where ‘1M’ denotes the concentration of 
meropenem selected on 1µg/ml), R11 and its meropenem/vaborbactam higher MIC mutant 
64M, R21 OXA and its meropenem/vaborbactam higher MIC mutant 16M and R30 and its 
meropenem/vaborbactam resistant mutant 2M. Confirming the vaborbactam/meropenem 
resistant phenotypes. Meropenem MICs were also determined against these four clinical 
isolates and their derived mutants in the presence and absence of vaborbactam. The MIC 
values are shown in table 16. The result shows a general concordance with the antimicrobial 
disc susceptibility testing. While R13 is susceptible to meropenem/vaborbactam with an MIC 
of 0.5 µg/ml, its mutant 1M is non-susceptible with an MIC of 2 µg/ml. Vaborbactam was 
able to restore meropenem susceptibility in R30 with a decrease in MIC of 256 µg/ml to 1 
µg/ml. Whereas vaborbactam was unable to restore sensitivity in the mutant 2M. 
Meropenem MICs in the presence and absence of vaborbactam remained the same in both 
R11 and 64M, reiterating the inability of vaborbactam to potentiate the activity of meropenem 


















       Meropenem mg/L 
Strain         — VAB 
R13 2       0.5 
1M 4 2 
   
R11 32 32 
64M  64 64 
   
R21 OXA 32 32 
16M 64 64 
   
R30 256 1 





Table 16. MICs of clinical isolates and derived mutants tested against meropenem and 
meropenem/vaborbactam. White, susceptible; Red, non-susceptible. MICs were performed 
according to CLSI guidelines. Breakpoints are based on a dosage regimen of 1g every 8h.To 
better understand the underlying meropenem/vaborbactam resistance mechanism, whole 
cell proteomics was carried out on the four clinical isolates R11, R13, R21 OXA and R30 and 
compared to their derived mutants 64M, 1M, 16M and 2M, according to the method outlined 
in section 2.10.3.  
 
4.2.1. Whole cell proteomics  
 
A comparison of the proteomics results of 1M, 64M,16M and 2M was performed to see what 
proteins were down-regulated or up-regulated in all four relative to their respective parent 
strains, and therefore whether there were any conserved proteins implicated in 
meropenem/vaborbactam resistance. Table 21 shows the proteins common to all four 
mutants that show either up-regulation or down-regulation. As we can see, there is only one 
protein that is common to all four mutants. This is the outer membrane porin OmpK36. This 
strongly implicates the importance of ompK36 loss or downregulation as an indicator of 
meropenem/vaborbactam non-susceptibility. Interestingly, the mutants 1M and 2M had very 
similar fold changes of OmpK36, 0.26 and 0.24 respectively (roughly 4-fold down-
regulation). Whereas the OXA-232, CTX-M-15 mutant 64M has a fold change of 0.02, which 
is a 50-fold down-regulation of OmpK36. The OXA-232 mutant 16M has a similar fold 
change of OmpK36 as seen with 64M, with a 20-fold down-regulation. This could indicate 
some similarity in the down-regulation mechanism shown in 1M and 2M and perhaps an 
alternative mechanism in 64M and 16M. It is important to note that all of these clinical 
isolates are already significantly impermeable with a non-functional ramR, ompK35 and in 
some cases oqxR mutations. Therefore, it may be that these mutations are required in 
combination with ompK36 loss to give meropenem/vaborbactam resistance and that without 
existing permeability mutations, loss of ompK36 is not sufficient to give 
meropenem/vaborbactam non-susceptibility, as suggested in Chapter 3. This requires 
significant further investigation, perhaps selected for meropenem/vaborbactam resistant 
mutants in strains that don’t have ramR, oqxR or ompk35 mutations or knockout of ompK36 
in an otherwise wild-type clinical isolate background. See section 4.2.5 for whole genome 












AAC(6')-Ib 2.48 0.012 
L0BW80 
Aminoglycoside 6'-N-acetyltransferase >20 <0.001 
A6TC15 
Chorismate synthase >20 <0.001 
A6TDK3 
Fimbrial like protein >20 <0.001 
A6TDK6 




Fimbrial usher protein >20 <0.001 
E2QPN9 
GltX >20 <0.001 
A6TI00 
Lipoate protein ligase >20 <0.001 
A6T6J2 
Molybdate transport protein >20 <0.001 
A6T6Y8 
Outer membrane lipoprotein carrier 2.27 0.021 
A6TGR3 
Purine biosynthesis protein >20 <0.001 
A6T6P5 
Putative ATP dependent RNA helicase >20 <0.001 
A6TGF3 
Putative transcriptional regulator 2.03 0.047 
A0A0E3GJ34 
Uncharacterised protein >20 <0.001 
A6T8F5 
Uncharacterised protein  >20 <0.001 
A6TCF0 
Uncharacterised protein >20 <0.001 
A6TEJ9 
Uncharacterised protein >20 <0.001 
A6TGL4 





ATP-binding component of transport system for maltose 
0.43 0.012 
A6TG34 






























































Phosphoribosylglycinamide formyltransferase <0.05 <0.001 
A6TD69 
Probable serine transporter 
0.45 0.005 
A6TFP1 







Putative dihydroxyacetone kinase 
0.38 <0.001 
A6THI5 
Putative enzyme contains P-loop 
0.41 <0.001 
A6TD68 
Putative uncharacterised protein 
0.22 <0.001 
A6TGC4 
Regulator for deo operon <0.05 <0.001 
A6TGP6 
Thiamine biosynthesis protein  <0.05 <0.001 
A6TGP9 









Type I restriction enzyme R protein 
0.48 0.041 
 
Table 17. Whole cell proteomics results of R13 compared to the derived mutant 1M. 
Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 1M. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-






A6T8Q6 Fumarase B  
>20 <0.001 
A6TF05 Nitrite reductase 
2.36 0.001 
A6T8K6 N-succinylarginine dihydrolase 
>20 <0.001 
A6T5D9 Preprotein translocase 
>20 <0.001 
C3TQB2 Pyruvate dehydrogenase 
>20 <0.001 
Q6KD45 
Aerobactin biosynthesis protein 0.44 0.002 
T2K1T3 
Aerobactin biosynthesis protein  0.35 <0.001 
Q3L7J1 
Aerobactin siderophore ferric receptor 0.42 0.026 
A6T5I0 
ATP-dependent Clp protease proteolytic subunit 0.49 0.030 
A6TGK6 
Conserved protein <0.05 <0.001 
A6T4N5 
D-alanine-D-alanine ligase 0.40 <0.001 
A6T642 
Dihydroxybenzoate synthetase 0.46 0.014 
A6TG67 
DNA polymerase I 0.34 0.027 
A6TIP6 
DNA-binding protein  0.47 0.010 
A6THJ4 
Inosose dehydratase <0.05 <0.001 
A6T640 
Isochorismate synthase <0.05 <0.001 
A6TC22 
Long-chain fatty acid transport protein <0.05 <0.001 
A6T7A5 
Multifunctional: proline dehydrogenase 0.49 <0.001 
C9E714 
OmpK35 0.05 0.000 
A6TBT2 
OmpK36 0.02 0.001 
A6T631 
Outer membrane porin 0.42 0.035 
A6THD2 
Peptide methionine sulfoxide reductase <0.05 <0.001 
A6T4W5 
Periplasmic serine protease 0.42 0.015 
A0A0A2R5A5 
Porin Morganella <0.05 <0.001 
A6TFG2 






Right origin-binding protein 0.49 <0.001 
A6T817 
Transcriptional regulation of aroF <0.05 <0.001 
 
Table 18. Whole cell proteomics results of R11 compared to the derived mutant 64M.  
Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 64M. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-








A6TF05 Nitrite reductase  
 >20   <0.001  
A6TB55 Ribose-5-phosphate isomerase 
 >20   <0.001  
A6T748 3-hydroxydecanoyl dehydratase               
0.46      0.037  
C3TDX2 3-oxoacyl synthase 
 <0.05   <0.001  
A6TCA1 4-hydroxy-tetrahydrodipicolinate synthase               
0.35      0.032  
A6T4W3 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase              
0.40      0.020  
A6TFX3 Acetolactate synthase  
 <0.05   <0.001  
A6T6W1 Arginine 3rd transport system periplasmic binding protein              
0.36      0.044  
A6TCJ1 Autonomous glycyl radical cofactor              
0.27      0.013  
A6T5R4 Bifunctional protein               
0.31      0.042  
A6T715 Chromosome partition protein  
 <0.05   <0.001  
A6TGW3 Class B acid phosphatase  
 <0.05   <0.001  
A6T685 Cold shock protein               
0.36      0.048  
A6TAZ5 Cold shock protein               
0.32      0.019  
A6TB57 Cytoplasmic ferritin               
0.34      0.020  
A6TBS4 Ecotin               
0.36      0.050  
A6T6C8 Ferric uptake regulator               
0.36      0.029  
A6T6C9 Flavodoxin               
0.41      0.045  
A6TFR3 Glutamate transport               
0.37      0.035  
A6T6Q5 Glutamine ABC transporter periplasmic-binding protein               
0.39      0.049  
A6TFK3 Glycerol-3-phosphate dehydrogenase 
 <0.05   <0.001  
A6TEK2 GTPase  
 <0.05   <0.001  
A6T6X2 Hydroxylamine reductase  
 <0.05   <0.001  
A6TEM9 Mannonate dehydratase  
 <0.05   <0.001  
A6T4X0 Methionine aminopeptidase               





A6TEU1 Methionyl-tRNA formyltransferase  
 <0.05   <0.001  
A6TBW4 NADH dehydrogenase  
 <0.05   <0.001  
A6TC39 Nucleoside transport protein  
 <0.05   <0.001  
A6TBT2 OmpK36 
 <0.05   <0.001  
A6TCK3 Outer membrane protein               
0.46      0.026  
A0A0A6U389 Pantothenate synthetase  
 <0.05   <0.001  
A6T693  Penicillin-binding protein 5               
0.49      0.042  
A6TEY5 Peptidyl-prolyl cis-trans isomerase               
0.37      0.044  
A6TFN0 Phosphopantothenoylcysteine synthase 
 <0.05   <0.001  
A6T700 Phosphoserine aminotransferase               
0.35      0.050  
A6T5D9 Preprotein translocase subunit               
0.35      0.038  
A6TD69 Probable serine transporter               
0.40      0.002  
A6TEN0 Putative dehydrogenase 
 <0.05   <0.001  
A6T7R8 Putative phosphoesterase              
0.44      0.005  
A6TC63 Putative uncharacterized protein               
0.38      0.045  
A6T681 Putative uncharacterized protein               
0.36      0.007  
A6T6Z5 Pyruvate formate lyase activating enzyme 
 <0.05   <0.001  
A6TGB5 Response regulator  
 <0.05   <0.001  
A6TCD6  RlmN  
 <0.05   <0.001  
A6TGW7 Single-stranded DNA-binding protein              
0.44      0.038  
A6TH72 Succinate dehydrogenase  
 <0.05   <0.001  
A6T4M9 UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase 
 <0.05   <0.001  
 
Table 19. Whole cell proteomics results of R21 OXA compared to the derived mutant 
16M.  Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 16M. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-




change  T-test 
D5KTT8 Conjugal transfer protein   >20  <0.001 
A6T8P0 Transcriptional regulation of aerobic, anaerobic respiration   >20  <0.001 
A6TGU0 UPF0597 protein  >20  <0.001 
A6T5F3 1-deoxy-D-xylulose-5-phosphate synthase   <0.05  <0.001 
A6T642 2,3-dihydro-2,3-dihydroxybenzoate synthetase, isochroismatase 
                
0.15  0.000 
A6T641 2,3-dihydroxybenzoate-AMP ligase   <0.05  <0.001 
A6TF13 3-dehydroquinate synthase  
                
0.20  0.004 





A6TGZ9 Acetyl-coenzyme A synthetase  
                
0.14  0.001 
A6TDU9 Agmatinase  <0.05  <0.001 
E2QHG9 Alkyl hydroperoxide reductase  
                
0.17  0.000 
A6TBZ8 Amidophosphoribosyltransferase  
                
0.13  0.007 
A6T6W1 Arginine 3rd transport system periplasmic binding protein  
                
0.17  0.020 
A6THH4 Aspartate carbamoyltransferase  
                
0.16  0.018 
A0A0A2R888 ATP synthase subunit  
                
0.19  0.001 
A6TG36 ATP synthase subunit beta 
                
0.20  0.002 
A6T614 Betaine aldehyde dehydrogenase   <0.05  <0.001 
Q2V9Y4 Beta-lactamase   <0.05  <0.001 
A6T6E9 Citrate synthase  
                
0.17  0.010 
A6T4N5 D-alanine--D-alanine ligase  
                
0.20  0.012 
C3SX72 Enolase   <0.05  <0.001 
A6TBN5 Galactose transport protein   <0.05  <0.001 
C3THM2 GlnH protein  
                
0.16  0.003 
A6T7C5 Glucans biosynthesis protein  
                
0.18  0.004 
A6T6B0 Glutamate/aspartate periplasmic binding protein  
                
0.18  0.002 
A6T6Q5 Glutamine ABC transporter periplasmic-binding protein 
                
0.17  0.003 
A6TDR5 Glycine dehydrogenase 
                
0.20  0.008 
A6T6L1 Histidine ammonia-lyase 
                
0.15  0.001 
C3SZX2 Histidine--tRNA ligase  <0.05  <0.001 
A6THJ2 Inositol 2-dehydrogenase   <0.05  <0.001 
A6T689 Lipoyl synthase  
                
0.19  0.020 
A6TFK0 L-lactate dehydrogenase   <0.05  <0.001 
A6TGU6 Maltoporin 2 LamB 0.29 0.034 
A6TGJ7 Mg2+ transport, system  <0.05  <0.001 
W1AXD8 N5-carboxyaminoimidazole ribonucleotide synthase  
                
0.17  0.010 
A6T521 Na(+)-translocating NADH-quinone reductase  
                
0.19  0.003 
A0A0A2R7X8 NAD(P) transhydrogenase   <0.05  <0.001 
A6TBX0 NADH dehydrogenase  
                
0.20  0.006 
A6T751 OmpA  
                
0.32  0.011 
A6TDJ4 OmpK26 0.22 0.011 
A6TBT2 OmpK36  
                
0.24  0.003 
A0A0A2R8C1 Peptide ABC transporter substrate-binding protein  
                
0.17  0.005 
A6TGU4 Periplasmic maltose-binding protein  
                
0.17  0.014 
A6T821 Periplasmic murein tripeptide   <0.05  <0.001 
A6TF26 Phosphoenolpyruvate carboxykinase  
                
0.20  0.008 
A6TGR2 Phosphoribosylamine--glycine ligase 
                
0.14  0.005 
A6TC99 Phosphoribosylaminoimidazole-succinocarboxamide synthase  
                





A6TCB3 Phosphoribosylformylglycinamidine cyclo-ligase  
                
0.18  0.007 
W1DKE2 Phosphoribosylglycinamide formyltransferase   <0.05  <0.001 
W1HLQ4 Phosphoribosylglycinamide formyltransferase   <0.05  <0.001 
A0A037YAR3 Phosphoserine aminotransferase   <0.05  <0.001 
A6TDP7 Protein disulfide isomerase   <0.05  <0.001 
A6TDI6 Putative ABC transporter periplasmic binding protein 
                
0.20  0.005 
A6TEL4 Putative ATP-binding component of a transport system 
                
0.20  0.008 
A6THT6 Putative synthesis protein  <0.05  <0.001 
A6T7H0 Putative TonB-dependent receptor  
                
0.15  0.011 
A6T7B0 Putative uncharacterized protein  
                
0.18  0.008 
A6T5B0 Pyrroline-5-carboxylate reductase   <0.05  <0.001 
A6TGC4 Regulator for deo operon  <0.05  <0.001 
A6T5E7 Riboflavin biosynthesis protein   <0.05  <0.001 
A6TCI1 Ribonuclease   <0.05  <0.001 
A6TGE6 Soluble pyridine nucleotide transhydrogenase  
                
0.20  0.001 
A6T7J1 Spermidine/putrescine ABC transporter  
                
0.13  0.000 
A6TCM7 SsrA-binding protein  
                
0.08  0.000 
A6T6F3 Succinate dehydrogenase  
                
0.20  0.006 
A6T4K6 Thiamin-binding periplasmic protein   <0.05  <0.001 
A6TDG3 Thymidylate synthase   <0.05  <0.001 
A6T7W6 Tryptophan synthase  <0.05  <0.001 
A6TBF7 Tyrosine autokinase  
                
0.17  0.001 
A6T6L0 Urocanate hydratase  
                
0.15  0.011 
 
Table 20. Whole cell proteomics results of R30 compared to the derived mutant 2M.  
Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 2M. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-














Figure 24. Whole cell proteomics Volcano-plots of clinical isolates vs mutants. Data 
points < -0.3 x-axis, > 1.3 y axis and > 0.3 x-axis, >1.3 y-axis is considered a significant fold 













Accession Description Fold-change T-test 
1M A6TBT2 OmpK36 0.26 0.023 
64M A6TBT2 OmpK36 0.02 0.001 
16M  A6TBT2 OmpK36 0.05 0.001 
2M A6TBT2 OmpK36 0.24 0.003 
 
Table 21.  A comparison of whole cell proteomics between the four 
meropenem/vaborbactam resistant mutants 1M, 64M, 16M and 2M. Whole cell 
proteomics were prepared in triplicate. Fold change and t-test indicates the average of the 
three repeats. Accession numbers highlighted in green show proteins significantly (p value = 
<0.05) up-regulated, with a fold change of >2, in the mutants. Accession numbers 
highlighted in red show proteins significantly (p-value = <0.05) down-regulated with a fold 
change of <0.5. 
 
4.2.5. Whole Genome sequence analysis 
 
4.2.5.1. Whole genome sequence indicates insertion sequence in the ompK36 
promoter of 64M, and introduction of a stop codon in 16M 
 
Upon analysis of the whole genome sequence of the meropenem/vaborbactam resistant 
mutant 64M and alignment to its parent R11 using progressive Mauve (235). A 263 bp 
insertion sequence was found in the promoter region of ompK36 in 64M that was absent in 
the parental clinical isolate R11 (figure 25). The 263 bp insertion sequence was identified as 
a transposase: protein id AOR89446.1 when using blastn (240). This insertion sequence is 
likely to be responsible for the decreased OmpK36 production seen in 64M relative to R11 in 
the whole cell proteomics data. Whole genome sequence alignment using progressive 
Mauve also indicated an ompK36 mutation in the mutant 16M. In this case, a stop codon 
was introduced at position 373 (figure 26) resulting in OmpK36 loss (figure 27, 28). However, 
no ompK36 mutation (figure 29, 30) could be found within the meropenem/vaborbactam 
resistant mutants 1M or 2M having relatively small reductions in OmpK36 production. This 
means there must be an alternative mutation that can give meropenem/vaborbactam 




























Figure 25.  Intergenic and coding regions of ompK36 in R11 and 64M. Sequence 
highlighted in red shows consensus between R11 and 64M. Sequence highlighted in black 
indicates unique sequence not present in R11. ompK36 start codon is at position 1040 
(underlined in blue) with its stop codon at position 2164. The stop codon of the previous 






Figure 26. Coding regions of ompK36 in R21 and 16M. Sequence highlighted in red 
shows consensus between R21 and 16M. Start codon is at position 1 (underlined in blue). 
Sequence highlighted in blue indicates a mismatch. In this case a stop codon is introduced 



















Figure 27. Protein alignment of OmpK36 between R21 and 16M. ‘*’ indicates sequence 
consensus between R21 and 16M. ‘-‘ indicates sequence present in R21 but not present in 
































Figure 28. OmpK36 DNA and amino acid sequence pairwise alignment in 16M. Figure 






































Figure 29. Intergenic and coding regions of ompK36 in R30 and 2M. Sequence 
highlighted in red shows consensus between R30 and 2M. ompK36 start codon is at position 
781(underlined in blue) with its stop codon at position 1994. The stop codon of the previous 

























Figure 30.  Intergenic and coding regions of ompK36 in R13 and 1M. Sequence 
highlighted in red shows consensus between R13 and 1M. ompK36 start codon is at position 
577 (underlined in blue) with its stop codon at position 1670. The stop codon of the previous 











4.3. Alternative β-lactam/vaborbactam combinations  
 
As the four mutants 1M, 2M, 64M and 16M showed resistance to meropenem/vaborbactam, 
a panel of alternative β-lactam partners were tested against them in combination with 
vaborbactam. The panel of β-lactams was the same as tested against the isogenic Ecl8 
strains in chapter 3. We were interested to see if vaborbactam could potentiate the activity of 
alternative β-lactam antibiotics even in meropenem/vaborbactam resistant mutants, 
potentially suggesting future clinical application.  
 
4.3.1. Activity of combinations in the presence of CTX-M 
 
The clinical isolate R13, along with being susceptible to meropenem/vaborbactam showed 
susceptibility to imipenem/vaborbactam and doripenem/vaborbactam (table 22). 
Vaborbactam was unable to restore susceptibility to ertapenem (which is caused by a 
combination of CTX-M plus efflux (192)) or cephalosporins apart from ceftazidime, which is a 
weak CTX-M substrate (244). The same combinations were also tested against the 
meropenem/vaborbactam resistant derivative of R13, mutant 1M. We can see that even 
though 1M is resistant to imipenem (but not doripenem) in the absence of vaborbactam, 
vaborbactam restores imipenem susceptibility. However, the mutation in 1M prevents 






μg in disc)  
R13 (CTX-M) R13 (CTXM) 
+Vab 
1M (CTX-M) 1M (CTX-M) 
+Vab 
ERT (10) 15.0 18.0 6.0 (-9.0) 6.0 (-12.0) 
MEM (10) 22.0 27.0 20.0 (-2.0) 22.0 (-5.0) 
IPM (10) 28.0 30.0 18.7 (-9.3) 27.0 (-3.0) 
DOR (10) 25.0 27.0 23.0 (-2.0) 24.0 (-3.0) 
CAZ (30) 10.0 21.0 6.7 (-3.3) 15.7 (-5.3) 
CXM (30) 6.0 6.0 6.0 (NC) 6.0 (NC) 
CTX (30)  6.0 16.0 6.0 (NC) 6.0 (-10.0) 
FEP (30) 9.0 20.0 6.0 (-3.0) 6.0 (-14.0) 





Table 22. Antimicrobial disc susceptibility testing of clinical isolate R13 and derived 
mutant 1M against a panel of β-lactams. White, susceptible; Red, non-susceptible. Disc 
susceptibility assays were performed on Cation Adjusted Ca2+ Mueller Hinton. Assays were 
performed according to CLSI guidelines in triplicate. Values in table represent the mean of 
the three repetitions adjusted to the nearest one decimal point. Numbers in brackets 
represent the difference in zone diameter compared to the parental strain. ‘NC’ denotes No 
Change in zone diameter compared to the parent. 
 
4.3.2. Activity of combinations in the presence of KPC 
 
Vaborbactam can efficiently restore susceptibility to ertapenem, meropenem, imipenem, 
doripenem, ceftazidime and ceftriaxone in the KPC producing clinical isolate R30 (table 23). 
In the meropenem/vaborbactam resistant mutant derivative 2M, vaborbactam can only 
restore susceptibility of imipenem and ceftriaxone. Similarly, to the CTX-M producing mutant 
1M, therefore, the KPC producing mutant 2M has lost ceftazidime/vaborbactam susceptibility 
as well as meropenem/vaborbactam susceptibility. This could indicate that OmpK36 
downregulation – the likely cause of meropenem/vaborbactam resistance in 1M and 2M is 
an important indicator of ceftazidime/vaborbactam non-susceptibility. As with 1M, 
imipenem/vaborbactam susceptibility was retained in 2M, suggesting that this combination 
has potential for dealing with meropenem/vaborbactam resistant mutants of isolates 




μg in disc)  
R30 (KPC)  R30 (KPC) + 
Vab  
2M (KPC) 2M (KPC) +Vab 
ERT (10) 6.0 23.0 6.0 (NC) 8.0 (-15) 
MEM (10) 6.0 25.0 6.0 (NC) 14.0 (-11.0) 
IPM (10) 6.0 27.7 6.0 (NC) 24.3 (-3.4) 
DOR (10) 6.0 26.7 6.0 (NC) 20.0 (-6.7) 
CAZ (30) 6.0 22.0 6.0 (NC) 14.7 (-7.3) 
CXM (30) 6.0 11.0 6.0 (NC) 6.0 (NC) 
CTX (30)  8.7 25.0 6.0 (-2.7) 22.0 (-3.0) 
FEP (30) 7.0 24.3 6.0 (-1.0) 20.7 (-3.6) 





Table 23. Antimicrobial disc susceptibility testing of clinical isolate R30 and derived 
mutant 2M against a panel of β-lactams White, susceptible; Red, non-susceptible. Disc 
susceptibility assays were performed on Cation Adjusted Ca2+ Mueller Hinton. Assays were 
performed according to CLSI guidelines in triplicate. Values in table represent the mean of 
the three repetitions adjusted to the nearest one decimal point. Numbers in brackets 
represent the difference in zone diameter compared to the parental strain. ‘NC’ denotes No 
Change in zone diameter compared to the parent. 
 
4.3.3. Activity of combinations in the presence of OXA-232 
 
Vaborbactam has been reported as a poor class D β-lactamase inhibitor in combination with 
meropenem. The results in section 4.1. and chapter 3, showed this to be true, where 
vaborbactam was unable to restore meropenem susceptibility in the OXA-232 producing 
strains R4, R11 and R21 OXA. We were interested to see whether vaborbactam could 
restore susceptibility to any of the β-lactams tested. Table 24 shows that R11 (which 
produces both OXA-232 and CTX-M-15) and the mutant derivative selected for very high 
meropenem/vaborbactam MICs, 64M are resistant to all β-lactams tested in the absence of 
vaborbactam. However, vaborbactam was able to potentiate the activity of ceftazidime and 
restore susceptibility in both R11 and 64M. Therefore, the addition of ceftazidime to the 
meropenem/vaborbactam effectively extends meropenem/vaborbactam activity to include 




μg in disc)  
R11 (OXA-232) R11 (OXA-232) 
+Vab 
64M (OXA-232) 64M (OXA-232) 
+Vab 
ERT (10) 6.0 6.0 6.0 (NC) 6.0 (NC) 
MEM (10) 11.0 15.3 6.7 (-3.3) 6.3 (-9.0) 
IPM (10) 12.7 11.3 7.0 (-5.7) 7.0 (-4.3) 
DOR (10) 10.7 12.7 6.3 (-4.4)  6.0 (-6.7) 
CAZ (30) 16.3 23.0 15.7 (-0.6) 24.3 (+1.3) 
CXM (30) 6.0 6.0 6.0 (NC) 6.0 (NC) 
CTX (30)  6.3 17.0 6.0 (-0.3) 15.7 (-1.3) 
FEP (30) 12.0 16.3 9.3 (-2.7) 21.7 (+5.4) 






Table 24. Antimicrobial disc susceptibility testing of clinical isolate R11 and derived 
mutant 64M against a panel of β-lactams White, susceptible; Red, non-susceptible. Disc 
susceptibility assays were performed on Mueller Hinton agar. Assays were performed 
according to CLSI guidelines in triplicate. Values in table represent the mean of the three 
repetitions adjusted to the nearest one decimal point. Numbers in brackets represent the 
difference in zone diameter compared to the parental strain. ‘NC’ denotes No Change in 
zone diameter compared to the parent. 
 
Since the OXA-232 producing isolate R11 also produces CTX-M15, which is a better target 
for vaborbactam, it is likely that this is the real reason for ceftazidime resistance, not OXA-
232. To test this hypothesis, the same panel of β-lactams was tested against the R21 OXA 
and the higher meropenem/vaborbactam MIC mutant 16M. R21 OXA and its mutant 16M 
only produces OXA-232 and does not produce CTX-M. The resulting antimicrobial disc 
susceptibility results (table 25) shows that R21 and indeed its mutant 16M are susceptible to 
ceftazidime and ceftazidime/vaborbactam. This shows that the CTX-M-15 enzyme present in 
R11 is indeed causing ceftazidime resistance in the absence of vaborbactam. Therefore, the 
reason vaborbactam is able to rescue ceftazidime resistance in R11 is due to its inhibitory 
effects on CTX-M-15 not on OXA-232. While R21 OXA was also susceptible to Cefotaxime, 
Cefepime and Ceftriaxone, both in the presence and absence of vaborbactam. The mutant 
16M was only susceptible to Ceftazidime and Ceftriaxone.  
Whilst the CTX-M-15 producing mutant 64M remained susceptible to 
ceftazidime/vaborbactam, the CTX-M-15 producing mutant 1M was resistant to 
ceftazidime/vaborbactam. As both, 1M and 64M have ramR mutation, ompK35 loss of 
function and OmpK36 down-regulation, we would expect them both to have the same 
ceftazidime/vaborbactam susceptibility phenotype. The reason that ompK36 loss in 64M 
does not stop vaborbactam from protecting ceftazidime could be due to an underlying 
difference in permeability, however. Both 1M and 64M contain a truncated non-functional 
ompK35. 1M contains a truncated ramR, whereas 64M contains a ramR point mutation 
(M184V). Although, both mutations have previously been shown to hyper-express acrB 
efflux pump gene by qRT-PCR, we hypothesise that the truncated ramR present in 1M to be 
a stronger mutation compared to the point mutations present in 64M. We believe this to be 
the key difference between the two mutants and leads to the inability of ompK36 loss to give 





production level of CTX-M-15 in the two mutants, meaning the ceftazidime hydrolysing 




μg in disc)  
R21 (OXA-232) R21 (OXA-232) 
+Vab 
16M (OXA-232) 16M (OXA-232) 
+Vab 
ERT (10) 14.0 18.0 6.0 (-8.0) 6.0 (-12.0) 
MEM (10) 21.0 21.0 6.7 (-14.3) 6.3 (-14.7) 
IPM (10) 22.0 20.3 9.0 (-13.0) 8.0 (-12.3) 
DOR (10) 19.0 19.0 10.0 (-9.0)  10.0 (-9.0) 
CAZ (30) 24.0 28.0 23.0 (-1.0) 26.0 (-2.0) 
CXM (30) 16.0 16.0 10.0 (-6.0) 12.0 (-4.0) 
CTX (30)  26.0 30.7 22.0 (-4.0) 24.3 (-6.4) 
FEP (30) 26.0 26.0 22.0 (-4.0) 23.0 (-3.0) 
CRO (30)  25.0 25.3 25.0 (NC) 27.0 (+1.7) 
 
Table 25. Antimicrobial disc susceptibility testing of clinical isolate R21 OXA and 
derived mutant 16M against a panel of β-lactams White, susceptible; Red, non-
susceptible. Disc susceptibility assays were performed on Cation Adjusted Ca2+ Mueller 
Hinton. Assays were performed according to CLSI guidelines in triplicate. Values in table 
represent the mean of the three repetitions adjusted to the nearest one decimal point. 
Numbers in brackets represent the difference in zone diameter compared to the parental 
strain. ‘NC’ denotes No Change in zone diameter compared to the parent. 
 
4.4. Ceftazidime, Imipenem and Doripenem as alternative partners for vaborbactam 
 
Ceftazidime was identified as a potential partner for vaborbactam against the OXA-232 
producers R11 (OXA-232, CTX-M15) and R21 OXA-232 even in mutants with OmpK36 
downregulation. Imipenem was identified as a potential partner for CTX-M-15 or KPC-3 
producers, even with highly impermeable envelopes and with OmpK36 downregulation, 
which are ceftazidime/vaborbactam non-susceptible. Doripenem/vaborbactam was also 
identified as a potential combination to combat highly impermeable isolate R13 (CTX-M-15) 
and its OmpK36 downregulated mutant 1M. These combinations are not clinically available, 





for clinicians to administer one of these agents at the same time as 
meropenem/vaborbactam, essentially creating these combinations. To ensure the 
effectiveness of these combinations, therefore, against our highly resistant clinical isolates 
and mutants, chequerboard MICs of ceftazidime, imipenem or doripenem each separately 
put in combination with meropenem/vaborbactam were carried out in the four 
meropenem/vaborbactam non-susceptible mutants: 1M (CTX-M-15), 2M (KPC-3), 64M 
(CTX-M-15, OXA-232) and 16M (OXA-232). 
 
4.4.1. Imipenem shows promise as an alternative partner for vaborbactam against 
CTX-M producers 
 
The results of the chequerboard MIC assays carried out against the 
meropenem/vaborbactam mutant 1M is shown in figure 31. Figure 31 A shows that, as 
predicted using disc susceptibility testing (table 22) 1M is ceftazidime non-susceptible, even 
in the presence of vaborbactam, which is provided by the meropenem/vaborbactam 
combination. It is also, as predicted, non-susceptible to meropenem/vaborbactam in the 
absence of ceftazidime. However, there is a synergistic effect. In the presence of 0.5 mg/L of 
meropenem (below the breakpoint for clinical non-susceptibility, and so clinically achievable) 
the MIC of ceftazidime reduces to ≤0.5, which is clinically susceptible. Hence, even though 
disc testing shows ceftazidime/vaborbactam does not work against this mutant, the clinical 
use of ceftazidime plus meropenem/vaborbactam should work.  
Figure 31 B confirms doripenem susceptibility in the presence of vaborbactam, also as 
predicted by the disc testing. Indeed, if used in combination with meropenem/vaborbactam 
the doripenem MIC drops further to ≤0.5 mg/L. Finally, figure 31 C) shows that the MIC of 
Imipenem is ≤0.5 mg/L with vaborbactam or meropenem/vaborbactam. Whilst synergy may 
also be present, the chequerboards used did not go to a low enough imipenem 
concentration to see it. We conclude therefore that whilst 
ceftazidime/meropenem/vaborbactam and doripenem/meropenem/vaborbactam should work 










A) Ceftazidime (X-axis) versus meropenem (Y axis) in the presence of vaborbactam 
(all wells) 
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B) Doripenem (X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells) 
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C) Imipenem (X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells) 
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Figure 31. Chequerboard MICs of R13 1M tested against ceftazidime, doripenem and 
imipenem. Meropenem/vaborbactam is indicated along the X-axis. Cells filled in grey 
indicate bacterial growth, cells filled white indicate no bacterial growth. Concentration 
highlighted in red shows the non-susceptible cut-off (growth above these concentrations 
indicates non-susceptibility). A) Chequerboard MIC of ceftazidime/vaborbactam Y-axis 
against meropenem/vaborbactam X-axis. B) Chequerboard MIC of doripenem/vaborbactam 
Y-axis against meropenem/vaborbactam X-axis. C) Chequerboard MIC of 
imipenem/vaborbactam Y-axis against meropenem/vaborbactam X-axis. Vaborbactam 
present at a fixed concentration of 8 mg/L 
 
4.4.2. Ceftazidime, imipenem and doripenem are unable to restore 
meropenem/vaborbactam resistance in KPC producers 
 
Similarly, ceftazidime, doripenem and imipenem in combination with 
meropenem/vaborbactam were tested against the KPC-3 meropenem/vaborbactam resistant 
mutant 2M. The chequerboard MIC results of these three combinations are shown in figure 
32. The mutant is resistant to ceftazidime, doripenem and imipenem in combination with 
vaborbactam alone (zero meropenem), even though the antimicrobial disc susceptibility tests 
in table 23 showed susceptibility to imipenem/vaborbactam. Unfortunately, against this KPC-
3 producing mutant, the MIC of ceftazidime, doripenem or imipenem did not reduce to below 







A) Ceftazidime (X-axis) versus meropenem (Y axis) in the presence of vaborbactam 
(all wells) 
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B) Doripenem (X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells)  
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C) Imipenem (X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells) 
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Figure 32. Chequerboard MICs of R30 2M tested against ceftazidime, doripenem and 
imipenem. meropenem vaborbactam is indicated along the X-axis. Cells filled in grey 
indicate bacterial growth, cells filled white indicate no bacterial growth. Concentration 
highlighted in red shows the non-susceptible cut-off standard for each antibiotic tested 
(growth above these concentrations indicates non-susceptibility). A) Chequerboard MIC of 
ceftazidime/vaborbactam Y-axis against meropenem/vaborbactam X-axis. B) Chequerboard 
MIC of doripenem/vaborbactam Y-axis against meropenem/vaborbactam X-axis. C) 
Chequerboard MIC of imipenem/vaborbactam Y-axis against meropenem/vaborbactam X-
axis. Vaborbactam present at a fixed concentration of 8 mg/L 
 
 
4.4.3. Ceftazidime shows promise as an alternative partner for vaborbactam against 
OXA-232 producers 
 
The chequerboard MIC results of ceftazidime, doripenem and imipenem against the mutant 
64M are shown in figure 33. The only combination 64M is susceptible to is 
ceftazidime/vaborbactam with meropenem or not. Susceptibility to doripenem and imipenem 








A) Ceftazidime (X-axis) versus meropenem (Y axis) in the presence of vaborbactam 
(all wells) 
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B) Doripenem (X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells) 
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C) Imipenem(X-axis) versus meropenem (Y axis) in the presence of vaborbactam (all 
wells) 
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Figure 33. Chequerboard MICs of R11 64M tested against Ceftazidime, Doripenem and 
Imipenem. meropenem vaborbactam is indicated along the X-axis. Cells filled in grey 
indicate bacterial growth, cells filled white indicate no bacterial growth. Concentration 
highlighted in red shows the non-susceptible cut-off (growth above these concentrations 
indicates non-susceptibility). A) Chequerboard MIC of ceftazidime/vaborbactam Y-axis 
against meropenem/vaborbactam X-axis. B) Chequerboard MIC of doripenem/vaborbactam 
Y-axis against meropenem/vaborbactam X-axis. C) Chequerboard MIC of 
imipenem/vaborbactam Y-axis against meropenem/vaborbactam X-axis. Vaborbactam 
present at a fixed concentration of 8 mg/L 
 
4.5. Characterising ceftazidime/vaborbactam resistance 
 
Of the three antibiotics tested in section 4.4., only imipenem and ceftazidime were shown to 
be efficacious partners for vaborbactam, or meropenem/vaborbactam. 
Ceftazidime/vaborbactam was shown to be an alternative combination to combat OXA-232 
producers, even if they have OmpK36 downregulated. Although the 
meropenem/vaborbactam resistant, CTX-M-15 producing, OmpK36 downregulated mutant 
R13 1M was resistant to ceftazidime/vaborbactam (though susceptible to 
ceftazidime/meropenem/vaborbactam), the original CTX-M-15 producing R13 isolate was 
susceptible to ceftazidime/vaborbactam. In order to understand if, and if so, how, 
ceftazidime/vaborbactam resistance might be achieved, ceftazidime/vaborbactam resistant 





transformant of the clinical isolate R21 and the meropenem/vaborbactam resistant mutant 
(64M) derived from the OXA-232/CTXM-15 producing clinical isolate R11.  
 
4.5.1. Ceftazidime/vaborbactam resistant mutants  
 
Three ceftazidime/vaborbactam resistant mutants were selected. These were the R13 
ceftazidime/vaborbactam resistant mutant 8CAZ (the number ‘8’ denotes the concentration 
of ceftazidime the mutant was selected on, 8 µg/ml), the R21 CTX-M mutant 2CAZ and 
finally the ceftazidime/vaborbactam resistant mutant, derived from R11 64M, 64M8CAZ. The 
antimicrobial disc susceptibility test results for these three mutants are shown in table 26. All 
three mutants have indeed lost susceptibility to ceftazidime/vaborbactam. The CTX-M-15 
producing ceftazidime/vaborbactam resistant mutants retain susceptibility to 
imipenem/vaborbactam and doripenem/vaborbactam, but the mutant 64M8CAZ is resistant 
to all β-lactam/vaborbactam combinations tested.  Whole cell proteomics was carried out to 
try and characterise ceftazidime/vaborbactam resistance. These mutants were also sent off 
for whole genome sequencing, but unfortunately, due to the time constraints of this project, 
the whole genome sequencing data of the ceftazidime/vaborbactam mutants 8CAZ and 






μg in disc)  
R13 (CTX-M) R13 (CTXM) 
+Vab 
8CAZ (CTX-M) 8CAZ (CTX-M) 
+Vab 
ERT (10) 15.0 18.0 9.0 (-4.0) 12.0 (-6.0) 
MEM (10) 22.0 27.0 20.0 (-3.0) 21.0 (-6.0) 
IPM (10) 28.0 30.0 30.0 (+2.0)) 32.0 (+2.0) 
DOR (10) 25.0 27.0 19.0 (-6.0) 24.0 (-3.0) 
CAZ (30) 10.0 21.0 6.0 (-3.7) 16.0 (-5.0) 
CXM (30) 6.0 6.0 6.0 (NC) 6.0 (NC) 
CTX (30)  6.0 16.0 6.0 (NC) 6.0 (-6.0) 
FEP (30) 9.0 20.0 6.0 (-3.0) 6.0 (-14.0) 















μg in disc)  
R21 (CTX-M) R21 (CTX-M) 
+Vab 
2CAZ (CTX-M) 2CAZ (CTX-M) 
+Vab 
ERT (10) 17.0  25.0 16.0 (-1.0) 24.0 (-1.0) 
MEM (10) 31.0 31.0 25.0 (-6.0) 30.0 (-1.0) 
IPM (10) 32.7 33.7 30.0 (-2.7) 28.0 (-5.7) 
DOR (10) 31.3 31.7 26.0 (-5.3) 27.0 (-4.7) 
CAZ (30) 9.0 26.3 6.0 (-3.0) 15.0 (-11.3) 
CXM (30) 6.0 6.0 6.0 (NC) 6.0 (NC) 
CTX (30)  6.0 25.0 6.0 (NC) 6.0 (-19.0) 
FEP (30) 6.0 14.0 6.0 (NC) 6.0 (-8.0) 
CRO (30)  6.0 22.0 6.0 (NC) 6.0 (-16.0) 
Antibiotic 
(concentration 











ERT (10) 6.0  6.0  6.0 (NC) 6.0 (NC) 
MEM (10) 6.7  6.3  7.0 (+0.3) 7.0 (+0.7) 
IPM (10) 7.0  7.0  6.0 (-1.0) 6.0 (-1.0) 
DOR (10) 6.3  6.0  7.0 (+0.3) 7.0 (+1.0) 
CAZ (30) 15.7  24.3  8.0 (-7.7) 19.0 (-5.3) 
CXM (30) 6.0  6.0  6.0 (NC) 6.0 (NC) 
CTX (30)  6.0  15.7  6.0 (NC) 6.0 (-9.7) 
FEP (30) 9.3  21.7  6.0 (NC) 6.0 (-15.7) 





Table 26. Antimicrobial disc susceptibility testing of Ceftazidime/vaborbactam 
resistant mutants. White, susceptible; Red, non-susceptible. Disc susceptibility assays 
were performed on Cation Adjusted Ca2+ Mueller Hinton. Assays were performed according 
to CLSI guidelines in triplicate. Values in table represent the mean of the three repetitions 
adjusted to the nearest one decimal point. Numbers in brackets represent the difference in 
zone diameter compared to the parental strain. ‘NC’ denotes No Change in zone diameter 
compared to the parent. 
 
 
4.5.2. Whole cell proteomics of Ceftazidime/vaborbactam mutants 
 
Phenotypically, both the CTX-M-15 Ceftazidime/vaborbactam mutants 2CAZ and 8CAZ 
show significant upregulation of CTX-M (Uniprot accession Q7AVW6) (tables 27-28) with 
fold changes of 4.67 and 11.15 respectively. 2CAZ also shows an increase in efflux and 
decrease in permeability, with a significant up-regulation of AcrA (A6T5M5) and TolC 
(A6TE24) and significant down-regulation of OmpK36 (A6TBT2). Our hypothesis is that the 
increase in expression of CTX-M increases ceftazidime hydrolysis activity in the presence of 
the inhibitory effects of vaborbactam against CTX-M. We were expecting to see a similar 
proteomics profile in the ceftazidime/vaborbactam mutant 64M8CAZ, since, as well as 
producing OXA-232 carbapenemase, it also produces CTX-M-15, which could, presumably 
be overproduced. However, this mutant does not show an increase in production of CTX-M 
(table 29). Instead, this mutant shows down-regulation of OmpK36, NlpD, AcrB and TolC. 
We have seen that in chapter 3 the mutant, Ecl8-16-1 has a mutation in nlpD (Ismah et al, 
unpublished). This mutant was selected for on the cephalosporin cefuroxime. Therefore 
down-regulation/loss of NlpD seems to be a novel cephalosporin resistance mechanism. No 
changes in the open reading frame or promoter region could be found in nlpD in 64M8CAZ 
according to PCR sequencing, and the mechanism of downregulation involved will await 
genome sequence results however an IS element was found in the promoter region of 
ompK36. Analysis of this IS element using IS finder, showed it was ISKpn14 which belongs 
to the IS1 family of IS elements (245, 246). As OmpK36 is already lost in 64M we do not 
think the additional IS element present in 64M8CAZ to be responsible for the antimicrobial 








Accession Description  Fold-change   T-test  
A6TFK7 2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase 
             2.12             0.021  
A6TF25 33 kDa chaperonin               2.20             0.036  
A6TI02 3-phosphoserine phosphatase               2.15             0.032  
A6TD51 7-carboxy-7-deazaguanine synthase   >20   <0.001  
Q6SJ71 AAC(6')-Ib               5.94             0.009  
A6TBY3 Acetate kinase               2.11             0.021  
A6T7U1 Activator of ntrL   >20   <0.001  
A6T9W8 Adenosine deaminase               2.59             0.023  
A6T5N7 Adenylate kinase               2.37             0.036  
A6T679 Alkyl hydroperoxide reductase              2.15             0.042  
A0A0N6WZQ7 Anaerobic nitric oxide reductase flavorubredoxin               7.35             0.005  
A6T5I1 ATP-dependent Clp protease               2.09             0.012  
A6TCK0 ATP-dependent protease              2.30             0.032  
A6T634 ATP-dependent serine activating enzyme   >20   <0.001  
A6TGR3 Bifunctional purine biosynthesis protein   >20   <0.001  
A6T4I0 Carbamoyl-phosphate synthase              4.40             0.009  
A6TA21 Carbonic anhydrase               2.33             0.044  
A6T4F4 Chaperone protein              2.05             0.041  
A6T5N6 Chaperone protein               2.04             0.037  
A0A0C4Y240 Chromosome partitioning protein   >20   <0.001  
A6TAT4 Cold shock protein E               2.44             0.023  
A6T8N9 Conserved protein  >20   <0.001  
Q7AVW6 CTX-M-1               4.67             0.038  
A6TCF1 Cysteine desulfurase              2.16             0.016  
A6TC50 Cysteine synthase               2.48             0.012  
A6TB70 Cysteine transport protein                2.38             0.036  
A6T5R2 Cysteine--tRNA ligase               2.30             0.035  
A6T5H5 Cytochrome o ubiquinol oxidase subunit               2.20             0.018  
A6T4N5 D-alanine--D-alanine ligase               2.77             0.002  
A6T4I4 Dihydrofolate reductase   >20   <0.001  
A0A0A2RH67 Dihydrolipoyl dehydrogenase               2.67             0.019  
A6TGP1 DNA-directed RNA polymerase             10.12             0.009  
A6TGP0 DNA-directed RNA polymerase subunit             11.64             0.010  
A0A0A2R562 Elongation factor G   >20   <0.001  
A6T6C9 Flavodoxin               3.53             0.015  
W8SYC3 Formate dehydrogenase   >20   <0.001  
A6T6K8 Formimidoylglutamase              2.76             0.043  
A6TBJ6 Fructose-bisphosphate aldolase               2.31             0.024  
A6T6C1 Glucosamine-6-phosphate deaminase               2.20             0.013  
A6TB22 Glucose-6-phosphate 1-dehydrogenase               2.39             0.030  
A6TEN3 Glutamate synthase  >20   <0.001  
A6T4V8 Glutamate-1-semialdehyde 2,1-aminomutase              2.11             0.024  
A6TFH5 Glycine--tRNA ligase               2.66             0.034  
A6TCD0 GTPase   >20   <0.001  





A6TGG1 Ketol-acid reductoisomerase              2.63             0.044  
A6T6A3 Leucine--tRNA ligase              2.54             0.020  
A6TAY5 L-serine deaminase              2.42             0.016  
A6T4X0 Methionine aminopeptidase               2.17             0.030  
A6T4E9 Molybdenum cofactor biosynthesis protein            84.24             0.026  
A6T7A5 Multifunctional: proline dehydrogenase               7.20             0.012  
A6TBW4 NADH dehydrogenase   >20   <0.001  
A6T6Y8 Outer-membrane lipoprotein carrier protein               2.02             0.026  
K9LL58 OXA-1   >20   <0.001  
D7EZP3 ParB  >20   <0.001  
A6TEY5 Peptidyl-prolyl cis-trans isomerase               2.84             0.031  
A6TBY6 Phosphodiesterase   >20   <0.001  
A6TF09 Phosphoglycolate phosphatase   >20   <0.001  
A6TAM2 Pleiotrophic regulation of anaerobic respiration   >20   <0.001  
A6TFK4 Protein-export protein SecB   >20   <0.001  
A6T7X7 Pseudouridine synthase               2.73             0.030  
A6T7G1 PTS family enzyme IIC/enzyme IIB               2.68             0.017  
A6TEM0 Putative ATP-binding component of a transport system              2.21             0.039  
A6TAP8 Putative GTP-binding protein               2.02             0.024  
A6TFG2 Putative outer membrane protein               4.02             0.009  
A6T7C0 Putative oxidoreductase component   >20   <0.001  
A6TBX9 Putative phosphatase  >20   <0.001  
A6TA14 Putative uncharacterized protein   >20   <0.001  
A6TDW6 Putative uncharacterized protein   >20   <0.001  
A6TGL4 Putative uncharacterized protein   >20   <0.001  
A6T8N5 Putative uncharacterized protein              2.38             0.029  
A6TFG8 Putative uncharacterized protein               2.05             0.044  
A6TGI5 Putative uncharacterized protein hemY               2.11             0.046  
A6T6Z5 Pyruvate formate lyase activating enzyme               2.59             0.031  
A6TBT9 Ribonucleotide-diphosphate reductase                2.36             0.020  
A6TEI6 Ribosome-binding factor  >20   <0.001  
A6T4J7 RNA polymerase-associated protein              2.50             0.032  
A6T4T4 RNA polymerase-binding transcription factor               2.39             0.033  
A6T7E5 RNase E              5.87             0.022  
A0A0A2RAJ9 Serine hydroxymethyltransferase  >20   <0.001  
C3TGI7 Serine--tRNA ligase   >20   <0.001  
A6TEN7 Stringent starvation protein               2.03             0.043  
A6TA04 Superoxide dismutase              2.68             0.013  
C4NV37 TEM-1   >20   <0.001  
A6TG65 Thiol:disulfide interchange protein              2.11             0.045  
A6TAI7 Threonine--tRNA ligase               2.21             0.047  
A6TDG3 Thymidylate synthase  >20   <0.001  
A6TEK0 Transcription elongation factor               3.06             0.013  
A6TGN4 Transcription termination/antitermination protein               2.46             0.007  
C3T7P7 Translation initiation factor               2.42             0.037  





A6TG45 tRNA uridine 5-carboxymethylaminomethyl 
modification enzyme  
             2.29             0.013  
A6TDQ2 tRNA-modifying protein               3.13             0.043  
A6T7K3 tRNA-specific 2-thiouridylase  >20   <0.001  
A6TGL3 Ubiquinone/menaquinone biosynthesis 
methyltransferase   
             3.33             0.015  
A6THE7 UPF0307 protein   >20   <0.001  
A6T4X3 Uridylate kinase               4.24             0.012  
A6T4T0 3-methyl-2-oxobutanoate hydroxymethyltransferase   <0.05   <0.001  
E2QPI4 3-oxoacyl-(Acyl-carrier-protein) synthase   <0.05   <0.001  
A6T4G3 4-hydroxy-3-methylbut-2-enyl diphosphate reductase   <0.05   <0.001  
B0CN74 60 kDa chaperonin   <0.05   <0.001  
A6TF98 Bifunctional polymyxin resistance protein   <0.05   <0.001  
A6TGQ7 DNA-binding protein               0.41             0.010  
A6TFP8 DNA-directed RNA polymerase   <0.05   <0.001  
Q798T6 FyuA   <0.05   <0.001  
A0A0A2RBF5 Glyceraldehyde-3-phosphate dehydrogenase   <0.05   <0.001  
W8T014 GTPase   <0.05   <0.001  
C3SZX2 Histidine--tRNA ligase  <0.05   <0.001  
A6TBJ8 Hydroxyethylthiazole kinase   <0.05   <0.001  
A6TAH5 Lipoprotein   <0.05   <0.001  
A6T5S9 Lysine decarboxylase 1   <0.05   <0.001  
A0A061YB63 Lysine--tRNA ligase   <0.05   <0.001  
A6TGU6 Maltoporin 2               0.45             0.004  
A6TCU9 Multidrug resistance secretion protein   <0.05   <0.001  
A6TAE1 Murein lipoprotein   <0.05   <0.001  
A6T9Z9 N-ethylmaleimide reductase   <0.05   <0.001  
A0A0G3B7F3 OXA-1   <0.05   <0.001  
A6TG32 Phosphate-binding protein              0.27             0.001  
A6TBJ7 Phosphomethylpyrimidine kinase   <0.05   <0.001  
A6TGQ1 Phosphomethylpyrimidine synthase   <0.05   <0.001  
A6TCB4 Phosphoribosylglycinamide formyltransferase   <0.05   <0.001  
A6THT4 Putative aldehyde dehydrogenase  <0.05   <0.001  
A6TFP1 Putative alpha helix protein               0.50             0.019  
A6T985 Putative LysM domain               0.46             0.003  
A6T9B7 Putative NADH  <0.05   <0.001  
A6TBQ4 Putative permease   <0.05   <0.001  
A6TE18 Putative uncharacterized protein  <0.05   <0.001  
A6TED7 Putative uncharacterized protein   <0.05   <0.001  
A6TGV9 Quinone oxidoreductase  <0.05   <0.001  
A6T7J8 Response regulator   <0.05   <0.001  
A6T7Q6 Scaffolding protein   <0.05   <0.001  
X2JHQ6 TEM   <0.05   <0.001  
A6T4K6 Thiamin-binding periplasmic protein   <0.05   <0.001  
A6TGP6 Thiamine biosynthesis protein   <0.05   <0.001  
A6TGP9 Thiamine biosynthesis protein   <0.05   <0.001  





A6TGP7 Thiazole synthase  <0.05   <0.001  
A0A0A2R7D6 Transaldolase   <0.05   <0.001  
A6T4M9 UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine 
ligase 
 <0.05   <0.001  
A6TCJ2 Uracil-DNA glycosylase   <0.05   <0.001  
 
 
Table 27. Whole cell proteomics results of R13 compared to the derived mutant 8CAZ. 
Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 8CAZ. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-
regulated with a fold change of <0.5. 
 
 
Accession Description  Fold-
change  
 T-test  
A6TI02 3-phosphoserine phosphatase   >20   <0.001  
A6TFX3 Acetolactate synthase   >20   <0.001  
A6T5M5 AcrA              5.44     0.043  
A6TB47 Alpha,alpha-trehalose-phosphate synthase   >20   <0.001  
A6T6W2 ATP-binding component of 3rd arginine transport system   >20   <0.001  
A6TBL5 Beta-D-glucoside glucohydrolase  >20   <0.001  
W1DMB9 Bifunctional purine biosynthesis protein   >20   <0.001  
Q7AVW6 CTX-M-1             11.15     0.017  
A6T702 Cytidylate kinase  >20   <0.001  
A6THZ6 Deoxyribose-phosphate aldolase   >20   <0.001  
A6T739 Dihydroorotate dehydrogenase   >20   <0.001  
A6TCT3 DNA-bending protein  >20   <0.001  
A6T9X6 Electron transport complex protein   >20   <0.001  
A6TF60 Gamma-glutamyltranspeptidase   >20   <0.001  
A6TEN3 Glutamate synthase  >20   <0.001  
A6T9Y3 Glutathionine S-transferase   >20   <0.001  
C3SZX2 Histidine--tRNA ligase   >20   <0.001  
A6TCF4 Inositol monophosphatase  >20   <0.001  
A6TEU4 Large-conductance mechanosensitive channel  >20   <0.001  
A6TC22 Long-chain fatty acid transport protein   >20   <0.001  
A6TH24 Low-affinity transport system; proline permease II   >20   <0.001  
A6T6S5 Molybdopterin biosynthesis protein   >20   <0.001  
A6T6C0 N-acetylglucosamine-6-phosphate deacetylase   >20   <0.001  
A6TBW4 NADH dehydrogenase subunit   >20   <0.001  
A6T9P4 N-hydroxyarylamine O-acetyltransferase  >20   <0.001  
A6TD34 NlpD             6.73  0.027 





A6TF28 OmpR  >20   <0.001  
A6TDX3 Ornithine decarboxylase isozyme   >20   <0.001  
A6T821 Periplasmic murein tripeptide   >20   <0.001  
A6TAZ0 PTS enzyme   >20   <0.001  
A6T6B4 Putative ATP-binding protein in pho regulon   >20   <0.001  
A6TBL4 Putative glycine/betaine/choline transport protein  >20   <0.001  
A6THT6 Putative synthesis protein  >20   <0.001  
A6TCJ3 Putative tRNA/rRNA methyltransferase   >20   <0.001  
A6T6Z8 Putative uncharacterized protein   >20   <0.001  
A6TBY0 Putative uncharacterized protein   >20   <0.001  
A6TCT6 Putative uncharacterized protein   >20   <0.001  
A6TE01 Putative uncharacterized protein   >20   <0.001  
A6THQ0 Putative uncharacterized protein   >20   <0.001  
A6T6Z5 Pyruvate formate lyase activating enzyme   >20   <0.001  
A0A0A2RNF5 Pyruvate kinase  >20   <0.001  
A6TFN5 Ribonuclease PH   >20   <0.001  
A6TES6 Ribosomal protein L11 methyltransferase  >20   <0.001  
A6T6T1 Ribosomal protein S12 methylthiotransferase   >20   <0.001  
A6THY6 Ribosomal RNA small subunit methyltransferase   >20   <0.001  
A6TEI9 Ribosome maturation factor   >20   <0.001  
A6TEI6 Ribosome-binding factor  >20   <0.001  
A0A0A2R1S6 RNA-binding protein   >20   <0.001  
A6T538 Succinate-semialdehyde dehydrogenase   >20   <0.001  
C4NV37 TEM-1               6.42     0.007  
A6TAK7 Thymidine kinase   >20   <0.001  
A6TE24 TolC              3.69     0.022  
A6TAI6 Translation initiation factor   >20   <0.001  
C3T7P7 Translation initiation factor   >20   <0.001  
A6TAV8 Trehalase, periplasmic   >20   <0.001  
A6T7K3 tRNA-specific 2-thiouridylase  >20   <0.001  
A6TGH5 UDP-N-acetyl-D-mannosaminuronate dehydrogenase  >20   <0.001  
A6TGW6 UvrABC system protein   >20   <0.001  
A6TBT2 OmpK36              0.45     0.035  
 
Table 28. Whole cell proteomics results of R21 CTX-M compared to the derived mutant 
2CAZ. Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates 
the average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 2CAZ. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-









change   T-test  
A6TC02 Acetyl-coenzyme A carboxylase carboxyl transferase  
 >20  
 
<0.001  
A6TEB5 Autoinducer 2-binding protein 
 >20  
 
<0.001  
A6TBL5 Beta-D-glucoside glucohydrolase 
 >20  
 
<0.001  
E2QPY3 Dual-specificity RNA methyltransferase 
 >20  
 
<0.001  
E2QJB4 Formate C-acetyltransferase  
 >20  
 
<0.001  
A6T9T4 Gamma-aminobutyraldehyde dehydrogenase  
 >20  
 
<0.001  
A6TCU5 Glycine/betaine/proline transport protein  
 >20  
 
<0.001  
A6TCD0 GTPase Der OS=Klebsiella pneumoniae  
 >20  
 
<0.001  
A6THJ2 Inositol 2-dehydrogenase  
 >20  
 
<0.001  
A6THJ4 Inosose dehydratase  
 >20  
 
<0.001  
A0A0A5SJ80 Leucine-responsive transcriptional 
 >20  
 
<0.001  
A6T5S8 Lysine/cadaverine transport protein  
 >20  
 
<0.001  
C3T0K2 Malate dehydrogenase  
 >20  
 
<0.001  
A6TBW4 NADH dehydrogenase subunit  
 >20  
 
<0.001  
A6TBW7 NADH-quinone oxidoreductase  
 >20  
 
<0.001  
A0A0U1YUK9  OXA-181  
 >20  
 
<0.001  
A6TF09 Phosphoglycolate phosphatase  
 >20  
 
<0.001  
A6TDI6 Putative ABC transporter  
 >20  
 
<0.001  
A6THJ0 Putative carbohydrate kinase  
 >20  
 
<0.001  
A6TG26 Putative xylanase  
 >20  
 
<0.001  
A6TB55 Ribose-5-phosphate isomerase  
 >20  
 
<0.001  
C3TPL7 Ribosome-recycling factor  
 >20  
 
<0.001  
A0A0A2RAJ9 Serine hydroxymethyltransferase  
 >20  
 
<0.001  
A6TD51 7-carboxy-7-deazaguanine synthase  
 <0.05  
 
<0.001  
A6TES2 Acetyl-CoA carboxylase 
 <0.05  
 
<0.001  
C3T1Y2 Acetyl-coenzyme A carboxylase carboxyl transferase  
 <0.05  
 
<0.001  
A6T5M5 AcrA               
0.24  
    
0.001  
A6T5M4 AcrB               
0.25  
    
0.007  
A6TF82 ATP-binding component  
 <0.05  
 
<0.001  
A6TF98 Bifunctional polymyxin resistance protein 
 <0.05  
 
<0.001  
A6T4N7 Cell division protein  
 <0.05  
 
<0.001  
A6TG04 Chromosomal replication initiator protein  
 <0.05  
 
<0.001  
A6TBY9 D-erythro-7,8-dihydroneopterin tri P epimerase 
 <0.05  
 
<0.001  
A6T5I3 DNA-binding protein HU-beta 
 <0.05  
 
<0.001  
A6TAW6 Fatty acid metabolism regulator protein  







A6T7S2 Glutamate dehydrogenase  
 <0.05  
 
<0.001  
A6TA02 Glutaredoxin  
 <0.05  
 
<0.001  
A6TAH5 Lipoprotein  
 <0.05  
 
<0.001  
A0A061YB63 Lysine--tRNA ligase  
 <0.05  
 
<0.001  
A6TD34 NlpD            
0.14  0.021 
A6T8K6 N-succinylarginine dihydrolase  









A6T6Q8 OmpX               
0.12  
    
0.003  
A6TCA0 Outer membrane protein assembly factor BamC NlpB              
0.20  
    
0.006  
A6T6Y8 Outer-membrane lipoprotein  
 <0.05  
 
<0.001  
M4JTK1 OXA-232               
0.33  
    
0.005  
A0A0U1XY39 OXA-48               
0.33  
    
0.020  
A6TGQ1 Phosphomethylpyrimidine synthase  
 <0.05  
 
<0.001  
A6TEL4 Putative ATP-binding component 
 <0.05  
 
<0.001  
A6T5H7 Putative lipoprotein  
 <0.05  
 
<0.001  
A6TEL2 Putative transport protein  
 <0.05  
 
<0.001  
A6TCV7 Putative uncharacterized protein 
 <0.05  
 
<0.001  
A6T5B7 Recombination-associated protein 
 <0.05  
 
<0.001  
A6T6Y6 Regulator for leucine  
 <0.05  
 
<0.001  
A6TGB9 Regulator of ribonuclease activity 
 <0.05  
 
<0.001  
A6T742 Ribosomal RNA large subunit methyltransferase  
 <0.05  
 
<0.001  
A6TEM7 Sigma cross-reacting protein  
 <0.05  
 
<0.001  
A6TEE8 Tartronate semialdehyde reductase 
 <0.05  
 
<0.001  
A6TGP6 Thiamine biosynthesis  
 <0.05  
 
<0.001  
A6TGP9 Thiamine biosynthesis protein  
 <0.05  
 
<0.001  
A6TGP7 Thiazole synthase  
 <0.05  
 
<0.001  




A6TE24 TolC               
0.20  
    
0.003  
A6T7Y3 Transcriptional regulator for cysteine  
 <0.05  
 
<0.001  
A6T4W7 UPF0325 protein  











Table 29. Whole cell proteomics results of R11 64M compared to the derived mutant 
64M8CAZ. Whole cell proteomics were prepared in triplicate. Fold change and t-test 
indicates the average of the three repeats. Accession numbers highlighted in green show 
proteins significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 
64M8CAZ. Accession numbers highlighted in red show proteins significantly (p-value = 










Figure 33. Intergenic and coding regions of ompK36 in R11, 64M and 64M8CAZ. 
Sequence highlighted in red shows consensus between R11, 64M and 64M8CAZ. Sequence 
highlighted in blue indicates the 263bp transposase introduced into 64M. Sequence 
highlighted in black shows a further 513bp insertion sequence, inserted directly into the 
middle of the transposase present in 64M.  
 
4.5.3. Imipenem/vaborbactam resistance   
 
The clinical isolate R13 as well as its meropenem/vaborbactam resistant mutant 1M 
remained susceptible to imipenem/vaborbactam as shown by the checkerboard MICs in 
figure 13. Ceftazidime/vaborbactam resistant mutants of R13 and R21 (CTX-M) also 
retained imipenem/vaborbactam susceptibility, as shown above. Therefore, an attempt was 
made to select for an imipenem/vaborbactam resistant mutant, derived from the 
meropenem/vaborbactam and ceftazidime/vaborbactam resistant mutant derivative of R13 
(CTX-M) 1M. The antimicrobial disc susceptibility tests of the resulting mutant 1 Imi (selected 
for on 1 µg/ml of imipenem) is shown in table 30. The mutant 1 Imi has lost susceptibility to 
imipenem/vaborbactam as well as doripenem/vaborbactam. This mutant is now resistant to 
all β-lactam/vaborbactam combinations tested. Whole cell proteomics was carried out to try 
and characterise imipenem/vaborbactam resistance. These mutants were also sent off for 
whole genome sequencing, but unfortunately, the data have not been returned in time to be 
discussed. The proteomics data (table 31) show a number of differences, but none suggest 
an obvious mechanism of resistance. Once the whole genome sequence data are available 














Table 30. Antimicrobial disc susceptibility testing of 1M and derived mutant 1 Imi 
against a panel of β-lactams White, susceptible; Red, non-susceptible. Disc susceptibility 
assays were performed on Cation Adjusted Ca2+ Mueller Hinton. Assays were performed 
according to CLSI guidelines in triplicate. Values in table represent the mean of the three 
repetitions adjusted to the nearest one decimal point. Numbers in brackets represent the 
difference in zone diameter compared to the parental strain. ‘NC’ denotes No Change in 
zone diameter compared to the parent. 
 
 
Accession Description  Fold-change   T-test  
A6T7U1 Activator of ntrL gene   >20   <0.001  
A6TEM8 Aerobic respiration sensor-response protein; histidine protein 
kinase/phosphatase, sensor for arcA  
 >20   <0.001  
A6T6Z1 Anaerobic dimethyl sulfoxide (DMSO) reductase  >20   <0.001  
A6TGS0 B12-dependent methionine synthase   >20   <0.001  
A6TAJ2 Conserved protein, protein kinase-like protein   >20   <0.001  
A6TDT2 D-erythrose-4-phosphate dehydrogenase   >20   <0.001  
A6TGP0 DNA-directed RNA polymerase                  7.27             0.018  
A6TGP1 DNA-directed RNA polymerase                  3.93             0.028  
A0A0A2R562 Elongation factor G   >20   <0.001  
E2QJB4 Formate C-acetyltransferase   >20   <0.001  
A6TH73 Fumarate reductase                  3.58             0.022  
A6TEN3 Glutamate synthase  >20   <0.001  
A6TE32 Glutamate-ammonia-ligase adenylyltransferase   >20   <0.001  
Antibiotic 
(concentration 
μg in disc)  
1M (CTX-M) 1M (CTX-M) 
+Vab 
1 Imi (CTX-M) 1 Imi (CTX-M) 
+Vab 
ERT (10) 6.0  6.0  6.0 (NC) 6.0 (NC) 
MEM (10) 20.0  22.0 14.0 (-6.0) 15.0 (-7.0) 
IPM (10) 18.7  27.0  19.0 (+0.3) 20.0 (-7.0) 
DOR (10) 23.0  24.0  15.0 (-8.0) 20.0 (-4.0) 
CAZ (30) 6.7  15.7  6.0 (-0.7) 12.0 (-3.7) 
CXM (30) 6.0 6.0  6.0 (NC) 6.0 (NC) 
CTX (30)  6.0  6.0  6.0 (NC) 6.0 (NC) 
FEP (30) 6.0  6.0  6.0 (NC) 6.0 (NC) 





A6TCD0 GTPase  >20   <0.001  
A6TD70 L-serine deaminase                 2.62             0.032  
A6T8N7 NAD(P) transhydrogenase subunit   >20   <0.001  
A6T8N6 NAD(P) transhydrogenase subunit                  2.16             0.004  
A6TG75 Phosphatase   >20   <0.001  
A6TD69 Probable serine transporter                  2.32             0.034  
A6THJ1 Putative acetolactate synthase  >20   <0.001  
A6TE06 Putative alcohol dehydrogenase  >20   <0.001  
A6THI7 Putative aldehyde dehydrogenase   >20   <0.001  
A6TDB9 Putative uncharacterized protein   >20   <0.001  
A6TBY1 Putative uncharacterized protein   >20   <0.001  
A6TC30 Putative uncharacterized protein   >20   <0.001  
A6TH72 Succinate dehydrogenase   >20   <0.001  
A0A0A5SIW7 Succinate--CoA ligase   >20   <0.001  
A6THC4 2',3'-cyclic nucleotide 2'-phosphodiesterase/3'-nucleotidase 
bifunctional periplasmic protein  
 <0.05   <0.001  
A6T641 2,3-dihydroxybenzoate-AMP ligase   <0.05   <0.001  
A6T4T0 3-methyl-2-oxobutanoate hydroxymethyltransferase   <0.05   <0.001  
A6TEE9 5-keto-4-deoxy-D-glucarate aldolase  <0.05   <0.001  
Q7DL18 Aldehyde-alcohol dehydrogenase   <0.05   <0.001  
A6TF98 Bifunctional polymyxin resistance protein ArnA   <0.05   <0.001  
A6TC15 Chorismate synthase   <0.05   <0.001  
A6T8V1 Dipeptidyl carboxypeptidase   <0.05   <0.001  
A6T5I3 DNA-binding protein HU-beta  <0.05   <0.001  
A6TFP8 DNA-directed RNA polymerase subunit omega   <0.05   <0.001  
E2QPN9 GltX   <0.05   <0.001  
A6T4S1 Glucose dehydrogenase   <0.05   <0.001  
A6T7S2 Glutamate dehydrogenase  <0.05   <0.001  
E2QF55 Hypoxanthine phosphoribosyltransferase   <0.05   <0.001  
A6TI00 Lipoate-protein ligase A   <0.05   <0.001  
A6TAH5 Lipoprotein   <0.05   <0.001  
A0A061YB63 Lysine--tRNA ligase   <0.05   <0.001  
C9E714 OmpF   <0.05   <0.001  
A6T631 Outer membrane porin, receptor for ferric enterobactin and 
colicins B and D fepA 
 <0.05   <0.001  
A6THD2 Peptide methionine sulfoxide reductase   <0.05   <0.001  
A6TGQ1 Phosphomethylpyrimidine synthase   <0.05   <0.001  
A6TCB4 Phosphoribosylglycinamide formyltransferase   <0.05   <0.001  
A6TG82 Protein FdhE homolog   <0.05   <0.001  
A6TEB0 Putative enzyme, ferredoxin reductase-like  <0.05   <0.001  
A6T5H7 Putative lipoprotein   <0.05   <0.001  
A6T985 Putative LysM domain  <0.05   <0.001  
A6TEG9 Putative periplasmic protein   <0.05   <0.001  
A6T5Q0 Putative thioredoxin protein   <0.05   <0.001  
A6TCF0 Putative uncharacterized protein   <0.05   <0.001  
A6TB03 Putative uncharacterized protein   <0.05   <0.001  
A6TE18 Putative uncharacterized protein  <0.05   <0.001  





A6TEP1 Putative uncharacterized protein  <0.05   <0.001  
A6TGL4 Putative uncharacterized protein   <0.05   <0.001  
A6TGB9 Regulator of ribonuclease activity A   <0.05   <0.001  
A6T7G8 Respiratory NADH dehydrogenase   <0.05   <0.001  
A6T7J8 Response regulator in two-component regulatory system with 
PhoQ 
 <0.05   <0.001  
A6TCL6 Ribosome maturation factor   <0.05   <0.001  
A6TGP9 Thiamine biosynthesis protein   <0.05   <0.001  
A6TGQ0 Thiamine-phosphate synthase   <0.05   <0.001  
A6TFA0 UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate 
aminotransferase 
 <0.05   <0.001  
A6T4W7 UPF0325 protein   <0.05   <0.001  
A6TCJ2 Uracil-DNA glycosylase   <0.05   <0.001  
A6T532 Xanthine phosphoribosyltransferase   <0.05   <0.001  
A6TF02 Peptidyl-prolyl cis-trans isomerase                  0.48             0.017  
A6TFR2 Glycerol kinase                  0.48             0.020  
A6T693 D-alanyl-D-alanine carboxypeptidase, fraction A; penicillin-
binding protein 5 
                0.47             0.012  
A6TBN8 GTP cyclohydrolase                 0.47             0.044  
A6T5M4 AcrB                  0.47             0.018  
A6T4E9 Molybdenum cofactor biosynthesis protein                  0.46             0.022  
A6TG48 Aspartate--ammonia ligase                  0.45             0.028  
A6T4Y2 3-hydroxyacyl-[acyl-carrier-protein] dehydratase                  0.45             0.032  
A6T5R1 Peptidyl-prolyl cis-trans isomerase                  0.45             0.027  
A6TBS4 Ecotin                  0.45             0.025  
A6T6C9 Flavodoxin                  0.45             0.037  
A6TGG1 Ketol-acid reductoisomerase                  0.45             0.008  
A6TF30 Putative uncharacterized protein                  0.44             0.014  
A6T5D9 Preprotein translocase subunit                  0.44             0.015  
A6TF37 Fe/S biogenesis protein                  0.44             0.050  
A6T4Q6 Transcriptional regulator of pyruvate dehydrogenase complex                  0.42             0.030  
A6THH2 Putative uncharacterized protein                  0.40             0.028  
A6T793 NAD(P)H dehydrogenase                  0.39             0.005  
A6TEL1 Putative transport protein                  0.39             0.019  
A6TCD7 Nucleoside diphosphate kinase                  0.39             0.013  
A6TBX0 NADH dehydrogenase                  0.38             0.018  
A6TFK6 Putative phosphatase                 0.37             0.023  
A6TB20 Keto-hydroxyglutarate-aldolase                 0.37             0.001  
A6TGH0 Thioredoxin                  0.35             0.014  
A6TF45 sn-glycerol-3-phosphate dehydrogenase                  0.35             0.010  
A6TER1 Suppresses inhibitory activity of CsrA                  0.34             0.035  
A6T7H0 Putative TonB-dependent receptor                 0.34             0.004  
A6TFG2 Putative outer membrane protein                 0.34             0.004  
A6TCT2 Putative uncharacterized protein                  0.34             0.038  
A6TGW7 Single-stranded DNA-binding protein                  0.33             0.007  
J7Q9Y1 ABC transporter maintaining OM lipid asymmetry                 0.33             0.011  
A6T7F4 Acyl carrier protein                  0.33             0.005  





A6T6Y8 Outer-membrane lipoprotein carrier protein                 0.30             0.008  
A6TCJ1 Autonomous glycyl radical cofactor                  0.30             0.006  
A6T5E9 N utilization substance protein B homolog                  0.29             0.001  
A6TEH9 Putative enzyme                  0.28             0.017  
A6T6G7 Peptidoglycan-associated lipoprotein                  0.28             0.009  
A6T685 Cold shock protein                  0.27             0.006  
A6T4V4 Outer membrane pore protein, receptor for ferrichrome                 0.26             0.001  
A6T6Q8 OmpX                  0.26             0.004  
A6T9R8 Putative receptor                 0.24             0.016  
A6TAW4 D-amino acid dehydrogenase                  0.21             0.045  
A6TDK6 Putative fimbrial-like protein                  0.11             0.003  
A6TAL7 Nitrate reductase 1, delta subunit  <0.05   <0.001  
A6TF14 Shikimate kinase 1   <0.05   <0.001  
A6TCI1 Ribonuclease 3   <0.05   <0.001  
A6TB01 Carboxy-terminal protease for penicillin-binding protein 3                  0.41             0.022  
A6T7Y9 Orotidine 5'-phosphate decarboxylase   <0.05   <0.001  
L0BW80 Aminoglycoside 6'-N-acetyltransferase   <0.05   <0.001  
A6TH52 10 kDa chaperonin                  0.37             0.020  
 
Table 31. Whole cell proteomics results of R13 1M compared to the derived mutant 1 
Imi. Whole cell proteomics were prepared in triplicate. Fold change and t-test indicates the 
average of the three repeats. Accession numbers highlighted in green show proteins 
significantly (p value = <0.05) up-regulated, with a fold change of >2, in the mutant 1 Imi. 
Accession numbers highlighted in red show proteins significantly (p-value = <0.05) down-






















Table 32. Summary of phenotypes and genotypes present in clinical isolates and 
selected mutants. * indicates missing genotype, either due to results not being returned or 










Strain Phenotype Genotype 
R13 CTX-M-15 RamR and OmpK35 loss ΔramR, ΔompK35 
1M (derived from R13) RamR and OmpK35 loss, 
down-regulation of OmpK36 
and LamB2 
*ΔramR, ΔompK35 
1 Imi (derived from 1M) RamR and OmpK35 loss, 
down-regulation of OmpK36 
and LamB2 
*ΔramR, ΔompK35 
8CAZ (derived from R13 RamR and OmpK35 loss, up-
regulation of CTX-M 
*ΔramR, ΔompK35 
   
R30 KPC-3 RamR, OqxR and OmpK35 
loss 
ΔramR, ΔoqxR, ΔompK35 
2M (derived from R30) RamR, OqxR and OmpK35 
loss, down-regulation of 
OmpK36 and LamB2 
*ΔramR, ΔoqxR, ΔompK35 
   
R21 CTX-M RamR loss ΔramR 
2CAZ (derived from R21 CTX-
M) 
RamR loss, up-regulation of 
CTX-M 
*ΔramR 
   
R21 OXA-232 RamR loss ΔramR 
16M (derived from R21 OXA) RamR and OmpK36 loss ΔramR, ΔompK36 
   
R11 OXA-232 CTX-M-15 RamR and OmpK35 loss ΔramR, ΔompK35 
64M (derived from R11) RamR, OmpK35 and OmpK36 
loss 
ΔramR, ΔompK35, ΔompK36 
64M8CAZ (derived from 64M) RamR, OmpK35 and OmpK36 
loss, down-regulation of NlpD 





4.7. Combining meropenem/vaborbactam with avibactam/ceftazidime 
 
Ceftazidime/avibactam is another β-lactam/β-lactamase inhibitor combination already 
licensed for clinical use. Since we could not find any β-lactam that could be universally 
efficacious against clinical isolates and mutants when used in combination with 
meropenem/vaborbactam, we decided to test the efficacy of combining 
ceftazidime/avibactam with meropenem/vaborbactam to combat β-lactam/vaborbactam 
resistance. All mutants made throughout this project were tested against 
ceftazidime/avibactam in combination with meropenem/vaborbactam using chequerboards. 
In fact, all mutants are susceptible to meropenem/vaborbactam in the presence of 
avibactam, even if there is no ceftazidime. Indeed, all the mutants are susceptible to 
ceftazidime/avibactam in the presence of vaborbactam, even if meropenem is not present. 
Hence, ceftazidime/avibactam plus meropenem/vaborbactam has great clinical potential 
against even these highly resistant mutants.  
 
A) R13 1M Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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B) R13 1 Imi Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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C) R21 2CAZ Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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D) R13 8CAZ Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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E) 2M Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and vaborbactam 
are present in all wells. 
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A) 64M Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and vaborbactam 
are present in all wells. 
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F) 64M8CAZ Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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G) R21 OXA 16M Ceftazidime (Y axis) versus meropenem (X axis). Avibactam and 
vaborbactam are present in all wells. 
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Figure 33. Chequerboard MICs of CTX-M, KPC and OXA β-lactam/vaborbactam 
mutants combining ceftazidime/avibactam and meropenem/vaborbactam. Cells filled in 
grey indicate bacterial growth, cells filled white indicate no bacterial growth. Concentration 
highlighted in red shows the non-susceptible cut-off (growth above these concentrations 
indicates non-susceptibility). Cell filled in green indicates the MIC of Ceftazidime/Avibactam 
in the presence of meropenem/vaborbactam. meropenem concentration is on the X-axis with 
ceftazidime concentration on the Y-axis. Vaborbactam and avibactam are present in each 




The first aim of this chapter was to select for in vitro produce in vitro 
meropenem/vaborbactam resistant mutants of clinical isolates, again either producing CTX-
M, KPC or OXA-232 and to characterise the resistant mechanism. Here we find that the two 
OXA-232 in vitro mutants had mutations in ompk36, resulting in loss of Ompk36. 
Conversely, no ORF or promoter ompk36 mutation could be found in the CTX-M or KPC 
meropenem/vaborbactam mutants ‘1M’ or ‘2M’, indicating an alternative resistance 






The second aim of this chapter was to test a range of alternative vaborbactam partners that 
could extend activity to also include OXA-232 and also overcome meropenem/vaborbactam 
resistance in CTX-M and KPC producers. Here we find that ceftazidime shows potential as 
an alternative partner for vaborbactam against OXA-232 and CTX-M producers. We also find 
that imipenem shows potential as an alternative partner for vaborbactam against 
meropenem/vaborbactam resistant CTX-M producers. Conversely, we were unable to 
identify a β-lactam/vaborbactam combination capable of overcoming 
meropenem/vaborbactam resistance in the KPC producer 2M. Although we were unable to 
identify a universal β-lactam/vaborbactam capable of targeting OXA-232 and 
meropenem/vaborbactam resistant CTX-M and KPC producers, we present here the first 
use of combining two β-lactam/ β-lactamase inhibitor combinations. All isolates and in vitro 
mutants generated remained susceptible to ceftazidime/avibactam-
meropenem/vaborbactam.  
The final aim of this chapter was to identify and characterise mutants resistant to these 
alternative β-lactam-vaborbactam combinations. He we find that ceftazidime/vaborbactam 
resistance in CTX-M producers is due to over-expressing of the CTX-M enzyme. We believe 
this to increase the ceftazidime hydrolysis potential of the CTX-M enzyme even in the 
presence of the inhibitory effects of vaborbactam. Correspondingly, 
ceftazidime/vaborbactam resistance in OXA-232 producers, seems to be due to permeability 






























Chapter 5: Discussion 


















The first part of this study sought to better understand meropenem/vaborbactam resistance 
in K. pneumoniae. This was achieved both through the construction of a panel of isogenic, 
permeability and efflux modified strains as well as the in vitro of meropenem/vaborbactam 
resistant mutants. It was found that OmpK36 loss or down-regulation was the strongest 
indicator of meropenem/vaborbactam resistance in both the panel of otherwise isogenic Ecl8 
derivatives and the meropenem/vaborbactam resistant mutants of clinical isolates. This 
seems to concur with the current literature as CRE has frequently been observed due to the 
carrying of carbapenemases in combination with porin loss and overproduction of efflux 
pumps. These carbapenem resistance indicators also seem to show a similar effect on 
meropenem/vaborbactam susceptibility. OmpK35 loss or downregulation also plays an 
important role in meropenem/vaborbactam non-susceptibility. Both meropenem and 
vaborbactam can enter through OmpK36 and OmpK35, although vaborbactam seems to 
show a greater preference for OmpK36 mediated entry (165). This explains why OmpK36 
shows a greater effect when compared to OmpK35. It has been hypothesised that loss of 
one of the major porins, either OmpK36 or OmpK35 could lead to competition for passage 
into the cell, increasing the importance of the other.  
Upon analysis of the whole genome sequence of the four meropenem/vaborbactam selected 
mutants. Two mutants showed mutational inactivation of ompK36. The OXA-232 mutant 
64M contained a 263bp insertion sequence in the upstream promoter region of the ompK36 
gene, which was not present in the parental clinical isolate R11. The OXA-232 mutant 16M 
showed ompK36 truncation via the introduction of a stop codon. The other two mutants 
showed an unchanged ompK36 open reading frame and promoter sequence. Additionally, 
no mutation could be found in the open reading frame or promoter sequence on the two-
component system ompR/envZ, which is known to play a role in ompC and ompF regulation 
in E. coli (247). This could indicate that merely down-regulating the expression of OmpK36 is 
sufficient to cause meropenem/vaborbactam non-susceptibility, and that there are currently 
unknown regulators in K. pneumoniae that control OmpK36 production. Alternatively, several 
other outer membrane proteins have previously been implicated in carbapenem resistance in 
K. pneumoniae. These are: OmpK26, the inducible OmpK37, the Maltoporin LamB and the 
phosphate-regulated porin PhoE (199, 248-250). OmpK26 and OmpK37 seem to be 
compensatory porins to maintain viability and allow import of nutrients as both OmpK26 and 
OmpK37 are significantly repressed under normal cell conditions but are often upregulated 
in strains that show loss of either OmpK35 or OmpK36 (248, 251). Although one 
meropenem/vaborbactam resistant mutant did show a significant change in abundance of 
OmpK26, this was a down-regulation event, with a fold-change of 0.22. Therefore, we do not 





these mutants. Loss or down-regulation of PhoE and LamB have previously been reported 
as having a role in carbapenem resistance in K. pneumoniae, however, their role in 
meropenem/vaborbactam resistance has not been described (199, 249). No observable 
change in abundance of PhoE was seen in any of the meropenem/vaborbactam resistant 
mutants, however down-regulation of LamB was found in both the CTX-M-15 mutant 1M and 
the KPC-3 mutant 2M with fold changes of 0.31 and 0.29 respectively alongside OmpK36 
downregulation. Again, no mutation could be found in the lamB open reading frame or 
promoter region. Perhaps the (potentially novel) mechanism of OmpK36 control also controls 
LamB porin production.  
Although there is limited knowledge regarding lamB in K. pneumoniae, in E. coli lamB is 
known to be located in the malKlamBmalM operon which combines with another operon 
malEFG (252). It is thought that that the promoter regions of these operons could overlap 
and that both operons are controlled by the positive regulatory gene malT (253). 
Furthermore in E. coli and Salmonella, the expression of LamB is known to be influenced 
through the expression of the inhibitory antisense microRNA micA, in a similar mechanism 
as seen with micF repression of ompK35 mRNA translation (219, 254). The levels of micA 
have been shown to be controlled by both the stress alarmone ppGpp and sigma factor E 
(255). It is unclear whether mutations in either ppGpp or sigma factor E could lead to down-
regulation of LamB. Therefore, the control of LamB is an incredibly complex signalling 
network combining positive and negative gene regulation with post transcriptional repression 
through the action of micA. The role of LamB in meropenem/vaborbactam susceptibility 
requires significant further investigation. Future work could involve the inclusion of long read 
whole genome sequencing to ‘finish’ the genomes of both the clinical isolates and the 
generated mutants allowing direct mapping to one another. The short comings of short read 
whole genome sequence is that if there is not a suitable, fully annotated, reference genome 
to map to, identification of SNPs is problematic. We found that the clinical isolates used 
throughout this project showed high variability when mapped to the reference genome 
GCF_000315385.1 making the identification of SNPs difficult. Therefore, it is highly probable 
that genuine mutations in candidate genes such as ompK36, lamB, phoE and their 
regulators could have been missed.  
The second part of this project sought to find if any other β-lactams could potentiate the 
activity of meropenem/vaborbactam. This was attempted because it is possible for clinicians 
to administer meropenem/vaborbactam with a β-lactam at the same time to the same 
patient, and so this work was designed to inform potential combination therapy when 
meropenem/vaborbactam emerges – as it surely will – in the clinic. Given that we have 





and then downregulation of OmpK36, we were therefore specifically whether β-lactams in 
combination with meropenem/vaborbactam could overcome meropenem/vaborbactam 
resistance (caused by OmpK36 downregulation/loss) in a CTX-M-15 producer with a ramR 
and ompK35 mutation (R13), a KPC-3 producer with ramR, oqxR and ompK35 mutations 
(R30) and finally an OXA-232, CTX-M-15 producer with ramR and ompK35 mutations (R11). 
Imipenem was shown to rescue meropenem/vaborbactam resistance in the 
meropenem/vaborbactam resistant mutant, CTX-M-15 producer, 1M, though further 
selection of imipenem/vaborbactam resistance was straightforward. Upon trying to 
characterise imipenem/vaborbactam resistance using LC-MS/MS proteomics, no obvious 
mechanism of resistance could be discerned. Once the whole genome sequencing results 
have been returned it may become clearer what the mechanism of resistance is, but we do 
believe it do be novel. Nonetheless, this shows a clear limitation for 
imipenem/meropenem/vaborbactam combination therapy. 
Ceftazidime/meropenem/vaborbactam was shown to be a combination that worked against 
the meropenem resistant mutants 1M and 64M (derived from the OXA-232, CTX-M-15 
producing R11) but again resistance to this combination was easily lost by mutation. 
Characterising ceftazidime/meropenem/vaborbactam resistance showed up-regulation of 
CTX-M-15 as the mechanism of resistance in two such mutants. We believe this to increase 
the ceftazidime hydrolysis potential of the CTX-M enzyme even in the presence of the 
inhibitory effects of vaborbactam. However, ceftazidime/vaborbactam resistance in the OXA-
232, CTX-M15 ceftazidime/vaborbactam resistant mutant 64M8CAZ (derived from 64M), 
showed no such up-regulation of CTX-M. Instead, a novel cephalosporin resistance 
mechanism was indicated which apparently involves down-regulation of the lipoprotein NlpD. 
In E. coli, nlpD has been characterised as forming an operon with rpoS and NlpD plays a 
role in the modelling and maintenance of the outer membrane (256, 257). It also plays an 
important role in peptidoglycan remodelling, by the activation of a peptidoglycan hydrolase 
AmiC, to carry out cytokinesis (258, 259). It has been reported that mutants lacking nlpD, 
exhibit a phenotype comparable to one which has outer membrane defects (258). 
Interestingly, PhD student Wan Nur Ismah selected cefuroxime resistant mutants of Ecl8 
derivative 4-4 and identified downregulation of NlpD. It seems therefore, that this is a novel 
cephalosporin resistance mechanism. However, in K. pneumoniae, the role of nlpD remains 
to be characterised. To better understand whether NlpD is indeed an indicator of 
ceftazidime/vaborbactam resistance, a knockout mutant of nlpD in R11 could be made to 
test whether this gives the same phenotype and proteomics profile as the 






Unfortunately, therefore, no β-lactam/meropenem/vaborbactam combination could be 
identified which was universally efficacious against the clinical isolates and mutants 
generated throughout this project. However, perhaps the most clinically important finding of 
this work, is that utilisation of ceftazidime/avibactam in combination with 
meropenem/vaborbactam showed great promise and rescued meropenem/vaborbactam 
resistance in all clinical isolates and mutants tested. A recent report identified the potential 
for using both ceftazidime/avibactam and meropenem/vaborbactam as a more favourable 
therapeutic option over colistin-based regimens (260). The work presented in this project is 
the first reported use of meropenem/vaborbactam in combination with ceftazidime/avibactam 
in vitro against characterised clinical isolates and resistant mutants. We have seen that 
ceftazidime/avibactam rescues meropenem/vaborbactam resistance, however, further work 
is required to evaluate whether meropenem/vaborbactam can restore ceftazidime/avibactam 
susceptibility in mutants having mutations in the avibactam target enzymes KPC and CTX-
M. To test this, it would be necessary to introduce point mutations into blaKPC 
(D179Y/T243M double substitution, D179Y or V240G) and blaCTX-M (P170S/T264I double 
substitution) that confer ceftazidime/avibactam resistance and then carry out antimicrobial 
susceptibility testing of ceftazidime/avibactam and ceftazidime/avibactam in combination 
with meropenem/vaborbactam (168, 169). Meropenem has previously been used to treat 
infections caused by ceftazidime/avibactam resistant isolates (due to the presence of a 
D179Y/T243M double substitution in the KPC-3 enzyme, which actually makes it a worse 
carbapenemase), (261). Therefore, we have provided significant evidence that combining 
meropenem/vaborbactam with ceftazidime/avibactam will restore susceptibility against 
isolates expressing meropenem/vaborbactam resistance or ceftazidime/avibactam 
resistance alone, and this combination could act as “salvage therapy” for an increasing 
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